

Ryan White HIV/AIDS Program

Annual Client-Level Data Report

Ryan White HIV/AIDS Program Services Report (RSR)

2015

The *Ryan White HIV/AIDS Program Annual Client-Level Data Report* is published by the Division of Policy and Data, HIV/AIDS Bureau (HAB), Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services, Rockville, Maryland.

Data are presented for clients reported to the HRSA/HAB Ryan White Services Report (RSR; non-ADAP) data system for calendar years 2011 through 2015.

The *Ryan White HIV/AIDS Program Annual Client-Level Data Report* is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested Citation

Health Resources and Services Administration. *Ryan White HIV/AIDS Program Annual Client-Level Data Report* 2015. <http://hab.hrsa.gov/data/data-reports>. Published December 2016. Accessed [date].

Health Resources and Services Administration

James Macrae, MA, MPP *Administrator (Acting)*

HIV/AIDS Bureau, Health Resources and Services Administration

Laura Cheever, MD, ScM *Associate Administrator*

Heather Hauck, MSW, LICSW *Deputy Associate Administrator*

Antigone Dempsey, MEd *Director, Division of Policy and Data*

Tracy Matthews, MHA, RN *CAPT, USPHS; Deputy Director, Division of Policy and Data*

Steven R. Young, MSPH *Director, Division of Metropolitan HIV/AIDS Programs*

Michael Goldrosen, MA *Director, Division of State HIV/AIDS Programs*

Mahyar Mofidi, DMD, PhD *CAPT, USPHS; Director, Division of Community HIV/AIDS Programs*

Harold J. Phillips, MRP *Director, Office of HIV Training & Capacity Development Programs*

April Stubbs-Smith, MPH *Director, Division of Domestic HIV Programs, Office of HIV Training & Capacity Development Programs*

Information about the Ryan White HIV/AIDS Program: www.hab.hrsa.gov

Educational and technical assistance materials about HIV infection and the Ryan White HIV/AIDS Program: www.careacttarget.org

Acknowledgments

Publication of this report was made possible by the contributions of the Ryan White HIV/AIDS Program grant recipients and subrecipients that provided RSR data to HRSA.

CONTENTS

Commentary	6
Technical Notes	14
Tables	
1a Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2011–2015—United States and 3 territories	21
1b Ryan White HIV/AIDS Program clients living with HIV (non-ADAP), by year and selected characteristics, 2011–2015—United States and 3 territories	23
2 Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	25
3 Ryan White HIV/AIDS Program clients (non-ADAP), by gender and selected characteristics, 2015—United States and 3 territories	26
4a Male clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and age group, 2015—United States and 3 territories	27
4b Female clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and age group, 2015—United States and 3 territories	27
4c Transgender clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and age group, 2015—United States and 3 territories	28
5 Ryan White HIV/AIDS Program clients (non-ADAP), by poverty level and selected characteristics, 2015—United States and 3 territories	29
6 Ryan White HIV/AIDS Program clients (non-ADAP), by housing status and selected characteristics, 2015—United States and 3 territories	31
7 Ryan White HIV/AIDS Program clients (non-ADAP), by health care coverage and selected characteristics, 2015—United States and 3 territories	33
8 Ryan White HIV/AIDS Program clients (non-ADAP), by HRSA region and selected characteristics, 2015—United States and 3 territories	35
9a Ryan White HIV/AIDS Program clients (non-ADAP), by state, 2015—United States and 3 territories	37
9b Ryan White HIV/AIDS Program clients (non-ADAP), by eligible metropolitan area and transitional grant area, 2015—United States and 3 territories	38
10a Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and state, 2015—United States and 3 territories	39
10b Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and eligible metropolitan area and transitional grant area, 2015—United States and 3 territories	41
11a-i Male clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and state, 2015—United States and 3 territories	43
11a-ii Female clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and state, 2015—United States and 3 territories	45

11a-iii	Transgender clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and state, 2015—United States and 3 territories	47
11b-i	Male clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and eligible metropolitan area and transitional grant area, 2015—United States and 3 territories	49
11b-ii	Female clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and eligible metropolitan area and transitional grant area, 2015—United States and 3 territories	51
11b-iii	Transgender clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and eligible metropolitan area and transitional grant area, 2015—United States and 3 territories	52
12a	Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2011–2015—United States and 3 territories	54
12b	Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and state, 2011–2015—United States and 3 territories	56
12c	Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and eligible metropolitan area and transitional grant area, 2011–2015—United States and 3 territories	58
13a	Viral suppression among Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2011–2015—United States and 3 territories	60
13b	Viral Suppression among Ryan White HIV/AIDS Program clients (non-ADAP), by year and state, 2011–2015—United States and 3 territories	62
13c	Viral suppression among Ryan White HIV/AIDS Program clients, by year and eligible metropolitan area and transitional grant area, 2011–2015—United States and 3 territories	64
14a	Retention in care among women (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	66
14b	Viral suppression among women (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	68
15a	Retention in care among men (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	70
15b	Viral suppression among men (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	72
16a	Retention in care among transgender adults and adolescents (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	74
16b	Viral suppression among transgender adults and adolescents (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	76

17a	Retention in care among youth and young adults (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	78
17b	Viral suppression among youth and young adults (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	80
18a	Retention in care among young men who have sex with men (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	82
18b	Viral suppression among young men who have sex with men (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	83
19a	Retention in care among young women (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	84
19b	Viral suppression among young women (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	85
20a	Retention in care among people who inject drugs (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	86
20b	Viral suppression among people who inject drugs (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories	88

COMMENTARY

The Ryan White HIV/AIDS Program (RWHAP) supports a comprehensive system of care that ensures ongoing access to high quality HIV care, treatment, and support services. The RWHAP provides services to low-income people living with HIV (PLWH), as well as their families, who have no health care coverage (public or private), have insufficient health care coverage, or lack financial resources to get the HIV care and treatment they need to achieve positive health outcomes.

The Legislation

The RWHAP is administered by the U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), HIV/AIDS Bureau (HAB). In 1990, Congress passed the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act to address the crisis of the HIV epidemic in the United States. This legislation has been amended and reauthorized four times: in 1996, 2000, 2006, and most recently in 2009 as the Ryan White HIV/AIDS Treatment Extension Act of 2009.

The RWHAP was funded at \$2.32 billion in fiscal year 2016. It is the largest federal program focused exclusively on HIV care, treatment, and support services. The RWHAP works dynamically to leverage other funding sources and health care coverage opportunities for PLWH.

The RWHAP has five statutorily defined Parts that provide funding for medical and support services, technical assistance, clinical training, and the development of innovative models of care to meet the needs of different communities and populations affected by HIV:

- **Part A** provides funding to Eligible Metropolitan Areas (EMAs) and Transitional Grant Areas (TGAs) that are most severely affected by the HIV epidemic to support HIV care and treatment services. To qualify for EMA status, an area must have reported at least 2,000 AIDS cases in the most recent 5 years and have a population of at least 50,000. To be eligible for TGA status, an area must have reported 1,000 to 1,999 AIDS cases in the most recent 5 years and have a population of at least 50,000. EMAs and TGAs range in size from one city or county to more than 26 different geographic entities; 11 contain portions of more than one state. The boundaries of EMAs and TGAs are based on the U.S. Census Bureau delineation of the metropolitan statistical area at the time of first eligibility.
- **Part B** provides funding to all 50 states, the District of Columbia, Puerto Rico, Guam, the U.S. Virgin Islands, and 5 U.S. Pacific Territories or Associated Jurisdictions to support HIV care and treatment services.
 - The RWHAP Part B grants include funding for the AIDS Drug Assistance Programs (ADAP) to fund medication and insurance assistance as well as other statutory components.
- **Part C** provides funding to local community-based organizations, community health centers, health departments, and hospitals in 49 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands to support comprehensive primary health care and support services in an outpatient setting for PLWH. Part C funds may also support planning grants and capacity development grants to more effectively deliver HIV care and services.
- **Part D** provides funding to support high quality family-centered HIV primary medical services and support services for women, infants, children, and youth living with HIV and their affected family members in 42 states.

- **Part F** provides funds for a variety of programs:
 - The Special Projects of National Significance (SPNS) Program supports the development of innovative models of care and effective delivery systems for HIV care, and the dissemination of successful models for replication and integration by RWHAP-funded recipients.
 - The AIDS Education and Training Center (AETC) Program supports a network of regional centers that conduct targeted, multidisciplinary education and training programs for health care providers serving PLWH in all states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and 6 Pacific jurisdictions.
 - The Dental Programs provide funding for oral health care for PLWH and support training dental and dental hygiene providers.
 - The Minority AIDS Initiative provides funding to evaluate and address the disproportionate impact of HIV on African Americans and other minorities.

Together, the Parts of the RWHAP provide the public health infrastructure needed to ensure access to a wide range of core medical and support services (e.g., non-medical case management, housing, transportation, nutritional services) aimed at early diagnosis of HIV, linkage to care, retention in care, medically appropriate treatment, and sustained virologic suppression.

2015 RWHAP Client-Level Data Report Overview

This report is the second annual publication of national RWHAP client-level data collected through the Ryan White HIV/AIDS Program Services Report (RSR). The RSR dataset is HAB's primary source of annual, client-level data collected from more than 2,000 funded grant recipients and subrecipients.

Since 2010, client-level RSR data have been used to assess the numbers and types of clients receiving services and their HIV-related outcomes. Project Officers at HAB share the data with recipients and subrecipients to monitor and support their progress to improve care and treatment for PLWH. It is through the hard work of these providers and the RWHAP community that clients are helped every day.

This report includes data reported to the RSR for all clients served by Parts A, B, C, and D during calendar years 2011 through 2015, regardless of the RWHAP funding stream. RSR data do not include information about ADAP; all ADAP-related information is collected through another data system. Although data presented in this report are "non-ADAP," many clients also receive ADAP services.

The data presented highlight the state of the RWHAP and include the demographic composition of clients served; socioeconomic factors, such as federal poverty level (FPL), health care coverage, and housing status; and the results of focused analyses to measure progress toward achieving selected HIV-related clinical outcome indicators [1]. The data are inclusive of the overall RWHAP client population and key priority populations served by RWHAP. This report does not include the specific services that were provided for individuals. All tables include all clients served regardless of the RWHAP funding stream.

Tables displaying sociodemographic data (Table 1a and Tables 2 through 11b-iii) include all RWHAP clients regardless of HIV serostatus; that is, data include PLWH, as well as clients who do not have HIV (e.g., families of PLWH served by the RWHAP). Table 1b and tables displaying retention in care and viral suppression data (Tables 12a through 20b) include only PLWH who meet the criteria for the specified analysis (see Technical Notes). All tables include data from all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and Guam. Tables 10b, 11b-i through 11b-iii, 12c, and 13c display data by EMAs and TGAs. Readers are encouraged to read carefully all table titles and footnotes to ensure a complete understanding of the data presented.

Ending the HIV Epidemic

HAB has focused on four goals to inform programmatic effort and funding to end the HIV epidemic: (1) reduce the number of people who become infected with HIV; (2) increase access to care and improve health outcomes for people living with HIV; (3) reduce HIV-related health disparities; and (4) achieve a more coordinated national response to the HIV epidemic [1].

HAB collects data to monitor progress toward achieving select indicators of HIV-related health outcomes [2], including retention in HIV medical care and viral suppression among RWHAP clients (related to goals 1–3). These data are displayed for the overall RWHAP client population by demographics, state, and EMA or TGA (Tables 12a through 13c).

HAB also has enhanced its efforts to improve health outcomes among several key populations: women; transgender individuals; gay, bisexual, and other men who have sex with men (MSM); blacks/African Americans; Hispanics/Latinos; youth; young black/African American MSM; young black/African American women; and people who inject drugs. Tables 14a through 20b display retention in care (“a” tables) and viral suppression (“b” tables) for these key populations.

Report Changes

Eligible scope

Beginning with the 2015 calendar year data collection period, recipients and subrecipients reported data for all clients who were eligible for and received services through the RWHAP, regardless of the funding source used to pay for the services (e.g., private employer health care coverage). This shift to eligible scope reporting allows for an enhanced understanding of the full volume of services received by clients of RWHAP recipients and subrecipients, and better captures the impact of the program for clients receiving services at RWHAP-funded sites and systems of care. The change also supports the continued collection of clinical data, which is essential for measuring client HIV-related outcomes.

Addition of PLWH and EMA/TGA data tables

In this report, a data table was added that includes only PLWH served by the RWHAP (Table 1b) during 2011 through 2015; as mentioned previously, all other demographic tables in this report (Table 1a and Tables 2 through 11b-iii) include all clients served by RWHAP, regardless of serostatus. In addition, data previously presented in the *RWHAP Supplemental Client-Level Data Report: Eligible Metropolitan Areas and Transitional Grant Areas, 2014* have been incorporated into this report (Tables 10b, 11b-i through 11b-iii, 12c, 13c).

Gender identity and transmission risk categories

This is the first report that implements the “two-step method” for determining current gender identity [3, 4]. During 2010–2013 data collection, the RSR collected *current gender*, with the options of male, female, and transgender; a subsequent *transgender type* variable captured female-to-male, male-to-female, or transgender unknown. In 2014, the RSR began collecting gender data using a two-step method: *sex assigned at birth* (male or female) was added and the *current gender* variable was replaced with *current gender identity* (male, female, transgender); the *transgender type* variable remained intact. For data analysis purposes, *current gender identity* and *transgender type* were used for 2014 data, consistent with the 2010–2013 method of reporting gender. The additional information gleaned from *sex assigned at birth* was not incorporated in 2014 in order for HAB to evaluate the quality of the new data and determine the most appropriate methodology for data analysis. Therefore, in this report, gender data displayed for 2011–2014 reflect only the *current gender* and *transgender type* variables. The 2015 data follow the two-step method for assigning gender identity, which takes into account *sex assigned at birth*, *current gender identity*, and *transgender type*.

In addition, transmission risk categories for transgender clients have been modified to be more reflective of the transgender experience of transmission risk, while continuing to follow a relative hierarchy of likelihood for transmission. Transmission risk category data for transgender clients are now presented as follows: sexual contact; injection drug use; sexual contact *and* injection drug use; perinatal infection; other. For more details, see Technical Notes section on Presentation of Data.

New to this report is the inclusion of transmission risk category data stratified by gender in all tables (i.e., male, female, transgender). This change necessitated that all tables presented by transmission risk category be separated into 3 tables (Tables 4a/b/c, 11a-i through 11b-iii).

Clients who reported transmission from the receipt of transfusion of blood, blood components, or tissue, or clients who report hemophilia/coagulation disorder, are classified as *other* transmission risk. Beginning with 2014 data collection, unknown transmission risk factor was no longer included in the classification of *other* transmission risk. All analyses in this report have been adjusted for consistency during 2011 through 2015 to only include blood transfusion or hemophilia/coagulation disorder.

HIGHLIGHTS OF ANALYSES

Ryan White HIV/AIDS Program Clients

The RWHAP serves over half a million people each year. In 2015, 533,036 clients received services from RWHAP-funded providers (Table 1a). Among all clients served in 2015, 97.0% (516,980) were living with HIV (Table 1b), an increase from 92.5% (512,911 out of 554,646) in 2011.

The RWHAP client population is aging. In 2015, people aged 50 years and older accounted for 42.5% of all RWHAP clients, an increase from 33.6% of clients in 2011. In total, this amounts to an increase of over 40,000 clients aged 50 years and older during this time (Table 1a; data not shown).

Nearly three-quarters of RWHAP clients are from racial/ethnic minority populations. In 2015, 47.1% of clients self-identified as black/African American, 22.7% Hispanic/Latino, and less than 2% each American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, and persons of multiple races (Table 1a). Whites accounted for 26.9% of clients. The percentage distribution has remained consistent since 2011.

The majority of RWHAP clients are male. In 2015, 71.3% of clients were male, 27.6% were female, and 1.1% were transgender (Table 1a).

Socioeconomic Factors and Health Care Coverage

Nearly two-thirds of RWHAP clients are living at or below 100% of the federal poverty level (FPL). In 2015, 65.4% of clients were living \leq 100% FPL.

More female and transgender clients are living below poverty than male clients. Among the 139,884 females with poverty level information in 2015, 74.7% (104,454) were living \leq 100% FPL. Among the 5,707 transgender individuals with poverty level information in 2015, 79.8% (4,553) were living \leq 100% FPL (Table 5; percentages presented in table are column percentages, while those presented here are row percentages).

Nearly 80% of RWHAP clients are covered by some form of health care coverage. Among all RWHAP clients in 2015, 32.8% were covered by Medicaid, 10.4% were covered by Medicare, and 10.4% had multiple forms of coverage (multiple coverages includes any combination of health care coverage types, except those who had Medicaid and Medicare, which is displayed separately. See Technical Notes for additional information. Table 1a). One-fifth (20.7%) of RWHAP clients had no health care coverage in 2015 (Table 1a), a decrease from 25.4% in 2014.

Approximately 10% of RWHAP clients have temporary housing, and 5% have unstable housing situations (Table 1a). Within each age group, the highest percentages of temporary or unstable housing were among those aged 20–24 (14.0%, 7.9% respectively), 25–29 (12.8%, 8.0%), and 30–34 (11.7%, 7.5%) years (Table 6).

- Among males, 10.2% had temporary housing and 6.3% had unstable housing; the highest percentages of temporary or unstable housing were among those with the following transmission risk categories: injection drug use (13.9%, 12.6%) and MSM contact *and* injection drug use (13.9%, 16.3%).
- Among females, 8.5% had temporary housing and 4.6% had unstable housing; the highest percentages of temporary or unstable housing were among females who injected drugs (12.0%, 9.2%).
- Among transgender individuals, 14.5% had temporary housing and 15.6% had unstable housing; the highest percentages of temporary or unstable housing were among transgender individuals who reported sexual contact *and* injection drug use (18.6%, 27.1%; Table 6; note: percentages presented in table are column percentages, while those presented here are row percentages). Given the low numbers within transmission risk subgroups among transgender clients, caution should be used in interpreting percentages in Tables 6.

RETENTION IN CARE AND VIRAL SUPPRESSION HIGHLIGHTS

Retention in HIV Medical Care

Retention in HIV medical care was defined as PLWH who had at least 1 outpatient ambulatory medical care (OAMC) visit by September 1 of the measurement year, with a second visit at least 90 days after.

The percentages of people retained in care were relatively consistent across years during 2011 through 2015. During 2015, 80.6% of 327,075 clients were retained in HIV care (Table 12a).

Across subpopulations, retention in care was generally consistent with the overall average; however, a few subpopulations had lower retention percentages (by at least 5 percentage points), most notably: clients aged 20–24 years (74.7%) and 25–29 years (74.1%); American Indian/Alaska Natives (74.6%); clients with Veterans Administration (74.7%) and Indian Health Service (68.4%) health care coverage; and clients with unstable housing (73.2%; Table 12a).

Viral Suppression

Viral suppression was based on data for PLWH who had at least 1 OAMC visit and at least 1 viral load test during the measurement year. Viral suppression is defined as a most recent viral load test result of <200 copies/mL.

More than 83% of RWHAP clients achieved viral suppression in 2015. During 2015, 83.4% of 340,085 clients had a suppressed viral load at their most recent test (Table 13a). During 2011 through 2015, the overall percentage of clients with viral suppression increased by 11 percentage points, from 72.6% in 2011 to 83.4% in 2015.

Young people aged 15–24 continue to have the lowest percentages of viral suppression across age groups. In 2015, clients aged 15–19 years (68.9%) and 20–24 years (68.3%) had the lowest percentages of viral suppression by age group (Table 13a). However, these percentages reflect a 17 percentage point increase for clients aged 15–19 and a 19 percentage point increase for those aged 20–24 from 2011 through 2015. Although great increases have been achieved, disparities remain.

Transgender women (transgender male-to-female clients) have the lowest percentages of viral suppression across gender subpopulations. In 2015, 77.0% of transgender women had achieved viral suppression (Table 13a), which reflects a 12 percentage point increase from 2011 through 2015.

Clients with unstable housing have lower percentages of viral suppression than clients with stable or temporary housing. In 2015, 69.3% of clients with unstable housing achieved viral suppression, compared to 78.4% of clients with temporary housing and 84.6% of clients with stable housing (Table 13a).

Retention in Care and Viral Suppression among Key Populations

This section highlights overall retention in care and viral suppression for each key population and highlights the subpopulations for which the most improvement is needed. Generally, this includes subpopulations with outcomes at least 5 percentage points lower than that of the overall key population. Data for subpopulations with very small numbers (<100) are not included in the highlights due to the variability in percentages resulting from small numbers.

Black/African American women (Tables 14a/b): Overall, the percentages of black/African American women who were retained in care (82.2%) and virally suppressed (80.6%) were relatively consistent with the national RWHAP averages (80.6% and 83.4%, respectively).

Retention in care was lower for black/African American women aged 25–29 years (75.3%) and 30–34 years (76.8%); those in HHS Regions 6 and 9 (75.3%, and 71.5%, respectively, see Technical Notes for states/territories included in each region); and those with unstable housing (77.1%).

Percentages of viral suppression among black/African American women were lower among those in each 5-year age group from 13–34 years (range: 61.8%–73.6%); those who were perinatally infected (63.6%); those in Region 6 (74.9%); and those with temporary (74.8%) and unstable (69.3%) housing.

Black/African American men (Tables 15a/b): The overall percentage of black/African American men who were retained in care (78.6%) was relatively consistent with the national RWHAP average (80.6%), while the percentage who achieved viral suppression was slightly lower (78.9%) than the average (83.4%).

Retention in care was lowest among black/African American men aged 25–29 years (72.5%); those in Regions 6, 9, and 10 (72.1%, 66.7%, and 71.5%, respectively); and those with unstable housing (72.0%).

Viral suppression was lowest among those in each 5-year age group from 15–34 years (range: 65.0%–73.4%); those who were perinatally infected (63.8%); those with no health care coverage (71.0%); and those with temporary (73.5%) and unstable (67.6%) housing.

Hispanic/Latino women (Tables 14a/b): Overall, Hispanic/Latino women had a higher retention in care percentage (86.6%) than the national RWHAP average (80.6%); viral suppression (85.2%) was relatively consistent with the national RWHAP average (83.4%).

Retention in care was lowest among clients aged 20–24 years (77.7%) and 25–29 years (79.9%); those in Regions 9 (79.4%) and 10 (80.0%); those with private individual insurance (79.6%); and those with unstable housing (80.0%).

The lowest percentages of viral suppression were among clients in each 5-year age group from 20–34 years (range: 68.0%–80.2%); those who were perinatally infected (68.3%); and those with unstable housing (75.3%).

Hispanic/Latino men (Tables 15a/b): Overall, for Hispanic/Latino men, retention in care (82.4%) was consistent with the national RWHAP average (80.6%); viral suppression (85.9%) was higher than the national RWHAP average (83.4%).

Retention in care was lowest among clients aged 20–24 years (75.6%) and 25–29 years (76.4%), those in Region 9 (76.3%); those with private individual insurance (72.4%); and those with unstable housing (75.5%).

Viral suppression was lowest among clients aged 15–19 years (76.0%), 20–24 years (72.5%), and 25–29 years (79.2%), those who were perinatally infected (67.3%); and those with unstable housing (69.4%).

Transgender adults and adolescents (Tables 16a/b): Overall, retention in care (78.7%) for transgender adults and adolescents was consistent with the national RWHAP average (80.6%), while viral suppression (77.3%) was lower than the average (83.4%).

Retention in care was lowest among those aged 20–24 years (73.0%) and 25–29 years (73.2%); those in Regions 6 (67.9%) and 9 (72.3%); those with private employer insurance (71.7%) and private individual insurance (70.3%); and those with unstable housing (69.6%).

Viral suppression was lowest among clients aged 20–24 years (60.6%), 25–29 years (67.7%), and 30–34 years (72.3%); those in Region 6 (70.3%); and those with temporary (68.8%) or unstable housing (63.9%). Generally, transgender blacks/African Americans had lower percentages of viral suppression across all other demographic subgroups compared to transgender Hispanic/Latinos and whites.

Given the low numbers within the various subpopulations for transgender adults and adolescents, caution should be used in interpreting the percentages in Tables 16a/b.

Gay, bisexual, and other men who have sex with men (MSM; Tables 15a/b): Overall, retention in care for MSM (79.7%) and for MSM who also inject drugs (79.4%) was consistent with the national RWHAP average; viral suppression was also consistent with the national RWHAP average for both subpopulations (84.7% and 82.0%, respectively).

For MSM, by race/ethnicity, retention in care was lowest among American Indian/Alaska Natives (74.6%) and Native Hawaiians/Pacific Islanders (73.3%).

For MSM, the lowest percentage of viral suppression was among blacks/African Americans (77.7%) among MSM who also inject drugs, viral suppression was relatively consistent across race/ethnicity subgroups.

Youth aged 13–24 years (Tables 17a/b): Among youth overall, retention in care (76.3%) was lower than the national RWHAP average (80.6%) and viral suppression (68.6%) was much lower than the average (83.4%).

The lowest percentages of retention in care were among young MSM who also inject drugs (69.3%) and male youth reporting heterosexual contact (67.6%); youth living in Regions 9 (65.6%) and 10 (70.9%); youth with private individual insurance (70.6%) and Medicare coverage (69.1%); and youth with unstable housing (66.6%).

Viral suppression was lowest among transgender youth (60.6%); young males who inject drugs (59.1%), young MSM who also inject drugs (60.7%), and transgender youth reporting sexual contact (61.7%); youth with no health care coverage (62.8%); and youth with unstable housing (58.1%).

Given the low numbers within the various subpopulations for youth, especially transgender youth, caution should be used in interpreting the percentages in Tables 17a/b.

Young black/African American MSM, aged 13–24 years (YBMSM; Tables 18a/b): Overall, retention in care for YBMSM (74.6%) was lower than the national RWHAP average (80.6%) but consistent with the average for young MSM overall (74.9%). Viral suppression for YBMSM (66.9%) was lower than the national RWHAP average (83.4%) and slightly lower than the average for young MSM overall (69.9%).

The lowest percentages of retention in care for YBMSM were among those in Regions 6, 7, and 9 (64.9%, 68.4%, and 52.1%, respectively) and among those with unstable housing (66.3%).

Viral suppression for YBMSM was lowest among those in Regions 6 (59.5%) and 9 (54.4%), those with no health care coverage (61.2%), and those with temporary (59.7%) and unstable housing (58.5%).

Given the low numbers within the various subpopulations of young MSM and young black MSM, caution should be used in interpreting the percentages in Tables 18a/b.

Young black/African American women, aged 13–24 years (Tables 19a/b): Overall, retention in care for young black/African American women (80.8%) was consistent with the national RWHAP average (80.6%) and with the average for young women overall (80.1%). Viral suppression for young black/African American women (63.6%) was lower than the national RWHAP average (83.4%) and slightly lower than the average for young women overall (66.7%).

The lowest percentages of retention in care for young black/African American women were among those in Regions 6 (73.4%) and 9 (70.0%); among those with no health care coverage (74.5%); and among those with temporary (74.1%) and unstable housing (75.0%)

Viral suppression for young black/African American women was lowest among those in Region 6 (57.1%), those with no health care coverage (58.3%), and those with temporary (58.4%) and unstable housing (58.7%).

Given the low numbers within the various subpopulations of young women and young black/African American women, caution should be used in interpreting the percentages in Tables 19a/b.

People who inject drugs (PWID; Tables 20a/b): Overall, for PWID, retention in care (82.3%) and viral suppression (82.8%) were consistent with the national RWHAP averages. Across all races/ethnicities, retention in care was generally lower among younger age groups and increased as age groups increased. Overall, PWID with the lowest percentages were in Regions 6 (74.1%), 9 (75.4%) and 10 (71.6%); those with no health care coverage (71.9%); and those with temporary (76.5%) and unstable housing (73.8%).

Viral suppression among PWID followed similar patterns to retention in care, with the lowest percentages among the younger age groups, and increased as age group increased. In addition, the lowest percentages of viral suppression among PWID were in Region 6 (77.7%), those with no health care coverage (73.3%), and those with unstable housing (67.3%).

PWID data are based on clients who reported “injection drug use” as their transmission risk category and may not be reflective of current behavior.

TECHNICAL NOTES

RYAN WHITE HIV/AIDS PROGRAM DATA

The Ryan White HIV/AIDS Services Report (RSR) is the U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), HIV/AIDS Bureau's (HAB) primary source of annual, client-level data collected from more than 2,000 grant recipients and subrecipients. These data are used to assess the number and type of clients receiving services and the quality of the care. Client-level RSR data have been used since 2010. Each year, grant recipients and subrecipients that use Ryan White HIV/AIDS Program (RWHAP) funds to provide core medical or support services during the reporting period are required to submit data to HAB in a specified format [5].

This report includes data reported to the RSR for all clients served by the RWHAP Parts A–D during calendar years 2011 through 2015. Beginning with the 2015 calendar year data collection period, recipients and subrecipients reported data for all clients who met the recipient's eligibility requirements for RWHAP participation (which varies by recipient based on criteria such as HIV status, income, and residency) and received at least one of the core medical or support services for which the recipient or subrecipient receives RWHAP funding, regardless of the actual funding used to pay for the services (i.e., some services may have been paid for by sources other than RWHAP). RSR data do not include information about the AIDS Drug Assistance Program (ADAP), as this information is collected through another data system. Although data presented in this report are “non-ADAP,” many clients in the RSR data also receive ADAP services.

After removal of personal identifying information, recipients and subrecipients submitted data to HAB. Data were reported by RWHAP grant recipients and subrecipients in 50 states, the District of Columbia, and 3 territories: Guam, Puerto Rico, and the U.S. Virgin Islands. The 5 U.S. Pacific Territories or Associated Jurisdictions do not submit client-level data and are therefore not included in this report.

RSR data include de-identified client-level information about people who received services from an RWHAP-funded provider. Clients of the RWHAP include people living with HIV (PLWH), as well as people who are affected by HIV (e.g., families of PLWH served by the RWHAP). The families of PLWH are able to receive certain services by Part D of the RWHAP. The data presented in Table 1a and Tables 2 through 11b-iii include all RWHAP clients, regardless of HIV serostatus. Table 1b and tables displaying retention in care and viral suppression (Tables 12a through 20b) include only PLWH.

PRESENTATION OF DATA

The data in this report include information received by HAB for clients served during calendar years 2011 through 2015. Data are organized into 3 sections:

- Section 1 (Tables 1–8): numbers and percentages of clients served by the RWHAP (non-ADAP), presented by selected demographic stratifications
- Section 2 (Tables 9a–11b-iii): numbers and percentages of clients served by the RWHAP (non-ADAP), presented by state and Eligible Metropolitan Area (EMA)/Transitional Grant Area (TGA)
- Section 3 (Tables 12a–20b): retention in care and viral suppression among clients served by the RWHAP (non-ADAP), presented by selected demographics, state, EMA/TGA, and priority population

Tables 1–3 and 5–8 display subtotals for each subpopulation, as well as the overall total. Subtotals are displayed to reflect the denominator used for the percentage calculation of each subpopulation. Due to missing data, the values in each column may not sum to the column total.

Age Group

RWHAP grant recipients and subrecipients report client birth year. This information is then used to calculate the client's age during the designated year as a discrete variable. For tables displaying age groups (Tables 1–8, 12a, 13a, 14a–16b, and 20a/b), client ages were categorized to align with the Centers for Disease Control and Prevention's (CDC) National HIV Surveillance System (NHSS) age group delineations: <13 years (if applicable), 13–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, and ≥65 years.

The designation “adults and adolescents” refers to clients aged 13 years and older. In Table 9, data are displayed separately for adults and adolescents and for children (aged less than 13 years).

Tables displaying retention in care and viral suppression for key populations (Tables 14a–20b) include clients aged 13 years and older (i.e., adults and adolescents) only. Tables 17a–19b focus more narrowly on youth and young adults aged 13–24 years.

Race/Ethnicity

Recipients and subrecipients report race/ethnicity information for RWHAP clients according to Office of Management and Budget standards. Race and ethnicity are submitted as separate variables and combined for analysis. The race/ethnicity variable is categorized as American Indian or Alaska Native, Asian, black or African American, Hispanic or Latino, Native Hawaiian or other Pacific Islander, white, and multiple races (2 or more categories of race reported).

In this report, clients categorized by race were not Hispanic or Latino; the number of clients reported in each race category may, however, include clients whose ethnicity was not reported.

RWHAP grant recipients and subrecipients are expected to make every effort to obtain and report race and ethnicity, based on each client's self-report. Self-identification is the preferred means of obtaining this information.

Gender

Gender designations in this report are male, female, or transgender. Transgender is an umbrella term used to identify persons whose sex assigned at birth does not match current gender identity or expression. Transgender clients are subsequently classified as male-to-female (MTF), female-to-male (FTM), or transgender unknown. Gender-related data are based on client self-report.

During 2010 through 2013, the RSR required reporting of *current gender*, with the options of male, female, and transgender; a subsequent *transgender type* variable captured female-to-male, male-to-female, or transgender unknown. In 2014, the RSR began requiring that gender be reported using a two-step method: *sex assigned at birth* (male or female) was added and the *current gender* variable was replaced with *current gender identity* (male, female, transgender); the *transgender type* variable remained intact.

Gender data displayed for 2011–2014 reflect only the *current gender* and *transgender type* variables. The additional information gleaned from *sex assigned at birth* was not incorporated for 2014 analyses in order for HAB to evaluate the quality of the data for that variable and to determine the methodology for data analysis. The 2015 data included in this report implement for the first time the two-step method for determining gender identity, which takes into account *sex assigned at birth*, *current gender identity*, and *transgender type*.

Transmission Risk Category

Transmission risk category is the term for the classification that summarizes a client's possible HIV risk factors; the summary classification results from selecting, from a presumed hierarchical order of probability, the single risk factor most likely to have been responsible for transmission.

For tables displaying data for all clients served by RWHAP (Table 1a and Tables 2 through 11b-iii), transmission risk category data include clients who are known to be living with HIV and those who have unknown HIV serostatus (i.e., children with indeterminant serostatus and other clients with transmission risk factors for HIV but missing HIV serostatus data).

Transmission risk categories are presented separately by gender (i.e., male, female, transgender).

- For male clients, transmission risk categories include male-to-male sexual contact, injection drug use, male-to-male sexual contact *and* injection drug use, heterosexual contact, perinatal infection, and other.
- For female clients, transmission risk categories include heterosexual contact, injection drug use, perinatal infection, and other.
- For transgender clients, transmission risk categories have been modified to be more reflective of the transgender experience of transmission risk, while continuing to follow a relative hierarchy of likelihood for transmission. That is, transmission risk category data for transgender clients are presented as sexual contact, injection drug use, sexual contact *and* injection drug use, perinatal infection, and other.

The definitions of transmission risk categories are adapted from CDC's NHSS definitions for transmission categories [6]. Clients with more than one reported risk factor are classified in the transmission risk category listed first in the hierarchy. The only exceptions are (1) men who had sexual contact with other men and who injected drugs and (2) perinatal infection; these groups make up separate transmission risk categories. The risk categories are defined, in order of the hierarchy, as follows:

- *Male-to-male sexual contact*: Male clients who report sexual contact with other men (i.e., homosexual contact) and males who report sexual contact with both men and women (i.e., bisexual contact).
- *Injection drug use*: Clients who report use of drugs intravenously or through skin-popping.
- *Male-to-male sexual contact and injection drug use*: Male clients who report sexual contact with other men, or sexual contact with both men and women, *and* report the use of drugs intravenously or through skin-popping.
- *Heterosexual contact*: Clients who report specific heterosexual contact with an individual with, or at increased risk for, HIV infection (e.g., a person who injects drugs).
- *Perinatal infection*: This category is exclusively for infants and children with infection attributed to perinatal transmission/mother-to-child transmission. This category includes clients born after 1980 who are known to be living with HIV and whose infection is attributed to perinatal transmission, as well as infants with indeterminant serostatus.
- *Other*: Clients who report transmission from the receipt of transfusion of blood, blood components, or tissue; clients who report hemophilia/coagulation disorder. Beginning with 2014 data collection, unknown risk factor was no longer included in the classification of *other* transmission risk, nor collected as a separate category for the RSR. All analyses in this report have been adjusted for consistency during 2011 through 2015 to only include blood transfusion or hemophilia/coagulation disorder.

For transgender clients, the following transmission risk category hierarchy is used:

- *Sexual contact*: Transgender clients who report any sexual transmission risk.
- *Injection drug use*: Transgender clients who report use of drugs intravenously or through skin-popping.

- *Sexual contact and injection drug use*: Transgender clients who report sexual contact *and* report the use of drugs intravenously or through skin-popping.
- *Perinatal infection*: as above.
- *Other*: as above.

Tables 18a/b display retention in care and viral suppression among young men who have sex with men (MSM). These tables include clients with infection attributed to male-to-male sexual contact as well as male-to-male sexual contact *and* injection drug use. Tables 20a/b display retention in care and viral suppression among people who inject drugs (PWID). These tables include only those clients whose reported transmission risk category is injection drug use; male clients with male-to-male sexual contact *and* injection drug use and transgender clients with sexual contact *and* injection drug use as their transmission risk category are not included.

It is important to note that data by transmission risk category presented in this report are based on the reported risk factor *most likely to have been responsible for the original transmission of HIV*; data may not be reflective of current behavior (e.g., injection drug use).

Poverty Level

Poverty level characterizes the client's income in terms of the percent of the federal poverty level (FPL) [7, 8] at the end of the reporting period. For 2011–2013, poverty levels were categorized as 0–100% FPL, 101–200% FPL, 201–300% FPL, >300% FPL. For 2014 and 2015, poverty levels were categorized as 0–100% FPL, 101–138% FPL, 139–250% FPL, 251–400% FPL, >400% FPL.

Health Care Coverage

RWHAP grant recipients and subrecipients are asked to report all sources of health care coverage that each client had for any part of the reporting period. These data are further categorized for analysis. In 2011 through 2013, health care coverage was categorized as private only, Medicare only, Medicaid only, other public, other private, multiple coverages, and no coverage (uninsured).

The categorization schema was changed in the 2014 RSR to include a more granular classification of health care coverage. For 2014 and 2015, health care coverage was categorized as private employer, private individual, Medicare, Medicaid, Medicare and Medicaid, Veterans Administration, Indian Health Service, other plan, multiple coverages, and no coverage. The Medicaid classification also includes the Children's Health Insurance Program (CHIP) and other public state health care coverage programs.

Housing Status

The housing status variable captures the client's housing status at the end of the reporting period and is categorized as stable permanent housing, temporary housing, or unstable housing. The definitions for each of these categories is based on the Housing Opportunities for Persons with AIDS (HOPWA) Program Annual Progress Report (APR) Measuring Performance Outcomes: form HUD-40110-C and the McKinney-Vento Act, Title 42 US Code, Sec. 11302, General definition of homeless individual [9, 10].

Region

HHS uses 10 geographic designations for classifying regions of the United States, which encompass all states and territories. The classification of states and territories within these regions is as follows:

- **Region 1**: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont
- **Region 2**: New Jersey, New York, Puerto Rico, U.S. Virgin Islands

- **Region 3:** Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia
- **Region 4:** Alabama, Georgia, Florida, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee
- **Region 5:** Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin
- **Region 6:** Arkansas, Louisiana, New Mexico, Oklahoma, Texas
- **Region 7:** Iowa, Missouri, Nebraska, Kansas
- **Region 8:** Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming
- **Region 9:** Arizona, California, Hawaii, Nevada, Guam
- **Region 10:** Alaska, Idaho, Oregon, Washington

The 5 U.S. Pacific Territories or Associated Jurisdictions are included in Region 9; however, these jurisdictions do not submit client-level data and are therefore not included in this report.

State

State data are displayed in Tables 9a, 10a, 11a-i/ii/iii, 12b, and 13b. State level analyses include data submitted by all Parts of the RWHAP. In addition, state delineation of data is based on provider location, rather than client location. Clients receiving services in multiple states were not included in state-specific totals; these clients make up less than 2% of the total RWHAP population.

Eligible Metropolitan Areas (EMAs) and Transitional Grant Areas (TGAs)

Part A of the RWHAP provides emergency assistance to EMAs and TGAs that are most severely affected by the HIV epidemic. To qualify for EMA status, an area must have reported at least 2,000 AIDS cases in the most recent 5 years and have a population of at least 50,000. To be eligible for TGA status, an area must have reported 1,000–1,999 AIDS cases in the most recent 5 years and have a population of at least 50,000. EMAs and TGAs range in size from one city or county to more than 26 different geographic entities; 11 include parts of more than one state.

The boundaries of EMAs and TGAs are based on the U.S. Census Bureau delineation of the metropolitan statistical area at the time of first eligibility. Client-level data are reported based on provider location, rather than client location. It is important to note that data shown for EMAs and TGAs are not mutually exclusive; clients may have received services from providers in multiple EMAs and TGAs.

Table 10b displays EMA and TGA data by race/ethnicity. To protect the confidentiality of clients, all values less than 5 were suppressed. In addition, all data on clients of multiple races have been suppressed. The Total column, on which percentages were based, includes all clients with reported race/ethnicity information.

For Tables 12c and 13c, EMA and TGA subtotals and the total for all EMAs/TGAs combined were calculated. These calculations were performed independently of the values for each of the individual EMAs and TGAs and include de-duplicated counts of clients receiving services in the EMAs and TGAs. Therefore, the values in each column do not sum to the column subtotals and total.

Retention in Care and Viral Suppression

Retention in HIV medical care was defined as PLWH who had at least 2 medical visit dates that were at least 90 days apart in the measurement year. Because the datasets are restricted to 1 calendar year of data each, the first of these HIV medical care visits in the year must have occurred before September 1 of the measurement year, thus giving the client an opportunity to meet the retention criteria by December 31.

Viral suppression was based on data for PLWH who had at least 1 OAMC visit and at least 1 viral load test during the measurement year. Viral suppression was defined as the most recent reported HIV RNA level <200 copies/mL in the calendar year.

Key Populations

While anyone can become infected with HIV, all people and communities are not impacted equally. HAB has enhanced its efforts to focus on communities where HIV is most concentrated.

The key populations include women; transgender individuals with a focus on women; gay, bisexual, and other MSM; blacks/African Americans; Hispanics/Latinos; youth; young, black/African American MSM; young, black/African American women; and people who inject drugs. Tables 14a through 20b display retention in care (“a” tables) and viral suppression (“b” tables) for these key populations.

REFERENCES

1. National HIV/AIDS Strategy for the United States, Updated to 2020. Available from: <https://www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf>.
2. National HIV/AIDS Strategy for the United States, Updated to 2020: Indicator Supplement. Available from: https://www.whitehouse.gov/sites/default/files/docs/nhas_2020_indicator_supplement_8-15.pdf.
3. Mulatu MS, Wang G, Zhang H, Begley E, Wan C, Gilford J. HIV testing, seropositivity, and linkage to care among transgender persons in CDC-funded sites in the U.S., 2012: Effects of improved data collection. National Transgender Health Summit, April 17-18, 2015, Oakland, CA.
4. The GenIUSS Group. Best Practices for Asking Questions to Identify Transgender and Other Gender Minority Respondents on Population-Based Surveys. J.L. Herman (Ed.). Los Angeles, CA: The Williams Institute, September 2014. Available from: <http://williamsinstitute.law.ucla.edu/wp-content/uploads/geniuss-report-sep-2014.pdf>.
5. Health Resources and Services Administration. Data Reporting Requirements and Technical Assistance. Available from: <http://hab.hrsa.gov/manageyourgrant/reportingrequirements.html>.
6. Centers for Disease Control and Prevention. HIV Surveillance Report, 2014; vol. 26. <http://www.cdc.gov/hiv/library/reports/surveillance>. Published November 2015.
7. Federal Register, Annual Update of the HHS Poverty Guidelines. Available from: <https://www.federalregister.gov/documents/2015/01/22/2015-01120/annual-update-of-the-hhs-poverty-guidelines>.
8. US Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. 2015 Poverty Guidelines. Available from: <https://aspe.hhs.gov/2015-poverty-guidelines#guidelines>.
9. McKinney-Vento Act, Title 42 US Code, Sec. 11302, General definition of homeless individual.
10. Housing Opportunities for Persons with AIDS (HOPWA) Program, Annual Progress Report (APR), Measuring Performance Outcomes, form HUD-40110-C.

ADDITIONAL RESOURCES

AIDS.gov, the nation's source for timely and relevant federal HIV policies, programs, and resources
Centers for Disease Control and Prevention, HIV prevention resources <http://www.cdc.gov/hiv>
Health Resources and Services Administration, HIV/AIDS programs <http://hab.hrsa.gov>
TARGET Center, tools for the Ryan White Community <https://careacttarget.org>

Table 1a. Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2011–2015—United States and 3 territories

	2011		2012		2013		2014		2015	
	No.	%	No.	%	No.	%	No.	%	No.	%
Age group (yr)										
<13	10,824	2.0	8,481	1.6	6,515	1.2	6,571	1.3	6,088	1.1
13–14	1,540	0.3	1,254	0.2	1,035	0.2	863	0.2	735	0.1
15–19	7,979	1.4	6,411	1.2	5,853	1.1	5,443	1.1	4,511	0.9
20–24	26,002	4.7	24,800	4.6	24,701	4.7	23,260	4.5	21,991	4.1
25–29	37,539	6.8	37,504	7.0	39,014	7.4	39,761	7.8	42,698	8.0
30–34	47,243	8.5	46,111	8.6	45,498	8.7	43,915	8.6	46,003	8.6
35–39	54,537	9.8	51,008	9.5	49,327	9.4	47,682	9.3	50,459	9.5
40–44	80,113	14.4	72,407	13.5	65,287	12.4	58,589	11.4	56,228	10.6
45–49	102,460	18.5	95,254	17.8	88,035	16.8	79,175	15.5	77,778	14.6
50–54	86,190	15.5	86,599	16.2	87,265	16.6	86,807	17.0	90,442	17.0
55–59	55,391	10.0	57,434	10.7	59,501	11.3	61,645	12.0	68,082	12.8
60–64	27,587	5.0	29,991	5.6	31,948	6.1	34,944	6.8	39,676	7.4
≥65	17,226	3.1	18,946	3.5	20,693	3.9	23,361	4.6	28,258	5.3
Subtotal	554,631	100.0	536,200	100.0	524,672	100.0	512,016	100.0	532,949	100.0
Race/ethnicity										
American Indian/Alaska Native	2,796	0.5	2,645	0.5	2,629	0.5	2,375	0.5	2,461	0.5
Asian	5,341	1.0	5,687	1.1	5,868	1.1	5,873	1.2	6,738	1.3
Black/African American	255,645	47.3	245,828	46.7	242,593	46.8	239,537	47.2	248,886	47.1
Hispanic/Latino ^a	118,800	22.0	119,676	22.7	116,862	22.6	112,833	22.2	120,254	22.7
Native Hawaiian/Pacific Islander	1,143	0.2	941	0.2	935	0.2	852	0.2	856	0.2
White	150,466	27.8	144,245	27.4	140,810	27.2	136,949	27.0	142,349	26.9
Multiple races	6,591	1.2	7,224	1.4	8,211	1.6	9,143	1.8	7,303	1.4
Subtotal	540,782	100.0	526,246	100.0	517,908	100.0	507,562	100.0	528,847	100.0
Gender										
Male	382,984	69.1	375,267	70.0	370,140	70.6	361,323	70.6	379,173	71.3
Female	166,711	30.1	155,752	29.1	149,152	28.4	144,982	28.3	146,623	27.6
Transgender	4,718	0.9	5,027	0.9	5,172	1.0	5,467	1.1	6,020	1.1
Subtotal	554,413	100.0	536,046	100.0	524,464	100.0	511,772	100.0	531,816	100.0
Transmission risk category										
Male client										
Male-to-male sexual contact	191,161	59.5	196,670	60.7	203,044	61.7	202,802	62.2	217,380	63.2
Injection drug use	29,705	9.3	27,578	8.5	26,620	8.1	24,034	7.4	23,570	6.8
Male-to-male sexual contact and injection drug use	10,796	3.4	11,092	3.4	10,843	3.3	11,004	3.4	10,321	3.0
Heterosexual contact ^b	81,222	25.3	80,713	24.9	80,992	24.6	80,882	24.8	85,610	24.9
Perinatal infection	5,718	1.8	5,347	1.7	5,147	1.6	5,002	1.5	4,875	1.4
Other ^c	2,460	0.8	2,489	0.8	2,667	0.8	2,340	0.7	2,454	0.7
Subtotal^d	321,062	100.0	323,889	100.0	329,313	100.0	326,064	100.0	344,210	100.0
Female client										
Injection drug use	15,014	11.3	13,637	10.6	13,596	10.6	12,310	9.8	11,993	9.2
Heterosexual contact ^b	109,337	82.3	107,256	83.2	107,262	83.3	106,271	84.3	110,744	85.0
Perinatal infection	6,684	5.0	6,178	4.8	5,864	4.6	5,755	4.6	5,777	4.4
Other ^c	1,738	1.3	1,846	1.4	1,975	1.5	1,734	1.4	1,734	1.3
Subtotal^d	132,773	100.0	128,917	100.0	128,697	100.0	126,070	100.0	130,248	100.0
Transgender client										
Sexual contact ^e	3,492	90.9	3,839	91.2	4,115	92.1	4,418	92.3	4,818	92.6
Injection drug use	78	2.0	78	1.9	66	1.5	75	1.6	100	1.9
Sexual contact ^e and injection drug use	251	6.5	266	6.3	258	5.8	256	5.3	248	4.8
Perinatal infection	8	0.2	10	0.2	9	0.2	17	0.4	16	0.3
Other ^c	14	0.4	18	0.4	20	0.4	20	0.4	23	0.4
Subtotal^d	3,843	100.0	4,211	100.0	4,468	100.0	4,786	100.0	5,205	100.0

Table 1a. Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2011–2015—United States and 3 territories (cont.)

	2011		2012		2013		2014		2015	
	No.	%	No.	%	No.	%	No.	%	No.	%
Poverty level^f										
0–100%	321,865	67.2	322,347	66.7	332,247	67.6	—	—	—	—
101–200%	102,499	21.4	105,421	21.8	107,631	21.9	—	—	—	—
201–300%	31,106	6.5	32,398	6.7	33,183	6.8	—	—	—	—
>300%	23,466	4.9	22,885	4.7	18,738	3.8	—	—	—	—
Subtotal	478,936	100.0	483,051	100.0	491,799	100.0	—	—	—	—
0–100%	—	—	—	—	—	—	304,168	64.2	333,580	65.4
101–138%	—	—	—	—	—	—	57,396	12.1	60,745	11.9
139–250%	—	—	—	—	—	—	69,999	14.8	76,444	15.0
251–400%	—	—	—	—	—	—	26,420	5.6	29,061	5.7
>400%	—	—	—	—	—	—	15,500	3.3	10,388	2.0
Subtotal	—	—	—	—	—	—	473,483	100.0	510,218	100.0
Health care coverage^f										
Private only	64,269	13.1	64,947	13.0	61,934	12.4	—	—	—	—
Medicare only	44,932	9.2	44,293	8.9	44,341	8.9	—	—	—	—
Medicaid only	137,114	27.9	130,062	26.0	127,096	25.5	—	—	—	—
Other public	34,347	7.0	41,381	8.3	41,473	8.3	—	—	—	—
Other private	13,427	2.7	9,100	1.8	6,609	1.3	—	—	—	—
No coverage	133,341	27.2	137,761	27.6	138,447	27.8	—	—	—	—
Multiple coverages	63,389	12.9	72,173	14.4	78,346	15.7	—	—	—	—
Subtotal	490,819	100.0	499,717	100.0	498,246	100.0	—	—	—	—
Private employer	—	—	—	—	—	—	30,410	6.3	43,464	8.4
Private individual	—	—	—	—	—	—	25,762	5.3	37,177	7.2
Medicare	—	—	—	—	—	—	48,750	10.0	53,734	10.4
Medicaid	—	—	—	—	—	—	162,372	33.4	169,425	32.8
Medicare and Medicaid	—	—	—	—	—	—	37,617	7.7	39,709	7.7
Veterans Administration	—	—	—	—	—	—	1,302	0.3	1,475	0.3
Indian Health Service	—	—	—	—	—	—	115	0.0	214	0.0
Other plan	—	—	—	—	—	—	19,425	4.0	11,231	2.2
No coverage	—	—	—	—	—	—	123,273	25.4	107,188	20.7
Multiple coverages	—	—	—	—	—	—	37,036	7.6	53,751	10.4
Subtotal	—	—	—	—	—	—	486,062	100.0	517,368	100.0
Housing status										
Stable	400,930	82.4	403,976	83.1	404,743	83.3	402,175	83.5	434,180	85.2
Temporary	66,727	13.7	62,468	12.9	60,233	12.4	56,868	11.8	49,696	9.8
Unstable	18,657	3.8	19,702	4.1	21,001	4.3	22,702	4.7	25,633	5.0
Subtotal	486,314	100.0	486,146	100.0	485,977	100.0	481,745	100.0	509,509	100.0
Total^g	554,646	—	536,219	—	524,675	—	512,214	—	533,036	—

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia and blood transfusion.

^d Subtotals are reflective of available gender and transmission risk category information. The subtotal values for each gender-specific transmission risk category may not sum to the subtotals for each gender overall.

^e Includes any sexual transmission risk category reported by transgender clients.

^f Data collected in 2014–2015 used different categories than previous years. See Technical Notes for additional details.

^g Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 1b. Ryan White HIV/AIDS Program clients living with HIV (non-ADAP), by year and selected characteristics, 2011–2015—United States and 3 territories

	2011		2012		2013		2014		2015	
	No.	%	No.	%	No.	%	No.	%	No.	%
Age group (yr)										
<13	2,241	0.4	2,100	0.4	1,778	0.4	1,658	0.3	1,614	0.3
13–14	894	0.2	693	0.1	566	0.1	503	0.1	478	0.1
15–19	5,345	1.0	4,646	0.9	4,035	0.8	3,596	0.7	3,352	0.7
20–24	22,119	4.3	22,719	4.5	22,737	4.5	21,163	4.3	20,531	4.0
25–29	34,222	6.7	35,731	7.0	37,499	7.4	37,967	7.7	41,245	8.0
30–34	44,148	8.6	44,255	8.7	44,044	8.7	42,435	8.6	44,873	8.7
35–39	51,376	10.0	49,338	9.7	48,097	9.5	46,364	9.4	49,284	9.5
40–44	76,547	14.9	70,456	13.8	64,041	12.7	57,378	11.7	55,373	10.7
45–49	98,260	19.2	93,188	18.2	86,829	17.2	77,894	15.8	76,692	14.8
50–54	82,508	16.1	84,557	16.6	85,957	17.0	85,374	17.4	89,368	17.3
55–59	52,840	10.3	55,971	11.0	58,619	11.6	60,645	12.3	67,240	13.0
60–64	26,285	5.1	29,069	5.7	31,422	6.2	34,328	7.0	39,146	7.6
≥65	16,117	3.1	18,155	3.6	20,260	4.0	22,762	4.6	27,784	5.4
Subtotal	512,902	100.0	510,878	100.0	505,884	100.0	492,067	100.0	516,980	100.0
Race/ethnicity										
American Indian/Alaska Native	2,678	0.5	2,566	0.5	2,586	0.5	2,329	0.5	2,413	0.5
Asian	5,063	1.0	5,526	1.1	5,703	1.1	5,700	1.2	6,588	1.3
Black/African American	234,157	46.6	233,106	46.4	232,554	46.5	227,298	46.6	239,203	46.6
Hispanic/Latino ^a	109,641	21.8	112,702	22.4	112,232	22.4	109,175	22.4	117,697	22.9
Native Hawaiian/Pacific Islander	1,105	0.2	920	0.2	918	0.2	829	0.2	829	0.2
White	143,599	28.6	140,967	28.0	138,130	27.6	133,933	27.4	139,801	27.2
Multiple races	6,346	1.3	7,044	1.4	8,065	1.6	8,976	1.8	7,011	1.4
Subtotal	502,589	100.0	502,831	100.0	500,188	100.0	488,240	100.0	513,542	100.0
Gender										
Male	359,661	70.1	361,490	70.8	360,102	71.2	351,077	71.4	370,478	71.8
Female	148,557	29.0	144,372	28.3	140,549	27.8	135,352	27.5	139,608	27.1
Transgender	4,521	0.9	4,920	1.0	5,075	1.0	5,405	1.1	5,922	1.2
Subtotal	512,739	100.0	510,782	100.0	505,726	100.0	491,834	100.0	516,008	100.0
Transmission risk category										
Male client										
Male-to-male sexual contact	189,487	59.9	196,466	61.1	202,712	61.9	202,553	62.5	217,061	63.4
Injection drug use	29,534	9.3	27,358	8.5	26,559	8.1	23,974	7.4	23,502	6.9
Male-to-male sexual contact and injection drug use	10,757	3.4	11,082	3.4	10,819	3.3	10,986	3.4	10,310	3.0
Heterosexual contact ^b	80,008	25.3	80,518	25.0	80,636	24.6	80,304	24.8	85,061	24.9
Perinatal infection	3,967	1.3	3,873	1.2	3,885	1.2	3,721	1.1	3,720	1.1
Other ^c	2,445	0.8	2,483	0.8	2,660	0.8	2,336	0.7	2,450	0.7
Subtotal^d	316,198	100.0	321,780	100.0	327,271	100.0	323,874	100.0	342,104	100.0
Female client										
Injection drug use	14,918	11.6	13,586	10.7	13,571	10.7	12,253	9.9	11,870	9.2
Heterosexual contact ^b	107,644	83.4	106,977	84.1	106,541	84.1	105,095	85.0	110,125	85.8
Perinatal infection	4,849	3.8	4,727	3.7	4,625	3.7	4,560	3.7	4,660	3.6
Other ^c	1,728	1.3	1,840	1.4	1,974	1.6	1,729	1.4	1,734	1.4
Subtotal^d	129,139	100.0	127,130	100.0	126,711	100.0	123,637	100.0	128,389	100.0
Transgender client										
Sexual contact ^e	3,471	90.9	3,838	91.2	4,091	92.1	4,405	92.3	4,806	92.6
Injection drug use	77	2.0	77	1.8	65	1.5	75	1.6	99	1.9
Sexual contact ^e and injection drug use	251	6.6	265	6.3	258	5.8	256	5.4	248	4.8
Perinatal infection	7	0.2	10	0.2	9	0.2	17	0.4	16	0.3
Other ^c	14	0.4	18	0.4	20	0.5	20	0.4	23	0.4
Subtotal^d	3,820	100.0	4,208	100.0	4,443	100.0	4,773	100.0	5,192	100.0

Table 1b. Ryan White HIV/AIDS Program clients living with HIV (non-ADAP), by year and selected characteristics, 2011–2015—United States and 3 territories (cont.)

	2011		2012		2013		2014		2015	
	No.	%	No.	%	No.	%	No.	%	No.	%
Poverty level^f										
0–100%	305,197	66.7	308,988	66.1	321,772	67.1	—	—	—	—
101–200%	99,569	21.8	104,104	22.3	106,595	22.2	—	—	—	—
201–300%	30,144	6.6	31,988	6.8	32,936	6.9	—	—	—	—
>300%	22,736	5.0	22,631	4.8	18,583	3.9	—	—	—	—
Subtotal	457,646	100.0	467,711	100.0	479,886	100.0	—	—	—	—
0–100%	—	—	—	—	—	—	293,882	63.6	325,417	65.0
101–138%	—	—	—	—	—	—	56,740	12.3	60,195	12.0
139–250%	—	—	—	—	—	—	69,521	15.1	75,912	15.2
251–400%	—	—	—	—	—	—	26,230	5.7	28,878	5.8
>400%	—	—	—	—	—	—	15,411	3.3	10,290	2.1
Subtotal	—	—	—	—	—	—	461,784	100.0	500,692	100.0
Health care coverage^f										
Private only	60,660	12.9	63,749	13.2	60,979	12.5	—	—	—	—
Medicare only	43,531	9.3	43,604	9.0	43,878	9.0	—	—	—	—
Medicaid only	126,597	26.9	120,247	24.9	119,545	24.6	—	—	—	—
Other public	33,570	7.1	40,831	8.4	41,254	8.5	—	—	—	—
Other private	13,054	2.8	8,953	1.9	6,338	1.3	—	—	—	—
No coverage	130,079	27.7	134,863	27.9	136,399	28.0	—	—	—	—
Multiple coverages	62,673	13.3	71,709	14.8	78,028	16.0	—	—	—	—
Subtotal	470,164	100.0	483,956	100.0	486,421	100.0	—	—	—	—
Private employer	—	—	—	—	—	—	29,970	6.3	42,942	8.5
Private individual	—	—	—	—	—	—	25,468	5.4	36,981	7.3
Medicare	—	—	—	—	—	—	48,403	10.2	53,434	10.6
Medicaid	—	—	—	—	—	—	154,972	32.7	162,568	32.2
Medicare and Medicaid	—	—	—	—	—	—	37,549	7.9	39,664	7.8
Veterans Administration	—	—	—	—	—	—	1,291	0.3	1,444	0.3
Indian Health Service	—	—	—	—	—	—	115	0.0	206	0.0
Other plan	—	—	—	—	—	—	19,065	4.0	10,625	2.1
No coverage	—	—	—	—	—	—	120,624	25.4	104,232	20.6
Multiple coverages	—	—	—	—	—	—	36,891	7.8	53,612	10.6
Subtotal	—	—	—	—	—	—	474,348	100.0	505,708	100.0
Housing status										
Stable	383,472	82.1	390,959	82.9	394,354	83.1	392,325	83.4	426,269	85.1
Temporary	65,046	13.9	60,905	12.9	59,484	12.5	55,981	11.9	49,071	9.8
Unstable	18,417	3.9	19,547	4.2	20,793	4.4	22,368	4.8	25,397	5.1
Subtotal	466,935	100.0	471,411	100.0	474,631	100.0	470,674	100.0	500,737	100.0
Total^g	512,911	—	510,897	—	505,887	—	492,240	—	516,980	—

^a Hispanics/Latinos can be of any race.^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.^c Includes hemophilia and blood transfusion.^d Subtotals are reflective of available gender and transmission risk category information. The subtotal values for each gender-specific transmission risk category may not sum to the subtotals for each gender overall.^e Includes any sexual transmission risk category reported by transgender clients.^f Data collected in 2014–2015 used different categories than previous years. See Technical Notes for additional details.^g Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 2. Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories

	American Indian/ Alaska Native		Asian		Black/African American		Hispanic/Latino ^a		Native Hawaiian/ Pacific Islander		White		Multiple races	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Age group (yr)														
<13	16	0.7	90	1.3	4,276	1.7	945	0.8	14	1.6	604	0.4	108	1.5
13–14	3	0.1	10	0.2	528	0.2	103	0.1	2	0.2	71	0.1	13	0.2
15–19	8	0.3	53	0.8	2,984	1.2	860	0.7	5	0.6	503	0.4	76	1.0
20–24	77	3.1	306	4.5	13,373	5.4	4,519	3.8	37	4.3	3,049	2.1	421	5.8
25–29	184	7.5	638	9.5	23,742	9.5	9,146	7.6	71	8.3	7,784	5.5	754	10.3
30–34	216	8.8	788	11.7	22,278	9.0	11,500	9.6	106	12.4	10,024	7.0	681	9.3
35–39	250	10.2	856	12.7	22,280	9.0	13,840	11.5	106	12.4	11,834	8.3	835	11.4
40–44	300	12.2	1,115	16.6	24,428	9.8	15,281	12.7	107	12.5	13,842	9.7	692	9.5
45–49	411	16.7	1,055	15.7	33,031	13.3	18,927	15.7	129	15.1	22,620	15.9	1,021	14.0
50–54	426	17.3	751	11.2	39,217	15.8	19,142	15.9	122	14.3	29,010	20.4	1,146	15.7
55–59	309	12.6	487	7.2	31,730	12.8	12,961	10.8	86	10.1	21,247	14.9	804	11.0
60–64	165	6.7	312	4.6	18,690	7.5	7,319	6.1	44	5.1	12,413	8.7	462	6.3
≥65	96	3.9	277	4.1	12,329	5.0	5,711	4.8	27	3.2	9,348	6.6	290	4.0
Subtotal	2,461	100.0	6,738	100.0	248,886	100.0	120,254	100.0	856	100.0	142,349	100.0	7,303	100.0
Gender														
Male	1,789	72.8	5,274	78.4	155,078	62.5	90,338	75.3	636	74.4	117,870	82.9	5,064	70.5
Female	626	25.5	1,350	20.1	90,120	36.3	27,970	23.3	189	22.1	23,534	16.6	1,961	27.3
Transgender	41	1.7	103	1.5	3,144	1.3	1,710	1.4	30	3.5	753	0.5	155	2.2
Subtotal	2,456	100.0	6,727	100.0	248,342	100.0	120,018	100.0	855	100.0	142,157	100.0	7,180	100.0
Transmission risk category														
Male client														
Male-to-male sexual contact	1,081	65.7	3,114	67.5	72,932	52.4	51,137	61.9	446	77.2	84,070	77.2	3,161	67.5
Injection drug use	126	7.7	145	3.1	9,780	7.0	6,804	8.2	21	3.6	6,275	5.8	294	6.3
Male-to-male sexual contact and injection drug use	139	8.4	73	1.6	2,289	1.6	1,860	2.3	18	3.1	5,643	5.2	277	5.9
Heterosexual contact ^b	264	16.0	1,148	24.9	50,138	36.0	21,319	25.8	74	12.8	11,455	10.5	812	17.3
Perinatal infection	12	0.7	49	1.1	3,188	2.3	966	1.2	12	2.1	522	0.5	98	2.1
Other ^c	24	1.5	87	1.9	808	0.6	497	0.6	7	1.2	955	0.9	41	0.9
Subtotal^d	1,646	100.0	4,616	100.0	139,135	100.0	82,583	100.0	578	100.0	108,920	100.0	4,683	100.0
Female client														
Injection drug use	104	18.4	28	2.4	5,405	6.8	2,194	8.7	14	9.0	3,924	18.4	260	14.6
Heterosexual contact ^b	440	78.0	1,003	86.5	69,335	87.3	21,605	85.4	126	81.3	16,466	77.2	1,360	76.6
Perinatal infection	8	1.4	71	6.1	3,803	4.8	1,112	4.4	12	7.7	622	2.9	126	7.1
Other ^c	12	2.1	58	5.0	920	1.2	379	1.5	3	1.9	313	1.5	29	1.6
Subtotal^d	564	100.0	1,160	100.0	79,463	100.0	25,290	100.0	155	100.0	21,325	100.0	1,775	100.0
Transgender client														
Sexual contact ^e	30	81.1	81	91.0	2,600	94.0	1,379	92.7	23	92.0	542	87.1	115	91.3
Injection drug use	2	5.4	0	0.0	43	1.6	26	1.7	1	4.0	22	3.5	3	2.4
Sexual contact ^e and injection drug use	3	8.1	7	7.9	106	3.8	74	5.0	1	4.0	51	8.2	6	4.8
Perinatal infection	0	0.0	1	1.1	8	0.3	2	0.1	0	0.0	3	0.5	2	1.6
Other ^c	2	5.4	0	0.0	10	0.4	7	0.5	0	0.0	4	0.6	0	0.0
Subtotal^d	37	100.0	89	100.0	2,767	100.0	1,488	100.0	25	100.0	622	100.0	126	100.0
Total^f	2,461	—	6,738	—	248,886	—	120,254	—	856	—	142,349	—	7,303	—

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia and blood transfusion.

^d Subtotals are reflective of available gender and transmission risk category information. The subtotal values for each gender-specific transmission risk category may not sum to the subtotals for each gender overall.

^e Includes any sexual transmission risk category reported by transgender clients.

^f Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 3. Ryan White HIV/AIDS Program clients (non-ADAP), by gender and selected characteristics, 2015—United States and 3 territories

	Male		Female		Transgender MTF		Transgender FTM		Transgender unknown		Total ^a	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Age group (yr)												
<13	2,961	0.8	3,106	2.1	*	*	*	*	*	*	6,088	1.1
13–14	341	0.1	388	0.3	*	*	*	*	*	*	735	0.1
15–19	2,526	0.7	1,916	1.3	51	0.9	4	1.2	4	3.1	4,511	0.9
20–24	16,641	4.4	4,871	3.3	365	6.6	34	10.4	7	5.5	21,991	4.1
25–29	33,433	8.8	8,181	5.6	880	15.9	63	19.3	16	12.6	42,698	8.0
30–34	33,777	8.9	11,186	7.6	861	15.5	52	16.0	17	13.4	46,003	8.6
35–39	34,312	9.1	15,126	10.3	769	13.9	38	11.7	17	13.4	50,459	9.5
40–44	37,311	9.8	18,042	12.3	699	12.6	38	11.7	15	11.8	56,228	10.6
45–49	54,908	14.5	21,928	15.0	754	13.6	35	10.7	19	15.0	77,778	14.6
50–54	65,521	17.3	24,155	16.5	579	10.4	23	7.1	10	7.9	90,442	17.0
55–59	48,810	12.9	18,798	12.8	348	6.3	24	7.4	9	7.1	68,082	12.8
60–64	28,549	7.5	10,884	7.4	170	3.1	9	2.8	4	3.1	39,676	7.4
≥65	20,083	5.3	8,042	5.5	74	1.3	6	1.8	9	7.1	28,258	5.3
Subtotal	379,173	100.0	146,623	100.0	5,550	100.0	326	100.0	127	100.0	532,949	100.0
Race/ethnicity												
American Indian/Alaska Native	1,789	0.5	626	0.4	39	0.7	2	0.6	0	0.0	2,461	0.5
Asian	5,274	1.4	1,350	0.9	98	1.8	2	0.6	3	2.2	6,738	1.3
Black/African American	155,078	41.2	90,120	61.8	2,924	53.3	136	43.5	84	61.3	248,886	47.1
Hispanic/Latino ^b	90,338	24.0	27,970	19.2	1,596	29.1	74	23.6	40	29.2	120,254	22.7
Native Hawaiian/Pacific Islander	636	0.2	189	0.1	26	0.5	4	1.3	0	0.0	856	0.2
White	117,870	31.3	23,534	16.2	654	11.9	90	28.8	9	6.6	142,349	26.9
Multiple races	5,064	1.4	1,961	1.4	149	2.7	5	1.6	1	0.7	7,303	1.4
Subtotal	376,049	100.0	145,750	100.0	5,486	100.0	313	100.0	137	100.0	528,847	100.0
Transmission risk category												
Male-to-male sexual contact	217,380	63.2	—	—	—	—	—	—	—	—	217,380	45.3
Injection drug use	23,570	6.8	11,993	9.2	92	1.9	6	2.7	2	13.3	35,663	7.4
Male-to-male sexual contact and injection drug use	10,321	3.0	—	—	—	—	—	—	—	—	10,321	2.2
Heterosexual contact ^c	85,610	24.9	110,744	85.0	—	—	—	—	—	—	196,354	40.9
Perinatal infection	4,875	1.4	5,777	4.4	8	0.2	8	3.7	0	0.0	10,668	2.2
Other ^d	2,454	0.7	1,734	1.3	22	0.4	1	0.5	0	0.0	4,211	0.9
Sexual contact ^e	—	—	—	—	4,614	92.8	192	87.7	12	80.0	4,818	1.0
Sexual contact ^e and injection drug use	—	—	—	—	235	4.7	12	5.5	1	6.7	248	0.1
Subtotal	344,210	100.0	130,248	100.0	4,971	100.0	219	100.0	15	100.0	479,663	100.0
Total^f	379,173	—	146,623	—	5,553	—	327	—	140	—	533,036	—

Abbreviations: MTF, male-to-female; FTM, female-to-male.

* To ensure confidentiality, data have been suppressed.

^a Row totals include all clients in the specified subpopulation, regardless of reported gender, except for transmission risk category subpopulations. Therefore, the values in each subpopulation for age group and race/ethnicity may not sum to the row total.

^b Hispanics/Latinos can be of any race.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia and blood transfusion.

^e Includes any sexual transmission risk category reported by transgender clients.

^f Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 4a. Male clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and age group, 2015—United States and 3 territories

Age group (yr)	Male-to-male sexual contact		Injection drug use		Male-to-male sexual contact and injection drug use		Heterosexual contact ^a		Perinatal infection		Other ^b	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
<13	—	—	—	—	—	—	—	—	1,795	36.8	2	0.1
13–14	5	0.0	0	0.0	0	0.0	4	0.0	195	4.0	1	0.0
15–19	954	0.4	4	0.0	10	0.1	153	0.2	750	15.4	4	0.2
20–24	12,040	5.5	92	0.4	198	1.9	1,389	1.6	1,230	25.2	38	1.6
25–29	25,545	11.8	349	1.5	571	5.5	3,209	3.8	718	14.7	57	2.3
30–34	23,810	11.0	634	2.7	862	8.4	5,080	5.9	187	3.8	118	4.8
35–39	21,669	10.0	1,071	4.5	1,031	10.0	7,199	8.4	—	—	174	7.1
40–44	21,642	10.0	1,515	6.4	1,139	11.0	9,497	11.1	—	—	211	8.6
45–49	31,255	14.4	2,958	12.6	1,738	16.8	13,926	16.3	—	—	359	14.6
50–54	35,376	16.3	5,024	21.3	2,119	20.5	17,020	19.9	—	—	483	19.7
55–59	23,153	10.7	5,730	24.3	1,495	14.5	13,781	16.1	—	—	448	18.3
60–64	12,942	6.0	4,142	17.6	783	7.6	7,917	9.3	—	—	271	11.0
≥65	8,989	4.1	2,051	8.7	375	3.6	6,435	7.5	—	—	288	11.7
Total	217,380	100.0	23,570	100.0	10,321	100.0	85,610	100.0	4,875	100.0	2,454	100.0

^a Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^b Includes hemophilia and blood transfusion.

Table 4b. Female clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and age group, 2015—United States and 3 territories

Age group (yr)	Injection drug use		Heterosexual contact ^a		Perinatal infection		Other ^b	
	No.	%	No.	%	No.	%	No.	%
<13	—	—	—	—	1,925	33.3	4	0.2
13–14	0	0.0	10	0.0	234	4.1	1	0.1
15–19	9	0.1	343	0.3	917	15.9	4	0.2
20–24	95	0.8	2,440	2.2	1,554	26.9	27	1.6
25–29	250	2.1	5,943	5.4	894	15.5	44	2.5
30–34	509	4.2	9,166	8.3	253	4.4	83	4.8
35–39	750	6.3	12,786	11.6	—	—	126	7.3
40–44	998	8.3	15,250	13.8	—	—	169	9.8
45–49	1,942	16.2	17,719	16.0	—	—	210	12.1
50–54	2,784	23.2	18,652	16.8	—	—	305	17.6
55–59	2,469	20.6	14,113	12.7	—	—	288	16.6
60–64	1,559	13.0	8,030	7.3	—	—	208	12.0
≥65	628	5.2	6,292	5.7	—	—	265	15.3
Total	11,993	100.0	110,744	100.0	5,777	100.0	1,734	100.0

^a Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^b Includes hemophilia and blood transfusion.

Table 4c. Transgender clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and age group, 2015—United States and 3 territories

Age group (yr)	Sexual contact ^a		Injection drug use		Sexual contact ^a and injection drug use		Perinatal infection		Other ^b	
	No.	%	No.	%	No.	%	No.	%	No.	%
<13	—	—	—	—	—	—	0	0.0	0	0.0
13–14	2	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	41	0.9	0	0.0	0	0.0	0	0.0	0	0.0
20–24	312	6.5	3	3.0	8	3.2	8	50.0	1	4.4
25–29	784	16.3	9	9.0	20	8.1	7	43.8	1	4.4
30–34	773	16.0	11	11.0	25	10.1	1	6.3	0	0.0
35–39	689	14.3	6	6.0	20	8.1	—	—	5	21.7
40–44	632	13.1	7	7.0	24	9.7	—	—	1	4.4
45–49	645	13.4	15	15.0	49	19.8	—	—	2	8.7
50–54	471	9.8	15	15.0	52	21.0	—	—	7	30.4
55–59	275	5.7	24	24.0	34	13.7	—	—	2	8.7
60–64	131	2.7	7	7.0	15	6.1	—	—	3	13.0
≥65	63	1.3	3	3.0	1	0.4	—	—	1	4.4
Total	4,818	100.0	100.0	100.0	248	100.0	16	100.0	23	100.0

^a Includes any reported sexual transmission risk category reported by transgender clients.

^b Includes hemophilia and blood transfusion.

Table 5. Ryan White HIV/AIDS Program clients (non-ADAP), by poverty level and selected characteristics, 2015—United States and 3 territories

	0–100% FPL		101–138% FPL		139–250% FPL		251–400% FPL		>400% FPL	
	No.	%	No.	%	No.	%	No.	%	No.	%
Age group (yr)										
<13	4,582	1.4	402	0.7	416	0.5	183	0.6	89	0.9
13–14	477	0.1	55	0.1	76	0.1	28	0.1	9	0.1
15–19	3,184	1.0	299	0.5	310	0.4	103	0.4	52	0.5
20–24	15,569	4.7	1,900	3.1	2,359	3.1	595	2.1	154	1.5
25–29	27,568	8.3	4,020	6.6	6,206	8.1	2,269	7.8	561	5.4
30–34	29,479	8.8	4,178	6.9	6,439	8.4	2,955	10.2	805	7.8
35–39	32,465	9.7	4,940	8.1	6,813	8.9	2,964	10.2	958	9.2
40–44	35,855	10.8	5,954	9.8	7,763	10.2	3,367	11.6	1,068	10.3
45–49	48,993	14.7	8,709	14.3	10,965	14.3	4,558	15.7	1,663	16.0
50–54	56,071	16.8	11,073	18.2	13,019	17.0	4,936	17.0	2,013	19.4
55–59	41,693	12.5	8,778	14.5	10,209	13.4	3,449	11.9	1,403	13.5
60–64	22,904	6.9	5,852	9.6	6,376	8.3	2,091	7.2	931	9.0
≥65	14,740	4.4	4,585	7.6	5,493	7.2	1,563	5.4	682	6.6
Subtotal	333,580	100.0	60,745	100.0	76,444	100.0	29,061	100.0	10,388	100.0
Race/ethnicity										
American Indian/Alaska Native	1,635	0.5	278	0.5	293	0.4	117	0.4	42	0.4
Asian	3,695	1.1	828	1.4	1,227	1.6	508	1.8	223	2.2
Black/African American	168,985	51.0	25,529	42.3	29,285	38.7	10,320	35.8	2,586	25.1
Hispanic/Latino ^a	80,416	24.2	13,536	22.4	16,246	21.5	5,507	19.1	1,701	16.5
Native Hawaiian/Pacific Islander	497	0.2	96	0.2	133	0.2	68	0.2	28	0.3
White	71,610	21.6	19,321	32.0	27,639	36.5	11,970	41.6	5,650	54.8
Multiple races	4,855	1.5	754	1.3	916	1.2	307	1.1	77	0.8
Subtotal	331,693	100.0	60,342	100.0	75,739	100.0	28,797	100.0	10,307	100.0
Gender										
Male	223,879	67.3	45,914	75.7	60,709	79.5	24,121	83.1	9,050	87.2
Female	104,454	31.4	14,207	23.4	15,212	19.9	4,751	16.4	1,260	12.1
Transgender	4,553	1.4	510	0.8	423	0.6	149	0.5	72	0.7
Subtotal	332,886	100.0	60,631	100.0	76,344	100.0	29,021	100.0	10,382	100.0
Transmission risk category										
Male client										
Male-to-male sexual contact	117,461	57.3	28,678	67.5	41,478	73.5	17,126	76.7	6,568	82.8
Injection drug use	18,077	8.8	2,197	5.2	1,847	3.3	587	2.6	157	2.0
Male-to-male sexual contact and injection drug use	7,085	3.5	1,283	3.0	1,167	2.1	354	1.6	136	1.7
Heterosexual contact ^b	57,572	28.1	9,528	22.4	11,069	19.6	3,930	17.6	952	12.0
Perinatal infection	3,567	1.7	420	1.0	474	0.8	173	0.8	63	0.8
Other ^c	1,363	0.7	355	0.8	414	0.7	166	0.7	60	0.8
Subtotal^d	205,125	100.0	42,461	100.0	56,449	100.0	22,336	100.0	7,936	100.0
Female client										
Injection drug use	9,855	10.4	845	6.6	665	4.8	217	5.0	52	4.8
Heterosexual contact ^b	79,357	83.9	11,181	87.7	12,408	89.5	3,845	89.0	924	84.7
Perinatal infection	4,205	4.4	504	4.0	555	4.0	192	4.4	91	8.3
Other ^c	1,141	1.2	215	1.7	241	1.7	68	1.6	24	2.2
Subtotal^d	94,558	100.0	12,745	100.0	13,869	100.0	4,322	100.0	1,091	100.0

Table 5. Ryan White HIV/AIDS Program clients (non-ADAP), by poverty level and selected characteristics, 2015—United States and 3 territories (cont.)

	0–100% FPL		101–138% FPL		139–250% FPL		251–400% FPL		>400% FPL	
	No.	%	No.	%	No.	%	No.	%	No.	%
Transgender client										
Sexual contact ^e	3,747	92.1	399	91.7	366	97.1	120	96.0	47	97.9
Injection drug use	78	1.9	13	3.0	3	0.8	2	1.6	0	0.0
Sexual contact ^e and injection drug use	211	5.2	21	4.8	6	1.6	2	1.6	1	2.1
Perinatal infection	14	0.3	0	0.0	1	0.3	1	0.8	0	0.0
Other ^c	19	0.5	2	0.5	1	0.3	0	0.0	0	0.0
Subtotal^d	4,069	100.0	435	100.0	377	100.0	125	100.0	48	100.0
Housing status										
Stable	266,377	81.1	54,678	91.1	70,169	93.0	27,273	95.3	9,779	95.3
Temporary	39,661	12.1	3,942	6.6	4,167	5.5	1,089	3.8	398	3.9
Unstable	22,462	6.8	1,414	2.4	1,139	1.5	259	0.9	80	0.8
Subtotal	328,500	100.0	60,034	100.0	75,475	100.0	28,621	100.0	10,257	100.0
Health care coverage										
Private employer	11,162	3.4	3,748	6.2	12,046	15.9	9,804	34.0	4,716	45.8
Private individual	15,178	4.6	4,357	7.2	9,923	13.1	5,062	17.6	1,650	16.0
Medicare	25,736	7.8	12,480	20.7	11,836	15.6	1,861	6.5	623	6.1
Medicaid	139,742	42.3	13,189	21.9	9,892	13.0	2,263	7.9	1,020	9.9
Medicare and Medicaid	28,265	8.6	6,853	11.4	3,573	4.7	393	1.4	174	1.7
Veterans Administration	637	0.2	325	0.5	308	0.4	126	0.4	46	0.5
Indian Health Service	167	0.1	10	0.0	16	0.0	7	0.0	3	0.0
Other plan	6,731	2.0	1,084	1.8	1,875	2.5	610	2.1	305	3.0
No coverage	73,769	22.3	11,134	18.5	15,001	19.8	4,068	14.1	728	7.1
Multiple coverages	29,143	8.8	7,126	11.8	11,426	15.1	4,625	16.1	1,034	10.0
Subtotal	330,530	100.0	60,306	100.0	75,896	100.0	28,819	100.0	10,299	100.0
Total^f	333,580	—	60,745	—	76,444	—	29,061	—	10,388	—

Abbreviation: FPL, federal poverty level.

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia and blood transfusion.

^d Subtotals are reflective of available gender and transmission risk category information. The subtotal values for each gender-specific transmission risk category may not sum to the subtotals for each gender overall.

^e Includes any sexual transmission risk category reported by transgender clients.

^f Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 6. Ryan White HIV/AIDS Program clients (non-ADAP), by housing status and selected characteristics, 2015—United States and 3 territories

	Stable		Temporary		Unstable	
	No.	%	No.	%	No.	%
Age group (yr)						
<13	5,425	1.3	246	0.5	53	0.2
13–14	611	0.1	31	0.1	5	0.0
15–19	3,437	0.8	368	0.7	122	0.5
20–24	16,389	3.8	2,867	5.8	1,287	5.0
25–29	32,694	7.5	5,164	10.4	2,621	10.2
30–34	35,942	8.3	5,133	10.3	2,685	10.5
35–39	40,078	9.2	5,266	10.6	2,737	10.7
40–44	45,518	10.5	5,610	11.3	2,877	11.2
45–49	63,410	14.6	7,290	14.7	4,034	15.7
50–54	74,683	17.2	7,936	16.0	4,449	17.4
55–59	57,094	13.2	5,514	11.1	2,832	11.1
60–64	34,023	7.8	2,712	5.5	1,314	5.1
≥65	24,876	5.7	1,559	3.1	617	2.4
Subtotal	434,180	100.0	49,696	100.0	25,633	100.0
Race/ethnicity						
American Indian/Alaska Native	1,858	0.4	246	0.5	229	0.9
Asian	5,628	1.3	624	1.3	200	0.8
Black/African American	200,536	46.5	23,065	46.9	13,352	52.4
Hispanic/Latino ^a	99,320	23.0	12,359	25.1	5,036	19.8
Native Hawaiian/Pacific Islander	679	0.2	88	0.2	53	0.2
White	118,170	27.4	11,878	24.2	5,983	23.5
Multiple races	5,334	1.2	912	1.9	640	2.5
Subtotal	431,525	100.0	49,172	100.0	25,493	100.0
Gender						
Male	306,853	70.8	36,910	74.4	19,322	75.6
Female	122,364	28.2	11,862	23.9	5,575	21.8
Transgender	4,194	1.0	820	1.7	656	2.6
Subtotal	433,411	100.0	49,592	100.0	25,553	100.0
Transmission risk category						
Male client						
Male-to-male sexual contact	181,993	64.3	20,390	59.9	8,915	51.0
Injection drug use	17,530	6.2	3,197	9.4	2,215	12.7
Male-to-male sexual contact and injection drug use	7,389	2.6	1,387	4.1	1,202	6.9
Heterosexual contact ^b	69,728	24.6	8,484	24.9	4,891	28.0
Perinatal infection	4,210	1.5	380	1.1	152	0.9
Other ^c	2,083	0.7	184	0.5	111	0.6
Subtotal^d	282,933	100.0	34,022	100.0	17,486	100.0
Female client						
Injection drug use	9,384	8.4	1,401	13.0	867	17.4
Heterosexual contact ^b	95,236	85.7	8,783	81.6	3,944	79.1
Perinatal infection	5,066	4.6	431	4.0	117	2.3
Other ^c	1,490	1.3	145	1.3	61	1.2
Subtotal^d	111,176	100.0	10,760	100.0	4,989	100.0
Transgender client						
Sexual contact ^e	3,462	93.3	678	91.7	518	89.0
Injection drug use	66	1.8	12	1.6	16	2.7
Sexual contact ^e and injection drug use	155	4.2	45	6.1	42	7.2
Perinatal infection	12	0.3	1	0.1	3	0.5
Other ^c	15	0.4	3	0.4	3	0.5
Subtotal^d	3,710	100.0	739	100.0	582	100.0

Table 6. Ryan White HIV/AIDS Program clients (non-ADAP), by housing status and selected characteristics, 2015—United States and 3 territories (cont.)

	Stable		Temporary		Unstable	
	No.	%	No.	%	No.	%
Health care coverage						
Private employer	40,029	9.3	1,821	3.7	402	1.6
Private individual	33,263	7.7	2,496	5.1	768	3.0
Medicare	47,289	11.0	3,685	7.5	1,636	6.5
Medicaid	135,771	31.5	18,433	37.4	11,731	46.3
Medicare and Medicaid	33,914	7.9	3,297	6.7	2,090	8.2
Veterans Administration	1,222	0.3	133	0.3	83	0.3
Indian Health Service	160	0.0	21	0.0	29	0.1
Other plan	8,653	2.0	1,257	2.6	575	2.3
No coverage	84,723	19.7	13,375	27.2	5,378	21.2
Multiple coverages	45,900	10.7	4,731	9.6	2,672	10.5
Subtotal	430,924	100.0	49,249	100.0	25,364	100.0
Total^f	434,180	—	49,696	—	25,633	—

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia and blood transfusion.

^d Subtotals are reflective of available gender and transmission risk category information. The subtotal values for each gender-specific transmission risk category may not sum to the subtotals for each gender overall.

^e Includes any sexual transmission risk category reported by transgender clients.

^f Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 7. Ryan White HIV/AIDS Program clients (non-ADAP), by health care coverage and selected characteristics, 2015—United States and 3 territories

	Private employer		Private individual		Medicare		Medicaid		Medicare & Medicaid		Veterans Administration		Indian Health Service		Other plan		No coverage		Multiple coverages		
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
Age group (yr)																					
<13	450	1.0	99	0.3	15	0.0	4,721	2.8	13	0.0	13	0.9	1	0.5	28	0.3	286	0.3	242	0.5	
13–14	58	0.1	15	0.0	2	0.0	501	0.3	4	0.0	4	0.3	0	0.0	4	0.0	31	0.0	37	0.1	
15–19	259	0.6	149	0.4	27	0.1	2,664	1.6	14	0.0	6	0.4	3	1.4	71	0.6	636	0.6	234	0.4	
20–24	2,043	4.7	1,694	4.6	182	0.3	7,941	4.7	275	0.7	53	3.6	9	4.2	452	4.0	6,552	6.1	1,788	3.3	
25–29	4,089	9.4	3,506	9.4	691	1.3	13,519	8.0	748	1.9	55	3.7	24	11.2	1,002	8.9	13,866	12.9	3,707	6.9	
30–34	4,254	9.8	3,627	9.8	1,360	2.5	14,914	8.8	1,292	3.3	68	4.6	23	10.8	1,157	10.3	13,775	12.9	4,107	7.6	
35–39	4,516	10.4	3,947	10.6	2,369	4.4	15,810	9.3	1,986	5.0	74	5.0	24	11.2	1,371	12.2	14,198	13.3	4,659	8.7	
40–44	5,211	12.0	4,412	11.9	3,647	6.8	17,426	10.3	3,092	7.8	86	5.8	32	15.0	1,272	11.3	13,988	13.1	5,606	10.4	
45–49	6,775	15.6	5,927	15.9	7,161	13.3	24,838	14.7	5,984	15.1	176	11.9	30	14.0	1,639	14.6	15,356	14.3	7,958	14.8	
50–54	7,346	16.9	6,485	17.4	10,983	20.4	28,910	17.1	8,717	22.0	234	15.9	25	11.7	1,807	16.1	14,042	13.1	9,483	17.6	
55–59	4,931	11.4	4,302	11.6	9,992	18.6	22,080	13.0	7,579	19.1	291	19.7	26	12.2	1,279	11.4	8,439	7.9	7,447	13.9	
60–64	2,699	6.2	2,404	6.5	6,868	12.8	12,300	7.3	4,558	11.5	253	17.2	13	6.1	741	6.6	4,212	3.9	4,565	8.5	
≥65	833	1.9	610	1.6	10,437	19.4	3,801	2.2	5,447	13.7	162	11.0	4	1.9	408	3.6	1,807	1.7	3,918	7.3	
Subtotal	43,464	100.0	37,177	100.0	53,734	100.0	169,425	100.0	39,709	100.0	1,475	100.0	214	100.0	11,231	100.0	107,188	100.0	53,751	100.0	
Race/ethnicity																					
American Indian/Alaska Native	148	0.3	154	0.4	210	0.4	842	0.5	227	0.6	11	0.8	138	64.5	51	0.5	267	0.3	346	0.7	
Asian	606	1.4	712	1.9	315	0.6	2,104	1.3	250	0.6	6	0.4	0	0.0	254	2.3	1,440	1.4	877	1.6	
Black/African American	18,948	43.7	14,892	40.2	24,387	45.7	87,114	51.6	18,238	46.0	713	48.4	41	19.2	3,967	35.6	51,515	48.8	20,865	39.0	
Hispanic/Latino ^a	6,510	15.0	6,727	18.2	7,282	13.7	42,908	25.4	7,071	17.8	132	9.0	15	7.0	3,627	32.6	32,660	31.0	10,911	20.4	
Native Hawaiian/Pacific Islander	85	0.2	65	0.2	53	0.1	281	0.2	52	0.1	4	0.3	0	0.0	28	0.3	123	0.1	137	0.3	
White	16,569	38.2	14,029	37.9	20,423	38.3	33,106	19.6	13,074	33.0	585	39.7	17	7.9	2,968	26.6	18,602	17.6	19,263	36.0	
Multiple races	465	1.1	455	1.2	648	1.2	2,420	1.4	740	1.9	22	1.5	3	1.4	248	2.2	880	0.8	1,144	2.1	
Subtotal	43,331	100.0	37,034	100.0	53,318	100.0	168,775	100.0	39,652	100.0	1,473	100.0	214	100.0	11,143	100.0	105,487	100.0	53,543	100.0	
Gender																					
Male	33,526	77.2	29,484	79.4	41,142	76.7	105,103	62.2	27,811	70.1	1,285	87.2	133	62.2	8,550	76.5	81,679	76.4	39,872	74.3	
Female	9,676	22.3	7,342	19.8	12,188	22.7	61,269	36.3	11,493	29.0	181	12.3	78	36.5	2,487	22.3	24,039	22.5	13,303	24.8	
Transgender	201	0.5	298	0.8	324	0.6	2,616	1.6	357	0.9	8	0.5	3	1.4	136	1.2	1,263	1.2	513	1.0	
Subtotal	43,403	100.0	37,124	100.0	53,654	100.0	168,988	100.0	39,661	100.0	1,474	100.0	214	100.0	11,173	100.0	106,981	100.0	53,688	100.0	
Transmission risk category																					
Male client																					
Male-to-male sexual contact	24,099	75.8	20,645	75.9	23,143	60.9	50,624	53.3	15,696	59.1	723	59.6	82	64.6	4,824	66.9	47,229	64.2	26,320	70.0	
Injection drug use	794	2.5	706	2.6	2,976	7.8	10,819	11.4	2,712	10.2	124	10.2	9	7.1	356	4.9	2,570	3.5	2,139	5.7	
Male-to-male sexual contact and injection drug use	482	1.5	511	1.9	1,284	3.4	3,632	3.8	1,216	4.6	44	3.6	8	6.3	178	2.5	1,338	1.8	1,444	3.8	
Heterosexual contact ^b	5,796	18.2	5,015	18.4	10,016	26.4	26,110	27.5	6,520	24.5	305	25.1	25	19.7	1,752	24.3	21,536	29.3	7,132	19.0	
Perinatal infection	378	1.2	154	0.6	86	0.2	3,123	3.3	140	0.5	10	0.8	3	2.4	55	0.8	539	0.7	327	0.9	
Other ^c	235	0.7	170	0.6	469	1.2	603	0.6	288	1.1	8	0.7	0	0.0	44	0.6	344	0.5	252	0.7	
Subtotal^d	31,784	100.0	27,201	100.0	37,974	100.0	94,911	100.0	26,572	100.0	1,214	100.0	127	100.0	7,209	100.0	73,556	100.0	37,614	100.0	
Female client																					
Injection drug use	358	3.9	310	4.7	1,042	9.4	6,525	12.0	1,360	12.5	6	3.5	12	17.1	119	5.8	1,033	4.9	1,052	8.3	
Heterosexual contact ^b	8,170	90.1	6,065	91.2	9,685	87.8	43,615	79.9	9,190	84.3	154	89.0	58	82.9	1,840	89.5	19,385	91.9	10,892	86.2	
Perinatal infection	431	4.8	178	2.7	82	0.7	3,840	7.0	167	1.5	11	6.4	0	0.0	63	3.1	411	1.9	520	4.1	
Other ^c	107	1.2	94	1.4	219	2.0	614	1.1	191	1.8	2	1.2	0	0.0	35	1.7	272	1.3	170	1.3	
Subtotal^d	9,066	100.0	6,647	100.0	11,028	100.0	54,594	100.0	10,908	100.0	173	100.0	70	100.0	2,057	100.0	21,101	100.0	12,634	100.0	

Table 7. Ryan White HIV/AIDS Program clients (non-ADAP), by health care coverage and selected characteristics, 2015—United States and 3 territories (cont.)

	Private employer		Private individual		Medicare		Medicaid		Medicare & Medicaid		Veterans Administration		Indian Health Service		Other plan		No coverage		Multiple coverages		
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
Transgender client																					
Sexual contact ^a	157	96.9	242	94.9	264	89.2	2,123	92.0	286	90.5	8	100.0	1	33.3	103	95.4	1,087	95.7	406	88.1	
Injection drug use	1	0.6	5	2.0	12	4.1	49	2.1	4	1.3	0	0.0	1	33.3	1	0.9	8	0.7	15	3.3	
Sexual contact ^a and injection drug use	2	1.2	7	2.7	14	4.7	117	5.1	23	7.3	0	0.0	1	33.3	4	3.7	34	3.0	39	8.5	
Perinatal infection	2	1.2	0	0.0	1	0.3	10	0.4	0	0.0	0	0.0	0	0.0	0	0.0	3	0.3	0	0.0	
Other ^c	0	0.0	1	0.4	5	1.7	8	0.3	3	0.9	0	0.0	0	0.0	0	0.0	4	0.4	1	0.2	
Subtotal^d	162	100.0	255	100.0	296	100.0	2,307	100.0	316	100.0	8	100.0	3	100.0	108	100.0	1,136	100.0	461	100.0	
Total^f	43,464	—	37,177	—	53,734	—	169,425	—	39,709	—	1,475	—	214	—	11,231	—	107,188	—	53,751	—	

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia and blood transfusion.

^d Subtotals are reflective of available gender and transmission risk category information. The subtotal values for each gender-specific transmission risk category may not sum to the subtotals for each gender overall.

^e Includes any sexual transmission risk category reported by transgender clients.

^f Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 8. Ryan White HIV/AIDS Program clients (non-ADAP), by HRSA region and selected characteristics, 2015—United States and 3 territories

	Region 1		Region 2		Region 3		Region 4		Region 5		Region 6		Region 7		Region 8		Region 9		Region 10			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		
Age group (yr)																						
<13	155	0.7	741	0.8	540	0.9	2,378	1.8	637	1.1	674	1.1	129	1.1	210	2.2	550	0.8	46	0.4		
13–14	23	0.1	61	0.1	90	0.2	303	0.2	82	0.1	75	0.1	14	0.1	23	0.2	51	0.1	6	0.1		
15–19	170	0.7	763	0.8	448	0.8	1,536	1.2	543	0.9	482	0.8	69	0.6	87	0.9	310	0.5	35	0.3		
20–24	605	2.6	3,134	3.5	2,165	3.7	6,216	4.7	2,938	5.1	3,079	5.0	545	4.7	288	3.0	2,133	3.2	241	2.1		
25–29	1,080	4.7	6,236	6.9	4,450	7.6	11,293	8.5	5,676	9.9	5,858	9.6	1,006	8.7	618	6.5	4,441	6.6	736	6.4		
30–34	1,381	6.0	6,874	7.6	4,527	7.8	11,519	8.7	5,539	9.6	6,251	10.2	1,062	9.2	866	9.1	5,771	8.6	1,003	8.7		
35–39	1,718	7.4	7,545	8.3	5,021	8.6	12,509	9.4	5,740	10.0	6,913	11.3	1,248	10.8	1,007	10.5	6,458	9.6	1,201	10.4		
40–44	2,273	9.8	8,835	9.7	5,605	9.6	14,106	10.6	6,160	10.7	7,056	11.6	1,364	11.8	1,165	12.2	7,235	10.8	1,346	11.7		
45–49	3,645	15.8	13,208	14.5	8,472	14.5	18,856	14.2	8,143	14.1	8,627	14.1	1,642	14.3	1,457	15.3	10,373	15.5	1,914	16.6		
50–54	4,549	19.7	15,940	17.5	10,399	17.8	22,065	16.7	9,192	16.0	9,393	15.4	1,956	17.0	1,631	17.1	11,820	17.7	2,085	18.1		
55–59	3,769	16.3	13,175	14.5	8,215	14.1	16,120	12.2	6,759	11.7	6,673	10.9	1,375	11.9	1,105	11.6	8,601	12.8	1,435	12.5		
60–64	2,178	9.4	8,073	8.9	5,065	8.7	9,101	6.9	3,773	6.6	3,634	6.0	681	5.9	653	6.8	5,231	7.8	867	7.5		
≥65	1,562	6.8	6,369	7.0	3,333	5.7	6,542	4.9	2,398	4.2	2,330	3.8	431	3.7	447	4.7	3,999	6.0	611	5.3		
Subtotal	23,108	100.0	90,954	100.0	58,330	100.0	132,544	100.0	57,580	100.0	61,045	100.0	11,522	100.0	9,557	100.0	66,973	100.0	11,526	100.0		
Race/ethnicity																						
American Indian/Alaska Native	71	0.3	165	0.2	69	0.1	276	0.2	243	0.4	358	0.6	55	0.5	171	1.8	618	0.9	366	3.2		
Asian	307	1.3	1,244	1.4	435	0.8	662	0.5	606	1.1	567	0.9	135	1.2	145	1.5	2,240	3.4	306	2.7		
Black/African American	7,077	30.9	38,232	42.5	38,246	65.9	81,572	61.7	29,437	52.6	28,806	47.2	4,975	43.2	1,671	17.6	13,111	19.8	1,813	15.9		
Hispanic/Latino ^a	6,711	29.3	36,810	40.9	5,636	9.7	16,223	12.3	7,195	12.9	15,299	25.1	764	6.6	2,093	22.0	25,865	39.0	1,691	14.8		
Native Hawaiian/Pacific Islander	26	0.1	89	0.1	47	0.1	48	0.0	43	0.1	48	0.1	12	0.1	15	0.2	455	0.7	67	0.6		
White	8,457	36.9	12,715	14.1	12,235	21.1	32,245	24.4	17,449	31.2	15,379	25.2	5,396	46.9	5,269	55.4	23,280	35.1	6,702	58.8		
Multiple races	282	1.2	750	0.8	1,392	2.4	1,237	0.9	991	1.8	550	0.9	180	1.6	146	1.5	820	1.2	447	3.9		
Subtotal	22,931	100.0	90,005	100.0	58,060	100.0	132,263	100.0	55,964	100.0	61,007	100.0	11,517	100.0	9,510	100.0	66,389	100.0	11,392	100.0		
Gender																						
Male	15,308	66.4	59,752	65.8	38,142	65.6	90,594	68.5	42,782	74.5	44,264	72.7	8,787	76.3	7,671	80.4	54,993	82.4	9,330	81.0		
Female	7,566	32.8	29,608	32.6	19,107	32.9	40,781	30.8	13,970	24.3	16,275	26.7	2,588	22.5	1,814	19.0	10,682	16.0	2,064	17.9		
Transgender	198	0.9	1,390	1.5	892	1.5	944	0.7	709	1.2	381	0.6	141	1.2	58	0.6	1,105	1.7	127	1.1		
Subtotal	23,072	100.0	90,750	100.0	58,141	100.0	132,319	100.0	57,461	100.0	60,920	100.0	11,516	100.0	9,543	100.0	66,780	100.0	11,521	100.0		
Transmission risk category																						
Male client																						
Male-to-male sexual contact	7,429	52.0	26,055	50.2	18,288	54.7	52,268	61.5	25,980	70.0	26,961	66.5	6,331	73.5	4,981	69.0	37,987	75.0	5,534	67.9		
Injection drug use	2,745	19.2	6,043	11.7	4,008	12.0	3,105	3.7	1,874	5.0	1,448	3.6	388	4.5	441	6.1	2,602	5.1	601	7.4		
Male-to-male sexual contact and injection drug use	377	2.6	759	1.5	797	2.4	1,535	1.8	650	1.8	783	1.9	85	1.0	783	10.8	3,305	6.5	854	10.5		
Heterosexual contact ^b	3,326	23.3	17,457	33.7	9,481	28.4	26,153	30.8	7,823	21.1	10,750	26.5	1,627	18.9	860	11.9	6,027	11.9	1,027	12.6		
Perinatal infection	244	1.7	1,131	2.2	590	1.8	1,377	1.6	487	1.3	410	1.0	81	0.9	91	1.3	351	0.7	47	0.6		
Other ^c	173	1.2	408	0.8	243	0.7	510	0.6	310	0.8	190	0.5	101	1.2	63	0.9	348	0.7	87	1.1		
Subtotal^d	14,294	100.0	51,853	100.0	33,407	100.0	84,948	100.0	37,124	100.0	40,542	100.0	8,613	100.0	7,219	100.0	50,620	100.0	8,150	100.0		
Female client																						
Injection drug use	1,406	20.2	2,592	10.0	2,274	14.1	1,870	5.0	971	8.1	777	5.3	113	4.5	229	14.6	1,210	13.3	352	19.8		
Heterosexual contact ^b	5,142	73.9	21,631	83.2	12,870	80.0	33,636	89.6	10,214	85.6	13,311	90.8	2,287	91.0	1,214	77.2	7,265	79.8	1,350	76.1		
Perinatal infection	289	4.2	1,355	5.2	726	4.5	1,633	4.4	581	4.9	450	3.1	76	3.0	98	6.2	433	4.8	36	2.0		
Other ^c	122	1.8	411	1.6	213	1.3	381	1.0	162	1.4	126	0.9	38	1.5	32	2.0	198	2.2	37	2.1		
Subtotal^d	6,959	100.0	25,989	100.0	16,083	100.0	37,520	100.0	11,928	100.0	14,664	100.0	2,514	100.0	1,573	100.0	9,106	100.0	1,775	100.0		

Table 8. Ryan White HIV/AIDS Program clients (non-ADAP), by HRSA region and selected characteristics, 2015—United States and 3 territories (cont.)

	Region 1		Region 2		Region 3		Region 4		Region 5		Region 6		Region 7		Region 8		Region 9		Region 10	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Transgender client																				
Sexual contact ^a	171	88.6	1,031	94.4	669	94.6	873	96.0	578	96.0	327	94.8	135	97.1	40	81.6	841	85.3	87	79.8
Injection drug use	6	3.1	22	2.0	11	1.6	3	0.3	7	1.2	5	1.4	3	2.2	4	8.2	29	2.9	10	9.2
Sexual contact ^a and injection drug use	11	5.7	30	2.7	24	3.4	27	3.0	13	2.2	12	3.5	1	0.7	4	8.2	108	11.0	11	10.1
Perinatal infection	3	1.6	4	0.4	0	0.0	2	0.2	3	0.5	0	0.0	0	0.0	0	0.0	3	0.3	0	0.0
Other ^c	2	1.0	5	0.5	3	0.4	4	0.4	1	0.2	1	0.3	0	0.0	1	2.0	5	0.5	1	0.9
Subtotal^d	193	100.0	1,092	100.0	707	100.0	909	100.0	602	100.0	345	100.0	139	100.0	49	100.0	986	100.0	109	100.0
Poverty level																				
0–100%	13,721	64.0	63,947	71.4	35,173	65.9	80,038	63.1	36,725	65.8	37,977	65.4	6,179	54.7	4,512	56.1	41,328	63.8	6,199	56.1
101–138%	2,181	10.2	8,408	9.4	6,155	11.5	15,984	12.6	6,317	11.3	7,466	12.9	1,453	12.9	1,020	12.7	9,335	14.4	1,585	14.3
139–250%	3,548	16.5	10,179	11.4	7,285	13.7	21,576	17.0	7,792	14.0	9,115	15.7	2,518	22.3	1,684	21.0	9,711	15.0	2,103	19.0
251–400%	1,190	5.6	4,891	5.5	3,365	6.3	8,026	6.3	2,786	5.0	2,896	5.0	1,026	9.1	662	8.2	3,118	4.8	911	8.2
>400%	807	3.8	2,127	2.4	1,387	2.6	1,299	1.0	2,220	4.0	656	1.1	121	1.1	161	2.0	1,325	2.0	252	2.3
Subtotal	21,447	100.0	89,552	100.0	53,365	100.0	126,923	100.0	55,840	100.0	58,110	100.0	11,297	100.0	8,039	100.0	64,817	100.0	11,050	100.0
Health care coverage																				
Private employer	1,228	5.5	4,537	5.1	5,978	10.8	15,246	11.9	5,111	9.1	4,285	7.2	1,523	13.8	1,763	19.5	2,363	3.7	880	7.9
Private individual	2,579	11.5	4,345	4.9	4,428	8.0	8,759	6.8	3,930	7.0	6,306	10.6	2,322	21.1	885	9.8	2,258	3.5	591	5.3
Medicare	2,412	10.8	5,817	6.5	7,078	12.8	15,383	12.0	5,746	10.2	8,138	13.7	652	5.9	1,088	12.1	5,223	8.1	1,410	12.6
Medicaid	9,249	41.2	44,793	50.0	21,665	39.2	25,586	19.9	19,673	34.9	11,059	18.6	2,026	18.4	2,296	25.5	26,911	41.7	3,383	30.3
Medicare and Medicaid	2,434	10.9	6,454	7.2	4,091	7.4	8,501	6.6	4,664	8.3	3,603	6.1	1,775	16.1	597	6.6	5,880	9.1	674	6.0
Veterans Administration	25	0.1	42	0.1	165	0.3	488	0.4	91	0.2	253	0.4	69	0.6	60	0.7	196	0.3	56	0.5
Indian Health Service	3	0.0	4	0.0	11	0.0	13	0.0	3	0.0	7	0.0	29	0.3	12	0.1	26	0.0	104	0.9
Other plan	812	3.6	1,336	1.5	1,052	1.9	2,084	1.6	1,562	2.8	698	1.2	23	0.2	159	1.8	3,129	4.9	215	1.9
No coverage	1,176	5.2	12,794	14.3	6,226	11.3	42,026	32.7	8,671	15.4	21,638	36.3	1,048	9.5	1,557	17.3	10,053	15.6	595	5.3
Multiple coverages	2,510	11.2	9,498	10.6	4,522	8.2	10,538	8.2	6,956	12.3	3,555	6.0	1,542	14.0	606	6.7	8,494	13.2	3,266	29.2
Subtotal	22,428	100.0	89,620	100.0	55,216	100.0	128,624	100.0	56,407	100.0	59,542	100.0	11,009	100.0	9,023	100.0	64,533	100.0	11,174	100.0
Housing status																				
Stable	19,114	86.9	75,524	84.4	47,646	88.4	117,057	91.8	47,520	86.4	44,358	75.8	9,699	88.6	6,425	83.6	52,569	82.2	7,831	72.9
Temporary	2,014	9.2	8,391	9.4	3,726	6.9	6,610	5.2	5,284	9.6	12,048	20.6	868	7.9	950	12.4	7,148	11.2	712	6.6
Unstable	875	4.0	5,564	6.2	2,559	4.7	3,835	3.0	2,199	4.0	2,095	3.6	380	3.5	314	4.1	4,220	6.6	2,203	20.5
Subtotal	22,003	100.0	89,479	100.0	53,931	100.0	127,502	100.0	55,003	100.0	58,501	100.0	10,947	100.0	7,689	100.0	63,937	100.0	10,746	100.0
Total^f	23,108	—	90,954	—	58,330	—	132,544	—	57,580	—	61,045	—	11,522	—	9,557	—	66,973	—	11,526	—

Note. See Technical Notes for the states/territories included in each region.

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia and blood transfusion.

^d Subtotals are reflective of available gender and transmission risk category information. The subtotal values for each gender-specific transmission risk category may not sum to the subtotals for each gender overall.

^e Includes any sexual transmission risk category reported by transgender clients.

^f Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 9a. Ryan White HIV/AIDS Program clients (non-ADAP), by state, 2015—United States and 3 territories

State	Adults and adolescents ^a		Children		Total
	No.	%	No.	%	No.
Alabama	8,616	98.1	166	1.9	8,782
Alaska	524	100.0	0	0.0	524
Arizona	7,106	99.1	66	0.9	7,172
Arkansas	2,114	99.9	2	0.1	2,116
California	55,018	99.3	407	0.7	55,425
Colorado	6,581	97.2	191	2.8	6,772
Connecticut	5,867	99.5	28	0.5	5,895
Delaware	1,884	99.9	2	0.1	1,886
District of Columbia	6,835	98.6	100	1.4	6,935
Florida	53,978	97.5	1,400	2.5	55,378
Georgia	20,906	98.4	347	1.6	21,253
Hawaii	970	100.0	0	0.0	970
Idaho	705	99.7	2	0.3	707
Illinois	23,392	98.8	296	1.3	23,688
Indiana	4,657	99.9	7	0.2	4,664
Iowa	1,505	99.8	3	0.2	1,508
Kansas	1,137	99.6	5	0.4	1,142
Kentucky	4,443	99.6	20	0.5	4,463
Louisiana	12,208	99.3	81	0.7	12,289
Maine	812	99.5	4	0.5	816
Maryland	14,790	99.0	143	1.0	14,933
Massachusetts	13,046	99.4	82	0.6	13,128
Michigan	8,710	98.6	122	1.4	8,832
Minnesota	4,135	99.5	20	0.5	4,155
Mississippi	4,421	98.1	88	2.0	4,509
Missouri	7,587	98.7	99	1.3	7,686
Montana	352	100.0	0	0.0	352
Nebraska	1,164	98.2	22	1.9	1,186
Nevada	3,298	97.8	75	2.2	3,373
New Hampshire	860	99.1	8	0.9	868
New Jersey	17,305	98.3	299	1.7	17,604
New Mexico	2,099	100.0	1	0.1	2,100
New York	60,572	99.4	373	0.6	60,945
North Carolina	15,337	99.0	157	1.0	15,494
North Dakota	179	97.8	4	2.2	183
Ohio	11,862	99.6	47	0.4	11,909
Oklahoma	2,836	100.0	0	0.0	2,836
Oregon	3,281	99.2	26	0.8	3,307
Pennsylvania	24,781	99.0	240	1.0	25,021
Rhode Island	1,831	98.2	33	1.8	1,864
South Carolina	10,356	99.0	106	1.0	10,462
South Dakota	361	99.2	3	0.8	364
Tennessee	12,109	99.2	94	0.8	12,203
Texas	41,114	98.6	590	1.4	41,704
Utah	1,737	99.6	7	0.4	1,744
Vermont	537	100.0	0	0.0	537
Virginia	8,726	99.4	55	0.6	8,781
Washington	6,970	99.7	18	0.3	6,988
West Virginia	774	100.0	0	0.0	774
Wisconsin	4,187	96.7	145	3.4	4,332
Wyoming	137	96.5	5	3.5	142
Subtotal	504,712	98.8	5,989	1.2	510,701
Territories					
Guam	31	93.9	2	6.1	33
Puerto Rico	12,116	99.4	69	0.6	12,185
U.S. Virgin Islands	220	100.0	0	0.0	220
Subtotal	12,367	99.4	71	0.6	12,438
Total	517,079	98.8	6,060	1.2	523,139

Note. Percentages shown are based on the row total.

Data are based on provider location. Clients receiving services in multiple states were not included in state-specific totals.

^a Adults and adolescents refers to clients aged 13 years and older during the calendar year.

Table 9b. Ryan White HIV/AIDS Program clients, by eligible metropolitan area and transitional grant area, 2015—United States and 3 territories

	Adults and adolescents ^a		Children		Total
	No.	%	No.	%	No.
Eligible metropolitan area					
Atlanta, GA	13,652	97.8	309	2.2	13,961
Baltimore, MD	11,863	99.0	125	1.0	11,988
Boston, MA	11,399	99.3	83	0.7	11,482
Chicago, IL	21,637	98.7	296	1.4	21,933
Dallas, TX	9,414	98.3	165	1.7	9,579
Detroit, MI	5,314	97.9	113	2.1	5,427
Ft. Lauderdale, FL	14,364	93.9	932	6.1	15,296
Houston, TX	14,556	98.3	246	1.7	14,802
Los Angeles, CA	26,043	99.2	206	0.8	26,249
Miami, FL	13,827	99.1	130	0.9	13,957
Nassau Suffolk, NY	3,387	98.4	55	1.6	3,442
New Haven, CT	1,964	99.7	6	0.3	1,970
New Orleans, LA	6,749	99.5	36	0.5	6,785
New York, NY	45,169	99.3	315	0.7	45,484
Newark, NJ	7,252	98.4	117	1.6	7,369
Orlando, FL	3,590	100.0	0	0.0	3,590
Philadelphia, PA	19,080	98.6	281	1.5	19,361
Phoenix, AZ	5,370	98.9	61	1.1	5,431
San Diego, CA	7,106	98.5	112	1.6	7,218
San Francisco, CA	6,900	100.0	2	0.0	6,902
San Juan, PR	10,564	99.3	70	0.7	10,634
Tampa-St. Petersburg, FL	6,342	98.1	120	1.9	6,462
Washington, DC	12,140	98.8	149	1.2	12,289
West Palm Beach, FL	3,847	99.8	8	0.2	3,855
Transitional grant area					
Austin, TX	5,728	99.9	5	0.1	5,733
Baton Rouge, LA	3,645	99.0	38	1.0	3,683
Bergen-Passaic, NJ	2,211	99.2	18	0.8	2,229
Charlotte, NC	3,240	100.0	1	0.0	3,241
Cleveland, OH	3,349	99.6	15	0.5	3,364
Columbus, OH	6,098	99.5	29	0.5	6,127
Denver, CO	6,420	97.0	196	3.0	6,616
Ft. Worth, TX	2,951	98.0	60	2.0	3,011
Hartford, CT	3,284	99.5	17	0.5	3,301
Indianapolis, IN	4,970	99.9	7	0.1	4,977
Jacksonville, FL	2,504	100.0	1	0.0	2,505
Jersey City, NJ	2,071	98.7	27	1.3	2,098
Kansas City, MO	2,701	99.2	23	0.8	2,724
Las Vegas, NV	2,398	98.1	46	1.9	2,444
Memphis, TN	5,077	98.8	62	1.2	5,139
Middlesex, NJ	1,544	96.1	62	3.9	1,606
Minneapolis-St. Paul, MN	4,303	99.5	20	0.5	4,323
Nashville, TN	5,604	99.4	32	0.6	5,636
Norfolk, VA	2,844	99.9	2	0.1	2,846
Oakland, CA	3,190	98.9	37	1.2	3,227
Orange County, CA	2,248	99.8	5	0.2	2,253
Portland, OR	4,086	99.4	24	0.6	4,110
Riverside-San Bernardino, CA	3,385	100.0	0	0.0	3,385
Sacramento, CA	3,040	98.8	37	1.2	3,077
San Antonio, TX	3,962	97.8	91	2.3	4,053
San Jose, CA	955	100.0	0	0.0	955
Seattle, WA	4,982	99.7	16	0.3	4,998
St. Louis, MO	6,596	98.9	77	1.2	6,673

Abbreviations: EMA, eligible metropolitan area; TGA, transitional grant area.

Note. Clients served include people living with HIV and affected family members.

Percentages shown are based on the row total.

EMA/TGA delineations are based on provider location.

Data shown for EMAs and TGAs are not mutually exclusive; clients may have received services from providers in multiple EMAs and/or TGAs.

^a Adults and adolescents refers to clients aged 13 years and older during the calendar year.

Table 10a. Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and state, 2015—United States and 3 territories

State	American Indian/ Alaska Native		Asian		Black/African American		Hispanic/Latino ^a		Native Hawaiian/ Pacific Islander		White		Multiple races		Total ^b
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Alabama	6	0.1	26	0.3	6,165	70.4	193	2.2	2	0.0	2,306	26.4	55	0.6	8,782
Alaska	180	34.4	19	3.6	74	14.1	53	10.1	2	0.4	186	35.5	10	1.9	524
Arizona	226	3.2	107	1.5	1,064	15.0	2,360	33.2	17	0.2	3,159	44.5	169	2.4	7,172
Arkansas	1	0.1	5	0.2	1,017	48.1	133	6.3	5	0.2	903	42.7	49	2.3	2,116
California	360	0.7	1,911	3.5	11,162	20.3	22,510	40.8	264	0.5	18,403	33.4	502	0.9	55,425
Colorado	78	1.2	90	1.3	1,295	19.3	1,678	24.9	8	0.1	3,471	51.6	107	1.6	6,772
Connecticut	5	0.1	28	0.5	2,431	41.3	2,196	37.3	6	0.1	1,177	20.0	42	0.7	5,895
Delaware	2	0.1	0	0.0	1,202	63.7	116	6.2	1	0.1	545	28.9	20	1.1	1,886
District of Columbia	13	0.2	41	0.6	5,710	83.6	558	8.2	8	0.1	482	7.1	20	0.3	6,935
Florida	50	0.1	273	0.5	28,572	51.8	12,741	23.1	26	0.1	12,922	23.4	575	1.0	55,378
Georgia	16	0.1	127	0.6	16,476	77.5	1,059	5.0	9	0.0	3,401	16.0	161	0.8	21,253
Hawaii	12	1.2	127	13.1	48	5.0	126	13.0	128	13.2	449	46.3	79	8.2	970
Idaho	9	1.3	7	1.0	56	7.9	94	13.3	1	0.1	529	74.8	11	1.6	707
Illinois	50	0.2	257	1.1	13,346	56.5	4,729	20.0	20	0.1	4,856	20.6	356	1.5	23,688
Indiana	8	0.3	86	2.7	1,424	44.1	355	11.0	6	0.2	1,305	40.4	47	1.5	4,664
Iowa	7	0.5	49	3.3	346	22.9	115	7.6	1	0.1	963	63.9	27	1.8	1,508
Kansas	6	0.5	14	1.2	294	25.7	110	9.6	2	0.2	682	59.7	34	3.0	1,142
Kentucky	9	0.2	30	0.7	1,594	35.7	233	5.2	1	0.0	2,510	56.3	85	1.9	4,463
Louisiana	15	0.1	26	0.2	9,188	74.8	377	3.1	7	0.1	2,515	20.5	157	1.3	12,289
Maine	8	1.0	5	0.6	132	16.2	34	4.2	0	0.0	597	73.2	40	4.9	816
Maryland	15	0.1	86	0.6	12,213	81.9	635	4.3	7	0.1	1,839	12.3	120	0.8	14,933
Massachusetts	37	0.3	223	1.7	3,817	29.4	3,851	29.7	17	0.1	4,866	37.5	153	1.2	13,128
Michigan	28	0.3	70	0.8	5,327	60.4	454	5.2	6	0.1	2,722	30.9	215	2.4	8,832
Minnesota	100	2.4	69	1.7	1,776	42.8	415	10.0	5	0.1	1,695	40.8	92	2.2	4,155
Mississippi	9	0.2	12	0.3	3,614	80.2	71	1.6	2	0.0	777	17.2	24	0.5	4,509
Missouri	27	0.4	46	0.6	4,001	52.1	365	4.8	6	0.1	3,137	40.8	104	1.4	7,686
Montana	30	8.6	1	0.3	16	4.6	13	3.7	1	0.3	280	79.8	10	2.9	352
Nebraska	15	1.3	26	2.2	334	28.3	174	14.7	3	0.3	614	52.0	15	1.3	1,186
Nevada	20	0.6	90	2.8	836	26.4	869	27.4	22	0.7	1,266	39.9	70	2.2	3,373
New Hampshire	3	0.4	16	1.8	126	14.5	122	14.1	0	0.0	580	66.8	21	2.4	868
New Jersey	12	0.1	170	1.0	9,972	56.7	4,516	25.7	22	0.1	2,759	15.7	149	0.9	17,604
New Mexico	100	4.8	9	0.4	98	4.7	971	46.8	4	0.2	869	41.9	22	1.1	2,100
New York	153	0.3	1,069	1.8	28,127	46.9	20,216	33.7	67	0.1	9,780	16.3	588	1.0	60,945
North Carolina	155	1.0	95	0.6	10,215	66.0	1,081	7.0	2	0.0	3,793	24.5	129	0.8	15,494
North Dakota	8	4.4	0	0.0	73	39.9	9	4.9	0	0.0	87	47.5	6	3.3	183
Ohio	14	0.1	61	0.5	5,750	48.4	652	5.5	1	0.0	5,172	43.5	233	2.0	11,909
Oklahoma	149	5.3	47	1.7	666	23.5	229	8.1	2	0.1	1,618	57.1	125	4.4	2,836
Oregon	32	1.0	65	2.0	267	8.1	512	15.5	13	0.4	2,170	65.8	238	7.2	3,307
Pennsylvania	25	0.1	190	0.8	13,296	53.4	3,576	14.4	24	0.1	6,735	27.1	1,045	4.2	25,021
Rhode Island	14	0.8	31	1.7	517	27.8	483	26.0	1	0.1	794	42.7	21	1.1	1,864
South Carolina	20	0.2	26	0.3	7,617	72.8	331	3.2	5	0.1	2,387	22.8	72	0.7	10,462
South Dakota	29	8.0	6	1.7	113	31.0	31	8.5	0	0.0	181	49.7	4	1.1	364
Tennessee	11	0.1	73	0.6	7,319	60.0	514	4.2	1	0.0	4,149	34.0	136	1.1	12,203
Texas	93	0.2	480	1.2	17,837	42.8	13,589	32.6	30	0.1	9,474	22.7	197	0.5	41,704
Utah	20	1.2	47	2.7	160	9.2	343	19.7	6	0.3	1,149	65.9	18	1.0	1,744
Vermont	4	0.7	4	0.7	54	10.1	25	4.7	2	0.4	443	82.5	5	0.9	537
Virginia	13	0.2	115	1.3	5,659	64.6	736	8.4	6	0.1	2,055	23.5	178	2.0	8,781
Washington	145	2.1	215	3.1	1,416	20.6	1,032	15.0	51	0.7	3,817	55.6	188	2.7	6,988
West Virginia	1	0.1	3	0.4	166	21.5	15	1.9	1	0.1	579	74.8	9	1.2	774
Wisconsin	43	1.0	63	1.5	1,814	42.6	590	13.8	5	0.1	1,699	39.9	48	1.1	4,332
Wyoming	6	4.2	1	0.7	14	9.9	19	13.4	0	0.0	101	71.1	1	0.7	142
Subtotal	2,392	0.5	6,637	1.3	244,806	47.9	106,209	20.8	826	0.2	138,948	27.2	6,782	1.3	510,701

Table 10a. Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and state, 2015—United States and 3 territories (cont.)

	American Indian/ Alaska Native		Asian		Black/African American		Hispanic/Latino ^a		Native Hawaiian/ Pacific Islander		White		Multiple races		Total ^b	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	
Territories																
Guam	0	0.0	5	15.2	1	3.0	0	0.0	24	72.7	3	9.1	0	0.0		33
Puerto Rico	0	0.0	4	0.0	15	0.1	11,990	98.4	0	0.0	163	1.3	13	0.1		12,185
U.S. Virgin Islands	0	0.0	1	0.5	118	53.6	88	40.0	0	0.0	13	5.9	0	0.0		220
Subtotal	0	0.0	10	0.1	134	1.1	12,078	97.1	24	0.2	179	1.4	13	0.1		12,438
Total	2,392	0.5	6,647	1.3	244,940	46.8	118,287	22.6	850	0.2	139,127	26.8	6,795	1.3		523,139

Note. Percentages shown are based on the row total.
 Data are based on provider location. Clients receiving services in multiple states were not included in state-specific totals.
^a Hispanics/Latinos can be of any race.
^b Includes all clients with reported race/ethnicity information.

Table 10b. Ryan White HIV/AIDS Program clients, by race/ethnicity and eligible metropolitan area and transitional grant area, 2015—United States and 3 territories

	American Indian/ Alaska Native		Asian		Black/African American		Hispanic/Latino ^a		Native Hawaiian/ Pacific Islander		White		Total ^b
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Eligible metropolitan area													
Atlanta, GA	10	0.1	102	0.7	11,078	79.4	814	5.8	6	0.0	1,836	13.2	13,961
Baltimore, MD	11	0.1	62	0.5	9,862	82.3	386	3.2	*	*	1,523	12.7	11,988
Boston, MA	29	0.3	211	1.9	3,528	31.2	3,116	27.5	17	0.2	4,273	37.7	11,482
Chicago, IL	41	0.2	242	1.1	12,608	57.7	4,716	21.6	19	0.1	3,813	17.4	21,933
Dallas, TX	17	0.2	116	1.2	4,922	51.4	2,083	21.8	6	0.1	2,352	24.6	9,579
Detroit, MI	*	*	20	0.4	4,278	78.8	188	3.5	*	*	831	15.3	5,427
Ft. Lauderdale, FL	11	0.1	67	0.4	8,447	55.5	3,010	19.8	6	0.0	3,376	22.2	15,296
Houston, TX	28	0.2	175	1.2	8,009	54.1	4,088	27.6	7	0.1	2,430	16.4	14,802
Los Angeles, CA	90	0.3	802	3.1	6,951	26.5	11,817	45.1	90	0.3	6,346	24.2	26,249
Miami, FL	*	*	35	0.3	6,005	43.3	6,613	47.6	*	*	1,160	8.4	13,957
Nassau Suffolk, NY	6	0.2	46	1.3	1,572	45.7	817	23.7	*	*	958	27.8	3,442
New Haven, CT	*	*	6	0.3	793	40.3	682	34.7	*	*	467	23.8	1,970
New Orleans, LA	9	0.1	14	0.2	4,920	72.5	269	4.0	*	*	1,480	21.8	6,785
New York, NY	91	0.2	742	1.7	22,146	49.2	16,234	36.1	42	0.1	5,210	11.6	45,484
Newark, NJ	6	0.1	24	0.3	5,365	72.8	1,430	19.4	10	0.1	501	6.8	7,369
Orlando, FL	*	*	26	0.7	1,417	39.5	1,121	31.3	*	*	991	27.7	3,590
Philadelphia, PA	12	0.1	169	0.9	11,901	61.9	2,758	14.3	15	0.1	3,380	17.6	19,361
Phoenix, AZ	151	2.8	97	1.8	932	17.4	1,793	33.4	13	0.2	2,226	41.5	5,431
San Diego, CA	46	0.6	205	2.8	1,004	13.9	3,111	43.1	26	0.4	2,732	37.9	7,218
San Francisco, CA	79	1.2	340	5.0	1,486	21.9	1,689	24.8	57	0.8	2,980	43.8	6,902
San Juan, PR	*	*	*	*	15	0.1	10,473	98.5	*	*	131	1.2	10,634
Tampa-St. Petersburg, FL	10	0.2	52	0.8	2,680	41.5	1,174	18.2	*	*	2,461	38.1	6,462
Washington, DC	20	0.2	143	1.2	9,502	78.1	1,365	11.2	10	0.1	1,068	8.8	12,289
West Palm Beach, FL	*	*	12	0.3	2,507	65.1	612	15.9	*	*	696	18.1	3,855
Transitional grant area													
Austin, TX	14	0.2	51	0.9	2,065	36.0	1,555	27.1	*	*	1,974	34.4	5,733
Baton Rouge, LA	*	*	10	0.3	2,999	81.4	106	2.9	*	*	508	13.8	3,683
Bergen-Passaic, NJ	*	*	21	0.9	1,102	49.5	785	35.2	*	*	297	13.3	2,229
Charlotte, NC	17	0.5	28	0.9	2,300	71.0	247	7.6	*	*	612	18.9	3,241
Cleveland, OH	*	*	8	0.2	1,924	57.2	320	9.5	*	*	1,057	31.4	3,364
Columbus, OH	6	0.1	41	0.7	2,545	41.6	291	4.8	*	*	3,058	50.0	6,127
Denver, CO	75	1.1	86	1.3	1,361	20.7	1,620	24.7	8	0.1	3,299	50.2	6,616
Ft. Worth, TX	8	0.3	51	1.7	1,420	47.2	577	19.2	*	*	939	31.2	3,011
Hartford, CT	*	*	21	0.6	1,166	35.4	1,355	41.1	5	0.2	709	21.5	3,301
Indianapolis, IN	9	0.3	88	2.5	1,544	43.6	392	11.1	6	0.2	1,446	40.8	4,977
Jacksonville, FL	*	*	25	1.0	1,477	59.0	180	7.2	*	*	777	31.0	2,505
Jersey City, NJ	*	*	48	2.3	856	40.8	918	43.8	*	*	262	12.5	2,098
Kansas City, MO	12	0.4	20	0.7	1,244	45.7	289	10.6	5	0.2	1,101	40.4	2,724
Las Vegas, NV	14	0.6	71	2.9	754	31.2	706	29.2	12	0.5	792	32.8	2,444
Memphis, TN	*	*	12	0.2	4,499	87.6	107	2.1	*	*	432	8.4	5,139
Middlesex, NJ	*	*	27	1.7	785	48.9	490	30.5	*	*	280	17.4	1,606
Minneapolis-St. Paul, MN	104	2.4	73	1.7	1,839	42.6	432	10.0	5	0.1	1,764	40.8	4,323

Table 10b. Ryan White HIV/AIDS Program clients, by race/ethnicity and eligible metropolitan area and transitional grant area, 2015—United States and 3 territories (cont.)

	American Indian/ Alaska Native		Asian		Black/African American		Hispanic/Latino ^a		Native Hawaiian/ Pacific Islander		White		Total ^b
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Transitional grant area													
Nashville, TN	*	*	55	1.0	2,588	45.9	367	6.5	*	*	2,550	45.2	5,636
Norfolk, VA	*	*	19	0.7	2,107	74.0	132	4.6	*	*	470	16.5	2,846
Oakland, CA	22	0.7	133	4.3	1,393	45.3	784	25.5	22	0.7	644	21.0	3,227
Orange County, CA	*	*	116	5.2	116	5.2	1,395	62.4	15	0.7	566	25.3	2,253
Portland, OR	30	0.7	195	4.8	435	10.6	1,090	26.6	19	0.5	2,117	51.7	4,110
Riverside-San Bernardino, CA	18	0.5	48	1.4	309	9.1	1,042	30.8	6	0.2	1,933	57.2	3,385
Sacramento, CA	39	1.3	81	2.6	603	19.6	738	24.0	17	0.6	1,517	49.3	3,077
San Antonio, TX	12	0.3	37	0.9	732	18.1	2,469	60.9	5	0.1	785	19.4	4,053
San Jose, CA	5	0.5	85	8.9	121	12.7	501	52.6	6	0.6	222	23.3	955
Seattle, WA	91	1.9	168	3.4	1,197	24.5	684	14.0	33	0.7	2,595	53.2	4,998
St. Louis, MO	29	0.4	46	0.7	3,652	54.7	293	4.4	*	*	2,560	38.4	6,673

Abbreviations: EMA, eligible metropolitan area; TGA, transitional grant area.

Note. Percentages shown are based on the row total.

* To ensure confidentiality, values less than (<) 5 have been suppressed; in addition, all data on clients of multiple races have been suppressed.

EMA/TGA delineations are based on provider location.

Data shown for EMAs and TGAs are not mutually exclusive; clients may have received services from providers in multiple EMAs and/or TGAs.

^a Hispanics/Latinos can be of any race.

^b Includes all clients with reported race/ethnicity information.

Table 11a-i. Male clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and state, 2015—United States and 3 territories

State	Male-to-male sexual contact		Injection drug use		Male-to-male sexual contact and injection drug use		Heterosexual contact ^a		Perinatal infection		Other ^b		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Alabama	3,311	63.7	264	5.1	52	1.0	1,475	28.4	79	1.5	13	0.3	5,194
Alaska	180	54.4	38	11.5	30	9.1	72	21.8	4	1.2	7	2.1	331
Arizona	3,981	70.0	276	4.9	582	10.2	736	12.9	69	1.2	43	0.8	5,687
Arkansas	1,092	68.9	92	5.8	58	3.7	326	20.6	6	0.4	11	0.7	1,585
California	31,652	75.7	2,161	5.2	2,632	6.3	4,856	11.6	239	0.6	274	0.7	41,814
Colorado	3,567	70.6	295	5.8	494	9.8	591	11.7	67	1.3	35	0.7	5,049
Connecticut	1,107	37.2	828	27.8	53	1.8	916	30.8	51	1.7	20	0.7	2,975
Delaware	642	52.3	183	14.9	27	2.2	361	29.4	10	0.8	4	0.3	1,227
District of Columbia	2,046	60.2	135	4.0	17	0.5	1,090	32.1	97	2.9	15	0.4	3,400
Florida	19,987	59.0	1,123	3.3	491	1.5	11,387	33.6	642	1.9	219	0.6	33,849
Georgia	9,622	66.1	396	2.7	293	2.0	3,932	27.0	264	1.8	42	0.3	14,549
Hawaii	677	86.4	32	4.1	6	0.8	61	7.8	2	0.3	6	0.8	784
Idaho	359	64.9	43	7.8	67	12.1	76	13.7	2	0.4	6	1.1	553
Illinois	9,248	66.7	896	6.5	189	1.4	3,210	23.2	201	1.5	111	0.8	13,855
Indiana	2,417	72.1	155	4.6	29	0.9	690	20.6	19	0.6	42	1.3	3,352
Iowa	788	70.7	83	7.4	52	4.7	166	14.9	5	0.4	21	1.9	1,115
Kansas	675	75.5	46	5.1	0	0.0	154	17.2	6	0.7	13	1.5	894
Kentucky	2,421	71.1	175	5.1	131	3.8	625	18.4	20	0.6	32	0.9	3,404
Louisiana	3,837	55.1	434	6.2	159	2.3	2,438	35.0	71	1.0	29	0.4	6,968
Maine	453	73.9	51	8.3	16	2.6	71	11.6	9	1.5	13	2.1	613
Maryland	3,073	45.1	1,168	17.2	93	1.4	2,284	33.5	150	2.2	41	0.6	6,809
Massachusetts	4,502	53.2	1,614	19.1	218	2.6	1,880	22.2	141	1.7	102	1.2	8,457
Michigan	4,536	70.7	215	3.4	132	2.1	1,364	21.3	117	1.8	48	0.7	6,412
Minnesota	1,662	65.3	144	5.7	129	5.1	561	22.0	29	1.1	20	0.8	2,545
Mississippi	1,691	57.5	49	1.7	20	0.7	1,107	37.7	55	1.9	17	0.6	2,939
Missouri	4,334	75.1	202	3.5	19	0.3	1,114	19.3	47	0.8	52	0.9	5,768
Montana	198	70.7	25	8.9	31	11.1	23	8.2	0	0.0	3	1.1	280
Nebraska	534	63.9	57	6.8	14	1.7	193	23.1	23	2.8	15	1.8	836
Nevada	1,658	71.7	133	5.8	84	3.6	372	16.1	40	1.7	25	1.1	2,312
New Hampshire	370	62.7	63	10.7	36	6.1	97	16.4	10	1.7	14	2.4	590
New Jersey	4,339	43.8	1,544	15.6	159	1.6	3,463	35.0	297	3.0	95	1.0	9,897
New Mexico	1,362	79.5	75	4.4	110	6.4	154	9.0	4	0.2	9	0.5	1,714
New York	18,613	55.0	3,011	8.9	525	1.6	10,732	31.7	691	2.0	263	0.8	33,835
North Carolina	5,913	59.2	494	4.9	283	2.8	3,104	31.1	143	1.4	52	0.5	9,989
North Dakota	68	59.1	1	0.9	13	11.3	32	27.8	0	0.0	1	0.9	115
Ohio	6,172	75.7	294	3.6	91	1.1	1,478	18.1	52	0.6	62	0.8	8,149
Oklahoma	1,630	71.6	137	6.0	148	6.5	333	14.6	5	0.2	24	1.1	2,277
Oregon	1,767	67.5	206	7.9	344	13.1	254	9.7	17	0.6	31	1.2	2,619
Pennsylvania	8,504	54.3	2,165	13.8	518	3.3	4,086	26.1	264	1.7	130	0.8	15,667
Rhode Island	695	56.1	159	12.8	31	2.5	306	24.7	29	2.3	18	1.5	1,238
South Carolina	4,033	58.8	243	3.5	91	1.3	2,331	34.0	83	1.2	79	1.2	6,860
South Dakota	152	62.0	14	5.7	8	3.3	66	26.9	1	0.4	4	1.6	245
Tennessee	5,290	64.8	361	4.4	174	2.1	2,192	26.8	91	1.1	56	0.7	8,164
Texas	19,040	68.0	710	2.5	308	1.1	7,499	26.8	324	1.2	117	0.4	27,998

Table 11a-i. Male clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and state, 2015—United States and 3 territories (cont.)

State	Male-to-male sexual contact		Injection drug use		Male-to-male sexual contact and injection drug use		Heterosexual contact ^a		Perinatal infection		Other ^b		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Utah	924	65.2	96	6.8	223	15.7	135	9.5	20	1.4	20	1.4	1,418
Vermont	302	71.7	30	7.1	23	5.5	56	13.3	4	1.0	6	1.4	421
Virginia	3,586	62.9	311	5.5	121	2.1	1,567	27.5	66	1.2	50	0.9	5,701
Washington	3,228	69.5	314	6.8	413	8.9	625	13.4	24	0.5	43	0.9	4,647
West Virginia	437	72.5	46	7.6	21	3.5	93	15.4	3	0.5	3	0.5	603
Wisconsin	1,945	69.2	170	6.0	80	2.8	520	18.5	69	2.5	27	1.0	2,811
Wyoming	72	64.3	10	8.9	14	12.5	13	11.6	3	2.7	0	0.0	112
Subtotal	208,692	63.5	21,767	6.6	9,852	3.0	81,267	24.7	4,665	1.4	2,383	0.7	328,626
Territories													
Guam	19	82.6	0	0.0	1	4.3	2	8.7	1	4.3	0	0.0	23
Puerto Rico	3,057	38.1	1,477	18.4	75	0.9	3,214	40.1	142	1.8	50	0.6	8,015
U.S. Virgin Islands	46	43.4	11	10.4	0	0.0	48	45.3	1	0.9	0	0.0	106
Subtotal	3,122	38.3	1,488	18.3	76	0.9	3,264	40.1	144	1.8	50	0.6	8,144
Total	211,814	62.9	23,255	6.9	9,928	2.9	84,531	25.1	4,809	1.4	2,433	0.7	336,770

Note. Percentages shown are based on the row total.

Data are based on provider location. Clients receiving services in multiple states were not included in state-specific totals.

^a Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^b Includes hemophilia and blood transfusion.

Table 11a-ii. Female clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and state, 2015—United States and 3 territories

State	Injection drug use		Heterosexual contact ^a		Perinatal infection		Other ^b		Total
	No.	%	No.	%	No.	%	No.	%	No.
Alabama	131	5.3	2,218	90.3	94	3.8	12	0.5	2,455
Alaska	26	19.4	106	79.1	1	0.7	1	0.7	134
Arizona	153	12.9	961	80.9	55	4.6	19	1.6	1,188
Arkansas	48	10.0	420	87.5	10	2.1	2	0.4	480
California	1,001	13.9	5,710	79.2	329	4.6	167	2.3	7,207
Colorado	173	16.1	790	73.6	87	8.1	23	2.1	1,073
Connecticut	376	18.8	1,520	76.0	78	3.9	27	1.3	2,001
Delaware	114	18.2	493	78.8	15	2.4	4	0.6	626
District of Columbia	95	6.0	1,334	84.7	128	8.1	18	1.1	1,575
Florida	725	4.6	14,048	89.3	762	4.8	195	1.2	15,730
Georgia	247	4.1	5,419	90.4	290	4.8	37	0.6	5,993
Hawaii	8	7.7	86	82.7	6	5.8	4	3.8	104
Idaho	21	18.1	90	77.6	2	1.7	3	2.6	116
Illinois	418	9.4	3,685	83.3	254	5.7	69	1.6	4,426
Indiana	156	13.2	992	84.1	17	1.4	14	1.2	1,179
Iowa	34	10.5	280	86.2	5	1.5	6	1.8	325
Kansas	17	7.5	196	86.0	9	3.9	6	2.6	228
Kentucky	93	9.9	800	85.6	22	2.4	20	2.1	935
Louisiana	266	7.2	3,323	90.1	74	2.0	27	0.7	3,690
Maine	27	16.2	126	75.4	4	2.4	10	6.0	167
Maryland	653	16.2	3,108	76.9	217	5.4	63	1.6	4,041
Massachusetts	852	21.5	2,879	72.6	164	4.1	68	1.7	3,963
Michigan	151	7.4	1,779	87.1	93	4.6	20	1.0	2,043
Minnesota	68	6.3	953	88.7	33	3.1	21	2.0	1,075
Mississippi	33	2.3	1,360	92.8	66	4.5	7	0.5	1,466
Missouri	44	2.7	1,541	92.8	51	3.1	24	1.4	1,660
Montana	11	19.0	45	77.6	0	0.0	2	3.4	58
Nebraska	18	6.0	270	89.7	11	3.7	2	0.7	301
Nevada	48	8.0	500	83.6	42	7.0	8	1.3	598
New Hampshire	35	17.5	146	73.0	14	7.0	5	2.5	200
New Jersey	807	14.0	4,495	78.2	351	6.1	93	1.6	5,746
New Mexico	45	19.0	185	78.1	4	1.7	3	1.3	237
New York	1,442	8.9	13,614	84.2	852	5.3	265	1.6	16,173
North Carolina	265	5.9	4,053	89.7	160	3.5	38	0.8	4,516
North Dakota	3	6.0	46	92.0	0	0.0	1	2.0	50
Ohio	113	4.9	2,082	89.7	102	4.4	23	1.0	2,320
Oklahoma	82	15.4	432	80.9	8	1.5	12	2.2	534
Oregon	107	23.8	327	72.8	10	2.2	5	1.1	449
Pennsylvania	1,163	16.6	5,496	78.2	276	3.9	89	1.3	7,024
Rhode Island	101	18.7	403	74.6	27	5.0	9	1.7	540
South Carolina	132	3.9	3,074	91.4	123	3.7	34	1.0	3,363
South Dakota	2	2.1	90	92.8	3	3.1	2	2.1	97
Tennessee	244	8.0	2,664	87.0	116	3.8	38	1.2	3,062
Texas	336	3.5	8,951	92.1	354	3.6	82	0.8	9,723

Table 11a-ii. Female clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and state, 2015—United States and 3 territories (cont.)

State	Injection drug use		Heterosexual contact ^a		Perinatal infection		Other ^b		Total
	No.	%	No.	%	No.	%	No.	%	No.
Utah	35	13.1	223	83.2	6	2.2	4	1.5	268
Vermont	15	17.0	68	77.3	2	2.3	3	3.4	88
Virginia	222	8.4	2,306	87.0	85	3.2	39	1.5	2,652
Washington	198	18.4	827	76.9	23	2.1	28	2.6	1,076
West Virginia	27	16.4	133	80.6	5	3.0	0	0.0	165
Wisconsin	65	7.3	723	81.7	82	9.3	15	1.7	885
Wyoming	5	18.5	20	74.1	2	7.4	0	0.0	27
Subtotal	11,451	9.2	105,390	85.0	5,524	4.5	1,667	1.3	124,032
Territories									
Guam	0	0.0	8	88.9	1	11.1	0	0.0	9
Puerto Rico	336	8.5	3,429	86.4	151	3.8	53	1.3	3,969
U.S. Virgin Islands	7	6.9	93	92.1	1	1.0	0	0.0	101
Subtotal	343	8.4	3,530	86.5	153	3.8	53	1.3	4,079
Total	11,794	9.2	108,920	85.0	5,677	4.4	1,720	1.3	128,111

Note. Percentages shown are based on the row total.

Data are based on provider location. Clients receiving services in multiple states were not included in state-specific totals.

^a Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^b Includes hemophilia and blood transfusion.

Table 11a-iii. Transgender clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and state, 2015—United States and 3 territories

State	Sexual contact ^a		Injection drug use		Sexual contact ^a and injection drug use		Perinatal infection		Other ^b		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Alabama	44	97.8	0	0.0	1	2.2	0	0.0	0	0.0	45
Alaska	6	60.0	0	0.0	3	30.0	0	0.0	1	10.0	10
Arizona	63	85.1	1	1.4	10	13.5	0	0.0	0	0.0	74
Arkansas	9	90.0	0	0.0	1	10.0	0	0.0	0	0.0	10
California	714	84.5	28	3.3	96	11.4	2	0.2	5	0.6	845
Colorado	31	77.5	4	10.0	4	10.0	0	0.0	1	2.5	40
Connecticut	46	88.5	3	5.8	3	5.8	0	0.0	0	0.0	52
Delaware	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	10
District of Columbia	216	98.6	0	0.0	2	0.9	0	0.0	1	0.5	219
Florida	311	97.5	0	0.0	8	2.5	0	0.0	0	0.0	319
Georgia	180	98.9	0	0.0	2	1.1	0	0.0	0	0.0	182
Hawaii	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	10
Idaho	4	80.0	0	0.0	1	20.0	0	0.0	0	0.0	5
Illinois	202	95.3	5	2.4	3	1.4	1	0.5	1	0.5	212
Indiana	61	98.4	0	0.0	1	1.6	0	0.0	0	0.0	62
Iowa	8	80.0	2	20.0	0	0.0	0	0.0	0	0.0	10
Kansas	9	100.0	0	0.0	0	0.0	0	0.0	0	0.0	9
Kentucky	65	95.6	0	0.0	2	2.9	1	1.5	0	0.0	68
Louisiana	130	94.9	3	2.2	4	2.9	0	0.0	0	0.0	137
Maine	5	83.3	0	0.0	1	16.7	0	0.0	0	0.0	6
Maryland	50	90.9	4	7.3	1	1.8	0	0.0	0	0.0	55
Massachusetts	104	91.2	3	2.6	5	4.4	0	0.0	2	1.8	114
Michigan	88	98.9	0	0.0	1	1.1	0	0.0	0	0.0	89
Minnesota	48	92.3	0	0.0	4	7.7	0	0.0	0	0.0	52
Mississippi	17	94.4	0	0.0	0	0.0	0	0.0	1	5.6	18
Missouri	113	98.3	1	0.9	1	0.9	0	0.0	0	0.0	115
Montana	2	100.0	0	0.0	0	0.0	0	0.0	0	0.0	2
Nebraska	5	100.0	0	0.0	0	0.0	0	0.0	0	0.0	5
Nevada	53	94.6	0	0.0	2	3.6	1	1.8	0	0.0	56
New Hampshire	5	83.3	0	0.0	1	16.7	0	0.0	0	0.0	6
New Jersey	73	88.0	2	2.4	5	6.0	0	0.0	3	3.6	83
New Mexico	13	86.7	0	0.0	2	13.3	0	0.0	0	0.0	15
New York	937	94.9	20	2.0	24	2.4	4	0.4	2	0.2	987
North Carolina	121	92.4	1	0.8	8	6.1	0	0.0	1	0.8	131
North Dakota	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Ohio	124	96.1	2	1.6	3	2.3	0	0.0	0	0.0	129
Oklahoma	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	10
Oregon	27	87.1	1	3.2	3	9.7	0	0.0	0	0.0	31
Pennsylvania	289	91.2	6	1.9	20	6.3	0	0.0	2	0.6	317
Rhode Island	11	91.7	0	0.0	1	8.3	0	0.0	0	0.0	12
South Carolina	57	95.0	0	0.0	2	3.3	0	0.0	1	1.7	60
South Dakota	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Tennessee	78	90.7	2	2.3	4	4.7	1	1.2	1	1.2	86
Texas	165	95.4	2	1.2	5	2.9	0	0.0	1	0.6	173

Table 11a-iii. Transgender clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and state, 2015—United States and 3 territories (cont.)

State	Sexual contact ^a		Injection drug use		Sexual contact ^a and injection drug use		Perinatal infection		Other ^b		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Utah	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0	7
Vermont	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Virginia	102	98.1	1	1.0	1	1.0	0	0.0	0	0.0	104
Washington	50	79.4	9	14.3	4	6.3	0	0.0	0	0.0	63
West Virginia	2	100.0	0	0.0	0	0.0	0	0.0	0	0.0	2
Wisconsin	55	94.8	0	0.0	1	1.7	2	3.4	0	0.0	58
Wyoming	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Subtotal	4,730	92.7	100	2.0	240	4.7	12	0.2	23	0.5	5,105
Territories											
Guam	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	1
Puerto Rico	21	95.5	0	0.0	1	4.5	0	0.0	0	0.0	22
U.S. Virgin Islands	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Subtotal	22	95.7	0	0.0	1	4.3	0	0.0	0	0.0	23
Total	4,752	92.7	100	2.0	241	4.7	12	0.2	23	0.4	5,128

Note. Percentages shown are based on the row total.

Data are based on provider location. Clients receiving services in multiple states were not included in state-specific totals.

^a Includes any sexual transmission risk category reported by transgender clients.

^b Includes hemophilia and blood transfusion.

Table 11b-i. Male clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and eligible metropolitan area and transitional grant area, 2015—United States and 3 territories

	Male-to-male sexual contact		Injection drug use		Male-to-male sexual contact and injection drug use		Heterosexual contact ^a		Perinatal infection		Other ^b		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Eligible metropolitan area													
Atlanta, GA	7,391	72.9	220	2.2	221	2.2	2,076	20.5	211	2.1	17	0.2	10,136
Baltimore, MD	2,408	44.7	1,078	20.0	81	1.5	1,652	30.6	147	2.7	25	0.5	5,391
Boston, MA	3,986	54.2	1,296	17.6	209	2.8	1,636	22.2	130	1.8	96	1.3	7,353
Chicago, IL	8,488	66.5	794	6.2	179	1.4	3,003	23.5	206	1.6	95	0.7	12,765
Dallas, TX	4,685	68.9	218	3.2	162	2.4	1,644	24.2	64	0.9	24	0.4	6,797
Detroit, MI	2,591	67.2	142	3.7	65	1.7	952	24.7	89	2.3	17	0.4	3,856
Ft. Lauderdale, FL	5,948	65.4	211	2.3	135	1.5	2,572	28.3	183	2.0	52	0.6	9,101
Houston, TX	5,032	60.8	296	3.6	150	1.8	2,594	31.3	159	1.9	45	0.5	8,276
Los Angeles, CA	15,914	76.1	668	3.2	1,061	5.1	3,039	14.5	115	0.6	108	0.5	20,905
Miami, FL	5,186	61.6	238	2.8	115	1.4	2,680	31.8	159	1.9	44	0.5	8,422
Nassau Suffolk, NY	694	45.5	165	10.8	23	1.5	520	34.1	94	6.2	28	1.8	1,524
New Haven, CT	469	40.9	334	29.1	21	1.8	293	25.6	13	1.1	16	1.4	1,146
New Orleans, LA	2,259	57.5	194	4.9	50	1.3	1,385	35.2	25	0.6	18	0.5	3,931
New York, NY	14,407	54.7	2,397	9.1	419	1.6	8,355	31.7	555	2.1	191	0.7	26,324
Newark, NJ	1,372	37.3	584	15.9	49	1.3	1,502	40.8	132	3.6	41	1.1	3,680
Orlando, FL	1,646	66.7	115	4.7	31	1.3	637	25.8	20	0.8	20	0.8	2,469
Philadelphia, PA	5,952	50.7	1,708	14.5	423	3.6	3,342	28.5	253	2.2	68	0.6	11,746
Phoenix, AZ	2,996	70.0	191	4.5	435	10.2	575	13.4	59	1.4	21	0.5	4,277
San Diego, CA	4,135	81.7	206	4.1	312	6.2	346	6.8	29	0.6	36	0.7	5,064
San Francisco, CA	3,627	73.2	489	9.9	627	12.7	178	3.6	8	0.2	25	0.5	4,954
San Juan, PR	2,541	36.7	1,274	18.4	64	0.9	2,861	41.3	136	2.0	43	0.6	6,919
Tampa-St. Petersburg, FL	2,929	64.7	171	3.8	100	2.2	1,154	25.5	121	2.7	50	1.1	4,525
Washington, DC	3,526	56.2	267	4.3	38	0.6	2,256	36.0	134	2.1	52	0.8	6,273
West Palm Beach, FL	859	38.0	50	2.2	25	1.1	1,295	57.2	24	1.1	10	0.4	2,263
Transitional grant area													
Austin, TX	3,650	80.3	54	1.2	23	0.5	801	17.6	6	0.1	9	0.2	4,543
Baton Rouge, LA	787	42.7	186	10.1	71	3.9	759	41.2	35	1.9	5	0.3	1,843
Bergen-Passaic, NJ	493	38.2	244	18.9	21	1.6	491	38.0	32	2.5	11	0.9	1,292
Charlotte, NC	1,515	64.9	103	4.4	34	1.5	654	28.0	16	0.7	11	0.5	2,333
Cleveland, OH	1,821	71.7	133	5.2	39	1.5	514	20.2	20	0.8	12	0.5	2,539
Columbus, OH	3,094	80.1	97	2.5	40	1.0	568	14.7	27	0.7	36	0.9	3,862
Denver, CO	3,476	70.6	278	5.6	515	10.5	556	11.3	69	1.4	31	0.6	4,925
Ft. Worth, TX	1,385	66.0	19	0.9	12	0.6	636	30.3	43	2.0	4	0.2	2,099
Hartford, CT	548	36.5	448	29.8	46	3.1	429	28.5	26	1.7	6	0.4	1,503
Indianapolis, IN	2,616	72.5	159	4.4	37	1.0	730	20.2	23	0.6	42	1.2	3,607
Jacksonville, FL	1,044	64.6	66	4.1	40	2.5	451	27.9	11	0.7	5	0.3	1,617
Jersey City, NJ	772	56.1	162	11.8	12	0.9	384	27.9	35	2.5	12	0.9	1,377
Kansas City, MO	1,657	77.2	72	3.4	5	0.2	377	17.6	16	0.7	18	0.8	2,145
Las Vegas, NV	1,343	73.5	81	4.4	85	4.7	276	15.1	28	1.5	14	0.8	1,827
Memphis, TN	1,816	55.8	69	2.1	36	1.1	1,267	38.9	53	1.6	12	0.4	3,253
Middlesex, NJ	391	44.4	149	16.9	22	2.5	267	30.3	46	5.2	6	0.7	881
Minneapolis-St. Paul, MN	1,743	65.4	148	5.6	145	5.4	580	21.8	29	1.1	20	0.8	2,665

Table 11b-i. Male clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and eligible metropolitan area and transitional grant area, 2015—United States and 3 territories (cont.)

	Male-to-male sexual contact		Injection drug use		Male-to-male sexual contact and injection drug use		Heterosexual contact ^a		Perinatal infection		Other ^b		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Transitional grant area													
Nashville, TN	2,726	70.0	203	5.2	117	3.0	778	20.0	35	0.9	34	0.9	3,893
Norfolk, VA	1,239	65.0	119	6.2	36	1.9	488	25.6	14	0.7	10	0.5	1,906
Oakland, CA	1,309	74.8	103	5.9	94	5.4	186	10.6	34	1.9	23	1.3	1,749
Orange County, CA	1,331	76.5	95	5.5	96	5.5	203	11.7	9	0.5	7	0.4	1,741
Portland, OR	2,375	72.5	179	5.5	344	10.5	346	10.6	14	0.4	20	0.6	3,278
Riverside-San Bernardino, CA	2,522	84.6	87	2.9	120	4.0	235	7.9	3	0.1	15	0.5	2,982
Sacramento, CA	1,521	69.1	175	8.0	201	9.1	254	11.5	28	1.3	21	1.0	2,200
San Antonio, TX	2,425	76.1	91	2.9	8	0.3	612	19.2	33	1.0	19	0.6	3,188
San Jose, CA	540	74.6	40	5.5	39	5.4	98	13.5	2	0.3	5	0.7	724
Seattle, WA	2,295	72.5	167	5.3	269	8.5	402	12.7	14	0.4	19	0.6	3,166
St. Louis, MO	3,717	75.7	151	3.1	37	0.8	924	18.8	35	0.7	44	0.9	4,908

Abbreviations: EMA, eligible metropolitan area; TGA, transitional grant area.

Note. Percentages shown are based on the row total.

EMA/TGA delineations are based on provider location.

Data shown for EMAs and TGAs are not mutually exclusive; clients may have received services from providers in multiple EMAs and/or TGAs.

^a Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^b Includes hemophilia and blood transfusion.

Table 11b-ii. Female clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and eligible metropolitan area and transitional grant area, 2015—United States and 3 territories

	Injection drug use		Heterosexual contact ^a		Perinatal infection		Other ^b		Total
	No.	%	No.	%	No.	%	No.	%	No.
Eligible metropolitan area									
Atlanta, GA	109	3.4	2,864	88.7	233	7.2	23	0.7	3,229
Baltimore, MD	615	20.8	2,115	71.6	187	6.3	37	1.3	2,954
Boston, MA	708	20.5	2,530	73.2	155	4.5	62	1.8	3,455
Chicago, IL	355	9.1	3,228	82.9	248	6.4	63	1.6	3,894
Dallas, TX	140	6.2	2,040	89.8	69	3.0	23	1.0	2,272
Detroit, MI	101	7.3	1,199	86.2	78	5.6	13	0.9	1,391
Ft. Lauderdale, FL	97	2.7	3,189	89.9	225	6.3	38	1.1	3,549
Houston, TX	139	4.2	2,962	89.3	186	5.6	29	0.9	3,316
Los Angeles, CA	225	6.6	2,977	87.2	152	4.5	60	1.8	3,414
Miami, FL	190	5.8	2,860	87.3	180	5.5	46	1.4	3,276
Nassau Suffolk, NY	131	8.6	1,230	81.0	123	8.1	35	2.3	1,519
New Haven, CT	148	19.8	568	76.1	21	2.8	9	1.2	746
New Orleans, LA	101	5.6	1,651	91.7	33	1.8	15	0.8	1,800
New York, NY	1,114	9.0	10,311	83.8	692	5.6	193	1.6	12,310
Newark, NJ	288	12.4	1,819	78.4	165	7.1	47	2.0	2,319
Orlando, FL	33	3.2	941	92.6	26	2.6	16	1.6	1,016
Philadelphia, PA	910	16.8	4,215	77.8	243	4.5	53	1.0	5,421
Phoenix, AZ	111	12.0	753	81.1	49	5.3	15	1.6	928
San Diego, CA	102	11.6	709	80.8	47	5.4	19	2.2	877
San Francisco, CA	250	41.5	329	54.6	12	2.0	12	2.0	603
San Juan, PR	309	8.5	3,124	86.2	142	3.9	49	1.4	3,624
Tampa-St. Petersburg, FL	94	5.3	1,532	85.6	132	7.4	32	1.8	1,790
Washington, DC	185	5.3	3,039	86.9	205	5.9	68	1.9	3,497
West Palm Beach, FL	42	2.8	1,410	94.0	35	2.3	13	0.9	1,500
Transitional grant area									
Austin, TX	20	1.8	1,074	96.9	7	0.6	7	0.6	1,108
Baton Rouge, LA	133	9.5	1,218	87.4	37	2.7	5	0.4	1,393
Bergen-Passaic, NJ	98	13.2	604	81.5	27	3.6	12	1.6	741
Charlotte, NC	40	4.6	795	91.6	17	2.0	16	1.8	868
Cleveland, OH	39	5.2	668	88.8	39	5.2	6	0.8	752
Columbus, OH	37	3.7	904	90.2	48	4.8	13	1.3	1,002
Denver, CO	166	15.9	764	73.3	93	8.9	20	1.9	1,043
Ft. Worth, TX	10	1.1	823	93.3	45	5.1	4	0.5	882
Hartford, CT	206	22.3	655	71.0	45	4.9	17	1.8	923
Indianapolis, IN	160	13.0	1,042	84.4	18	1.5	15	1.2	1,235
Jacksonville, FL	53	6.3	780	92.3	7	0.8	5	0.6	845
Jersey City, NJ	81	12.0	547	80.9	30	4.4	18	2.7	676
Kansas City, MO	19	3.7	466	91.9	14	2.8	8	1.6	507
Las Vegas, NV	42	8.8	404	84.7	26	5.5	5	1.0	477
Memphis, TN	47	3.1	1,408	91.4	77	5.0	8	0.5	1,540
Middlesex, NJ	91	14.8	447	72.9	67	10.9	8	1.3	613
Minneapolis-St. Paul, MN	72	6.4	989	88.5	35	3.1	21	1.9	1,117
Nashville, TN	137	11.4	1,006	83.9	36	3.0	20	1.7	1,199
Norfolk, VA	72	8.6	740	88.4	19	2.3	6	0.7	837
Oakland, CA	84	14.2	435	73.7	51	8.6	20	3.4	590
Orange County, CA	30	11.3	217	81.9	10	3.8	8	3.0	265
Portland, OR	86	17.3	395	79.3	8	1.6	9	1.8	498
Riverside-San Bernardino, CA	32	8.7	323	87.5	4	1.1	10	2.7	369
Sacramento, CA	96	19.2	362	72.5	26	5.2	15	3.0	499
San Antonio, TX	24	3.1	706	91.0	39	5.0	7	0.9	776
San Jose, CA	14	11.5	102	83.6	2	1.6	4	3.3	122
Seattle, WA	139	19.3	552	76.6	15	2.1	15	2.1	721
St. Louis, MO	50	3.3	1,417	92.9	41	2.7	17	1.1	1,525

Abbreviations: EMA, eligible metropolitan area; TGA, transitional grant area.

Note. Percentages shown are based on the row total.

EMA/TGA delineations are based on provider location.

Data shown for EMAs and TGAs are not mutually exclusive; clients may have received services from providers in multiple EMAs and/or TGAs.

^a Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^b Includes hemophilia and blood transfusion.

Table 11b-iii. Transgender clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and eligible metropolitan area and transitional grant area, 2015—United States and 3 territories

	Sexual contact ^a		Injection drug use		Sexual contact ^a and injection drug use		Perinatal infection		Other ^b		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Eligible metropolitan area											
Atlanta, GA	150	98.0	0	0.0	3	2.0	0	0.0	0	0.0	153
Baltimore, MD	35	87.5	4	10.0	1	2.5	0	0.0	0	0.0	40
Boston, MA	89	85.6	3	2.9	7	6.7	3	2.9	2	1.9	104
Chicago, IL	199	96.1	5	2.4	1	0.5	1	0.5	1	0.5	207
Dallas, TX	62	92.5	1	1.5	3	4.5	0	0.0	1	1.5	67
Detroit, MI	72	98.6	0	0.0	1	1.4	0	0.0	0	0.0	73
Ft. Lauderdale, FL	72	97.3	0	0.0	2	2.7	0	0.0	0	0.0	74
Houston, TX	106	98.1	1	0.9	1	0.9	0	0.0	0	0.0	108
Los Angeles, CA	316	93.5	8	2.4	12	3.6	1	0.3	1	0.3	338
Miami, FL	49	96.1	0	0.0	2	3.9	0	0.0	0	0.0	51
Nassau Suffolk, NY	11	78.6	3	21.4	0	0.0	0	0.0	0	0.0	14
New Haven, CT	20	87.0	3	13.0	0	0.0	0	0.0	0	0.0	23
New Orleans, LA	81	96.4	1	1.2	2	2.4	0	0.0	0	0.0	84
New York, NY	889	95.1	17	1.8	23	2.5	4	0.4	2	0.2	935
Newark, NJ	1	25.0	2	50.0	1	25.0	0	0.0	0	0.0	4
Orlando, FL	33	100.0	0	0.0	0	0.0	0	0.0	0	0.0	33
Philadelphia, PA	263	92.0	6	2.1	16	5.6	0	0.0	1	0.3	286
Phoenix, AZ	55	90.2	1	1.6	5	8.2	0	0.0	0	0.0	61
San Diego, CA	63	81.8	2	2.6	12	15.6	0	0.0	0	0.0	77
San Francisco, CA	152	68.8	12	5.4	55	24.9	0	0.0	2	0.9	221
San Juan, PR	18	94.7	0	0.0	1	5.3	0	0.0	0	0.0	19
Tampa-St. Petersburg, FL	65	98.5	0	0.0	1	1.5	0	0.0	0	0.0	66
Washington, DC	249	98.4	0	0.0	3	1.2	0	0.0	1	0.4	253
West Palm Beach, FL	9	100.0	0	0.0	0	0.0	0	0.0	0	0.0	9
Transitional grant area											
Austin, TX	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Baton Rouge, LA	30	90.9	1	3.0	2	6.1	0	0.0	0	0.0	33
Bergen-Passaic, NJ	9	81.8	0	0.0	1	9.1	0	0.0	1	9.1	11
Charlotte, NC	32	88.9	1	2.8	3	8.3	0	0.0	0	0.0	36
Cleveland, OH	44	97.8	1	2.2	0	0.0	0	0.0	0	0.0	45
Columbus, OH	51	89.5	1	1.8	4	7.0	1	1.8	0	0.0	57
Denver, CO	30	78.9	3	7.9	4	10.5	0	0.0	1	2.6	38
Ft. Worth, TX	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Hartford, CT	22	84.6	1	3.8	3	11.5	0	0.0	0	0.0	26
Indianapolis, IN	62	98.4	0	0.0	1	1.6	0	0.0	0	0.0	63
Jacksonville, FL	32	94.1	0	0.0	2	5.9	0	0.0	0	0.0	34
Jersey City, NJ	24	88.9	0	0.0	2	7.4	0	0.0	1	3.7	27
Kansas City, MO	47	97.9	1	2.1	0	0.0	0	0.0	0	0.0	48
Las Vegas, NV	41	95.3	0	0.0	2	4.7	0	0.0	0	0.0	43
Memphis, TN	37	97.4	0	0.0	1	2.6	0	0.0	0	0.0	38
Middlesex, NJ	5	83.3	0	0.0	1	16.7	0	0.0	0	0.0	6
Minneapolis-St. Paul, MN	51	92.7	0	0.0	4	7.3	0	0.0	0	0.0	55
Nashville, TN	34	85.0	2	5.0	2	5.0	1	2.5	1	2.5	40
Norfolk, VA	44	97.8	1	2.2	0	0.0	0	0.0	0	0.0	45

Table 11b-iii. Transgender clients served by the Ryan White HIV/AIDS Program (non-ADAP), by transmission risk category and eligible metropolitan area and transitional grant area, 2015—United States and 3 territories (cont.)

	Sexual contact ^a		Injection drug use		Sexual contact ^a and injection drug use		Perinatal infection		Other ^b		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Transitional grant area											
Oakland, CA	73	90.1	0	0.0	8	9.9	0	0.0	0	0.0	81
Orange County, CA	45	97.8	0	0.0	1	2.2	0	0.0	0	0.0	46
Portland, OR	46	92.0	0	0.0	4	8.0	0	0.0	0	0.0	50
Riverside-San Bernardino, CA	13	100.0	0	0.0	0	0.0	0	0.0	0	0.0	13
Sacramento, CA	18	66.7	3	11.1	4	14.8	1	3.7	1	3.7	27
San Antonio, TX	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0	2
San Jose, CA	18	85.7	1	4.8	2	9.5	0	0.0	0	0.0	21
Seattle, WA	37	74.0	9	18.0	4	8.0	0	0.0	0	0.0	50
St. Louis, MO	88	98.9	0	0.0	1	1.1	0	0.0	0	0.0	89

Abbreviations: EMA, eligible metropolitan area; TGA, transitional grant area.

Note. Percentages shown are based on the row total.

EMA/TGA delineations are based on provider location.

Data shown for EMAs and TGAs are not mutually exclusive; clients may have received services from providers in multiple EMAs and/or TGAs.

^a Includes any sexual transmission risk category reported by transgender clients.

^b Includes hemophilia and blood transfusion.

Table 12a. Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2011–2015—United States and 3 territories

	2011			2012			2013			2014			2015		
	Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained	
		No.	%		No.	%		No.	%		No.	%		No.	%
Age group (yr)															
<13	1,298	1,144	88.1	1,199	1,067	89.0	1,061	935	88.1	1,002	898	89.6	1,178	1,053	89.4
13–14	560	498	88.9	433	390	90.1	339	298	87.9	328	290	88.4	357	339	95.0
15–19	3,025	2,539	83.9	2,637	2,164	82.1	2,226	1,863	83.7	2,123	1,745	82.2	2,134	1,773	83.1
20–24	12,046	9,176	76.2	12,698	9,524	75.0	13,055	9,825	75.3	12,280	9,016	73.4	12,828	9,579	74.7
25–29	19,216	14,714	76.6	20,526	15,693	76.5	21,676	16,377	75.6	22,153	16,464	74.3	26,377	19,534	74.1
30–34	24,828	19,493	78.5	25,091	19,669	78.4	25,429	19,669	77.4	24,803	18,898	76.2	28,971	22,063	76.2
35–39	28,812	23,253	80.7	28,122	22,546	80.2	27,421	21,697	79.1	26,802	20,899	78.0	32,041	25,069	78.2
40–44	41,606	33,880	81.4	39,137	31,993	81.8	35,917	29,167	81.2	32,960	26,293	79.8	35,837	28,545	79.7
45–49	52,345	43,640	83.4	51,049	42,300	82.9	47,306	38,759	81.9	43,037	34,892	81.1	48,922	39,763	81.3
50–54	43,108	36,412	84.5	44,991	37,927	84.3	45,827	38,007	82.9	45,790	37,851	82.7	56,078	46,170	82.3
55–59	27,421	23,427	85.4	29,753	25,478	85.6	30,525	25,698	84.2	31,719	26,577	83.8	41,471	34,857	84.1
60–64	13,675	11,818	86.4	15,226	13,136	86.3	16,308	13,866	85.0	17,814	15,182	85.2	24,054	20,505	85.3
≥65	8,126	7,001	86.2	9,232	8,013	86.8	9,931	8,338	84.0	11,275	9,657	85.7	16,827	14,441	85.8
Race/ethnicity															
American Indian/Alaska Native	1,219	952	78.1	1,175	941	80.1	1,234	959	77.7	1,136	871	76.7	1,317	983	74.6
Asian	2,901	2,473	85.3	3,261	2,741	84.1	3,239	2,662	82.2	3,265	2,605	79.8	4,283	3,496	81.6
Black/African American	129,427	104,448	80.7	130,189	105,467	81.0	128,931	103,283	80.1	126,317	100,807	79.8	153,656	122,785	79.9
Hispanic/Latino ^a	60,834	51,901	85.3	64,142	54,625	85.2	66,143	55,783	84.3	66,470	55,401	83.4	78,744	65,668	83.4
Native Hawaiian/Pacific Islander	615	504	82.0	477	376	78.8	426	317	74.4	375	279	74.4	450	344	76.4
White	73,029	60,229	82.5	73,424	59,701	81.3	70,139	55,942	79.8	67,749	53,465	78.9	82,730	65,858	79.6
Multiple races	3,365	2,841	84.4	3,819	3,230	84.6	4,452	3,705	83.2	5,141	4,167	81.1	4,414	3,609	81.8
Gender															
Male	192,187	157,534	82.0	197,210	161,044	81.7	194,526	156,233	80.3	191,109	152,075	79.6	231,732	184,862	79.8
Female	81,551	67,605	82.9	80,362	66,834	83.2	80,011	66,329	82.9	78,281	64,512	82.4	91,495	75,793	82.8
Transgender MTF	2,017	1,615	80.1	2,291	1,839	80.3	2,280	1,780	78.1	2,445	1,917	78.4	3,162	2,480	78.4
Transgender FTM	86	63	73.3	80	60	75.0	56	46	82.1	85	65	76.5	206	170	82.5
Transgender unknown	188	152	80.9	131	110	84.0	123	94	76.4	116	92	79.3	5	3	60.0
Transmission risk category															
Male client															
Male-to-male sexual contact	105,435	87,707	83.2	111,787	91,879	82.2	112,557	90,747	80.6	113,199	89,910	79.4	140,108	111,625	79.7
Injection drug use	14,910	12,026	80.7	13,980	11,382	81.4	14,072	11,411	81.1	12,563	10,221	81.4	14,365	11,759	81.9
Male-to-male sexual contact and injection drug use	6,140	5,064	82.5	6,296	5,043	80.1	5,601	4,338	77.5	5,819	4,519	77.7	6,480	5,143	79.4
Heterosexual contact ^b	44,443	36,214	81.5	45,311	37,096	81.9	45,312	36,677	80.9	45,588	36,974	81.1	56,088	45,434	81.0
Perinatal infection	2,595	2,205	85.0	2,450	2,074	84.7	2,445	2,005	82.0	2,406	2,010	83.5	2,669	2,197	82.3
Other ^c	1,099	895	81.4	1,172	937	80.0	1,258	974	77.4	1,064	856	80.5	1,367	1,104	80.8
Female client															
Injection drug use	8,083	6,641	82.2	7,523	6,177	82.1	7,702	6,306	81.9	6,852	5,693	83.1	7,647	6,346	83.0
Heterosexual contact ^b	62,169	51,827	83.4	62,365	52,009	83.4	63,056	52,624	83.5	63,027	52,149	82.7	75,145	62,460	83.1
Perinatal infection	3,198	2,830	88.5	3,025	2,604	86.1	3,001	2,569	85.6	3,075	2,612	84.9	3,454	2,938	85.1
Other ^c	793	675	85.1	812	687	84.6	936	742	79.3	854	687	80.4	977	809	82.8
Transgender client															
Sexual contact ^d	1,857	1,507	81.2	2,041	1,630	79.9	2,080	1,628	78.3	2,250	1,764	78.4	2,862	2,253	78.7
Injection drug use	27	21	77.8	31	27	87.1	28	19	67.9	29	24	82.8	45	38	84.4
Sexual contact ^d and injection drug use	142	117	82.4	146	120	82.2	118	85	72.0	126	104	82.5	151	128	84.8
Perinatal infection	4	2	50.0	2	1	50.0	3	2	66.7	9	8	88.9	12	10	83.3
Other ^c	5	3	60.0	7	6	85.7	9	8	88.9	8	5	62.5	8	7	87.5

Table 12a. Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2011–2015—United States and 3 territories (cont.)

	2011			2012			2013			2014			2015		
	Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained	
		No.	%		No.	%		No.	%		No.	%		No.	%
Poverty level^a															
0–100%	169,186	139,015	82.2	173,195	141,076	81.5	178,686	144,088	80.6	—	—	—	—	—	—
101–200%	53,505	45,707	85.4	56,265	47,660	84.7	58,725	48,873	83.2	—	—	—	—	—	—
201–300%	15,200	12,875	84.7	16,453	13,856	84.2	17,871	14,930	83.5	—	—	—	—	—	—
>300%	12,385	10,073	81.3	12,274	10,212	83.2	11,479	9,598	83.6	—	—	—	—	—	—
0–100%	—	—	—	—	—	—	—	—	—	169,482	136,345	80.5	210,631	169,911	80.7
101–138%	—	—	—	—	—	—	—	—	—	31,748	26,237	82.6	37,877	31,169	82.3
139–250%	—	—	—	—	—	—	—	—	—	37,932	31,042	81.8	45,540	37,029	81.3
251–400%	—	—	—	—	—	—	—	—	—	13,813	10,986	79.5	17,547	13,980	79.7
>400%	—	—	—	—	—	—	—	—	—	7,075	5,771	81.6	8,015	6,409	80.0
Health care coverage^b															
Private only	31,844	26,560	83.4	33,602	27,572	82.1	32,315	26,257	81.3	—	—	—	—	—	—
Medicare only	22,002	18,537	84.3	21,077	17,672	83.8	20,906	17,190	82.2	—	—	—	—	—	—
Medicaid only	66,549	54,173	81.4	63,976	52,464	82.0	62,512	50,469	80.7	—	—	—	—	—	—
Other public	19,309	16,370	84.8	25,813	22,052	85.4	24,692	20,931	84.8	—	—	—	—	—	—
Other private	9,080	7,772	85.6	5,634	4,733	84.0	3,306	2,613	79.0	—	—	—	—	—	—
No coverage	33,292	28,840	86.6	39,791	33,959	85.3	40,886	34,758	85.0	—	—	—	—	—	—
Multiple coverages	81,221	65,660	80.8	82,715	66,181	80.0	85,908	68,157	79.3	—	—	—	—	—	—
Private employer	—	—	—	—	—	—	—	—	—	17,083	13,766	80.6	29,464	23,511	79.8
Private individual	—	—	—	—	—	—	—	—	—	14,052	10,879	77.4	22,956	17,499	76.2
Medicare	—	—	—	—	—	—	—	—	—	24,077	20,079	83.4	33,302	27,813	83.5
Medicaid	—	—	—	—	—	—	—	—	—	85,873	69,850	81.3	103,251	83,318	80.7
Medicare and Medicaid	—	—	—	—	—	—	—	—	—	18,048	15,515	86.0	24,185	20,574	85.1
Veterans Administration	—	—	—	—	—	—	—	—	—	399	324	81.2	411	307	74.7
Indian Health Service	—	—	—	—	—	—	—	—	—	60	47	78.3	133	91	68.4
Other plan	—	—	—	—	—	—	—	—	—	10,859	8,683	80.0	6,610	5,352	81.0
No coverage	—	—	—	—	—	—	—	—	—	77,353	60,966	78.8	68,605	53,837	78.5
Multiple coverages	—	—	—	—	—	—	—	—	—	18,991	15,418	81.2	34,995	29,464	84.2
Housing status															
Stable	213,613	178,186	83.4	220,306	183,340	83.2	224,318	184,530	82.3	223,834	182,808	81.7	277,469	226,426	81.6
Temporary	33,327	26,641	79.9	33,133	26,059	78.7	32,289	25,677	79.5	32,203	24,861	77.2	30,652	23,705	77.3
Unstable	7,770	5,970	76.8	7,217	5,283	73.2	8,925	6,445	72.2	10,057	7,327	72.9	13,160	9,631	73.2
Total^f	276,067	226,996	82.2	280,109	229,909	82.1	277,023	224,501	81.0	272,193	218,758	80.4	327,075	263,691	80.6

Retention in care was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit by September 1 of the measurement year, with a second visit at least 90 days after.

Abbreviations: MTF, male-to-female; FTM, female-to-male.

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia and blood transfusion.

^d Includes any sexual transmission risk category reported by transgender clients.

^e Data collected in 2014–2015 used different categories than previous years. See Technical Notes for additional details.

^f Because column totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 12b. Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and state, 2011–2015—United States and 3 territories

State	2011			2012			2013			2014			2015		
	Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained	
		No.	%		No.	%		No.	%		No.	%		No.	%
Alabama	3,853	3,215	83.4	3,723	3,163	85.0	3,958	3,527	89.1	3,636	3,107	85.5	4,743	4,074	85.9
Alaska	319	236	74.0	312	228	73.1	297	213	71.7	305	221	72.5	312	230	73.7
Arizona	2,144	1,829	85.3	2,346	2,000	85.3	2,393	2,024	84.6	1,963	1,467	74.7	2,149	1,718	79.9
Arkansas	979	683	69.8	1,026	756	73.7	982	700	71.3	784	500	63.8	637	499	78.3
California	37,655	31,379	83.3	38,468	31,277	81.3	30,615	23,266	76.0	26,668	19,399	72.7	34,617	26,061	75.3
Colorado	2,893	2,301	79.5	2,620	2,140	81.7	3,328	2,697	81.0	3,442	2,827	82.1	3,960	3,286	83.0
Connecticut	4,067	3,411	83.9	4,462	3,801	85.2	3,624	3,099	85.5	3,413	2,907	85.2	3,660	3,152	86.1
Delaware	1,496	1,339	89.5	1,509	1,323	87.7	1,492	1,307	87.6	1,459	1,276	87.5	1,489	1,272	85.4
District of Columbia	5,680	4,855	85.5	5,194	4,373	84.2	5,485	4,576	83.4	5,017	4,151	82.7	4,998	4,204	84.1
Florida	27,186	22,101	81.3	28,190	23,131	82.1	26,666	20,137	75.5	27,136	22,132	81.6	29,226	23,126	79.1
Georgia	16,069	13,517	84.1	16,552	14,081	85.1	17,166	14,562	84.8	17,184	14,872	86.6	17,818	15,107	84.8
Hawaii	498	375	75.3	511	364	71.2	433	292	67.4	365	265	72.6	521	372	71.4
Idaho	183	155	84.7	221	171	77.4	227	189	83.3	180	141	78.3	606	486	80.2
Illinois	12,392	9,986	80.6	13,457	10,703	79.5	12,984	10,118	77.9	12,442	9,781	78.6	14,240	11,016	77.4
Indiana	159	59	37.1	628	340	54.1	713	458	64.2	2,474	1,836	74.2	2,613	1,982	75.9
Iowa	901	737	81.8	600	453	75.5	607	461	76.0	475	383	80.6	1,070	845	79.0
Kansas	755	655	86.8	877	781	89.1	517	449	86.9	384	336	87.5	713	604	84.7
Kentucky	2,888	2,320	80.3	2,993	2,427	81.1	2,552	2,040	79.9	2,359	2,022	85.7	3,302	2,803	84.9
Louisiana	6,471	5,041	77.9	6,318	5,142	81.4	5,304	3,880	73.2	4,845	3,430	70.8	6,399	4,323	67.6
Maine	317	273	86.1	477	399	83.7	507	433	85.4	499	424	85.0	501	422	84.2
Maryland	7,311	5,936	81.2	7,804	6,539	83.8	8,850	7,209	81.5	7,383	6,009	81.4	10,236	8,428	82.3
Massachusetts	4,208	3,759	89.3	5,008	4,396	87.8	6,232	5,508	88.4	6,636	5,710	86.1	6,866	5,804	84.5
Michigan	5,186	4,064	78.4	5,550	4,292	77.3	4,651	3,601	77.4	4,308	3,238	75.2	5,906	4,460	75.5
Minnesota	2,045	1,611	78.8	1,910	1,449	75.9	2,361	1,960	83.0	1,924	1,488	77.3	1,969	1,624	82.5
Mississippi	1,346	1,109	82.4	1,657	1,194	72.1	1,516	1,204	79.4	1,359	1,156	85.1	2,554	2,159	84.5
Missouri	1,824	1,326	72.7	1,672	1,181	70.6	1,929	1,478	76.6	1,529	854	55.9	3,692	2,950	79.9
Montana	221	190	86.0	217	189	87.1	167	139	83.2	188	145	77.1	211	173	82.0
Nebraska	485	414	85.4	472	408	86.4	439	379	86.3	400	347	86.8	790	635	80.4
Nevada	956	693	72.5	983	779	79.3	1,150	791	68.8	1,147	710	61.9	1,632	1,066	65.3
New Hampshire	426	359	84.3	269	145	53.9	352	158	44.9	143	100	69.9	605	430	71.1
New Jersey	10,207	8,187	80.2	9,489	7,938	83.7	9,809	8,357	85.2	8,636	6,969	80.7	9,498	7,661	80.7
New Mexico	923	789	85.5	940	811	86.3	1,450	1,254	86.5	1,598	1,357	84.9	1,575	1,279	81.2
New York	30,940	25,325	81.9	28,863	24,068	83.4	26,632	22,414	84.2	26,623	22,564	84.8	31,086	26,685	85.8
North Carolina	10,170	8,353	82.1	10,855	9,018	83.1	9,773	8,223	84.1	9,421	7,937	84.3	12,394	10,288	83.0
North Dakota	43	26	60.5	53	30	56.6	0	—	—	0	—	—	79	0	0.0
Ohio	4,283	3,470	81.0	5,486	4,075	74.3	6,653	5,051	75.9	6,433	4,373	68.0	6,575	4,806	73.1
Oklahoma	1,271	1,067	84.0	1,433	1,140	79.6	1,819	1,370	75.3	1,790	1,330	74.3	1,934	1,293	66.9
Oregon	1,321	1,247	94.4	1,366	1,306	95.6	1,406	1,173	83.4	1,083	908	83.8	1,109	923	83.2
Pennsylvania	14,336	12,080	84.3	15,462	13,067	84.5	16,525	13,932	84.3	15,576	13,217	84.9	17,724	15,098	85.2
Rhode Island	1,259	1,083	86.0	1,345	1,168	86.8	1,486	1,259	84.7	1,446	1,229	85.0	1,505	1,233	81.9
South Carolina	7,110	6,282	88.4	7,826	6,687	85.5	8,343	7,304	87.6	8,266	7,200	87.1	8,879	7,663	86.3
South Dakota	211	160	75.8	256	160	62.5	230	97	42.2	266	172	64.7	241	202	83.8
Tennessee	5,757	4,831	83.9	3,825	3,291	86.0	3,633	3,078	84.7	4,475	3,662	81.8	8,089	6,670	82.5
Texas	18,361	14,417	78.5	17,564	13,462	76.7	20,438	16,401	80.3	20,289	15,328	75.6	28,803	22,629	78.6
Utah	509	415	81.5	603	469	77.8	589	504	85.6	523	422	80.7	1,365	1,093	80.1
Vermont	387	326	84.2	400	321	80.3	404	351	86.9	405	340	84.0	396	327	82.6
Virginia	4,927	3,895	79.1	5,051	4,017	79.5	5,703	4,553	79.8	4,859	3,311	68.1	4,835	3,399	70.3
Washington	2,203	1,866	84.7	2,187	1,507	68.9	1,983	1,111	56.0	1,977	1,589	80.4	2,785	1,939	69.6
West Virginia	640	505	78.9	634	514	81.1	690	528	76.5	678	518	76.4	655	514	78.5
Wisconsin	1,456	1,009	69.3	1,444	1,188	82.3	1,542	1,227	79.6	1,996	1,654	82.9	2,251	1,829	81.3
Wyoming	99	62	62.6	129	76	58.9	122	79	64.8	98	70	71.4	74	38	51.4
Subtotal	267,326	219,323	82.0	271,237	221,938	81.8	266,727	215,121	80.7	256,485	205,384	80.1	309,887	248,880	80.3

Table 12b. Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and state, 2011–2015—United States and 3 territories (cont.)

	2011			2012			2013			2014			2015		
	Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained	
		No.	%		No.	%		No.	%		No.	%		No.	%
Territories															
Guam	19	12	63.2	20	18	90.0	23	19	82.6	23	16	69.6	28	11	39.3
Puerto Rico	6,440	5,785	89.8	7,141	6,583	92.2	8,517	7,855	92.2	8,713	8,005	91.9	9,484	8,774	92.5
U.S. Virgin Islands	217	147	67.7	201	137	68.2	157	113	72.0	201	150	74.6	194	154	79.4
Subtotal	6,676	5,944	89.0	7,362	6,738	91.5	8,697	7,987	91.8	8,937	8,171	91.4	9,706	8,939	92.1
Total^a	276,067	226,996	82.2	280,109	229,909	82.1	277,023	224,501	81.0	272,193	218,758	80.4	327,075	263,691	80.6

Note. Data are based on provider location. Clients receiving services in multiple states were not included in state-specific totals.

Retention in care was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit by September 1 of the measurement year, with a second visit at least 90 days after.

^a Because column totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 12c. Retention in care among Ryan White HIV/AIDS Program clients, by year and eligible metropolitan area and transitional grant area, 2011–2015—United States and 3 territories

	2011			2012			2013			2014			2015		
	Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained	
		No.	%		No.	%		No.	%		No.	%		No.	%
Eligible metropolitan area															
Atlanta, GA	9,251	7,952	86.0	9,703	8,365	86.2	10,372	9,020	87.0	10,739	9,300	86.6	11,378	9,554	84.0
Baltimore, MD	6,314	5,235	82.9	6,730	5,751	85.5	7,493	6,151	82.1	5,955	4,994	83.9	8,605	7,153	83.1
Boston, MA	3,907	3,493	89.4	4,675	4,096	87.6	4,908	4,293	87.5	5,339	4,576	85.7	5,559	4,664	83.9
Chicago, IL	11,044	9,140	82.8	12,025	9,753	81.1	11,531	8,969	77.8	11,674	9,292	79.6	13,918	10,795	77.6
Dallas, TX	3,621	2,824	78.0	4,282	3,250	75.9	4,343	3,683	84.8	4,598	3,783	82.3	6,200	5,041	81.3
Detroit, MI	3,618	2,731	75.5	3,678	2,805	76.3	2,364	1,741	73.7	2,098	1,463	69.7	3,732	2,663	71.4
Ft. Lauderdale, FL	3,788	2,982	78.7	5,343	4,539	85.0	4,626	3,759	81.3	4,922	4,021	81.7	6,912	5,009	72.5
Houston, TX	6,320	4,556	72.1	4,644	3,014	64.9	6,411	4,670	72.8	7,065	5,007	70.9	9,495	6,982	73.5
Los Angeles, CA	15,780	13,103	83.0	17,358	14,313	82.5	11,327	8,574	75.7	9,722	7,278	74.9	18,421	12,633	68.6
Miami, FL	7,798	6,504	83.4	8,133	6,577	80.9	7,332	5,513	75.2	7,632	6,166	80.8	7,188	5,424	75.5
Nassau Suffolk, NY	1,116	945	84.7	734	526	71.7	1,030	853	82.8	1,127	877	77.8	1,258	1,033	82.1
New Haven, CT	1,634	1,386	84.8	2,067	1,798	87.0	1,329	1,144	86.1	1,299	1,111	85.5	1,515	1,326	87.5
New Orleans, LA	3,005	2,361	78.6	2,678	2,075	77.5	2,454	1,812	73.8	2,574	1,832	71.2	3,640	2,329	64.0
New York, NY	25,984	21,441	82.5	24,192	20,065	82.9	22,495	18,892	84.0	23,083	19,474	84.4	27,909	23,943	85.8
Newark, NJ	4,336	3,080	71.0	3,512	2,729	77.7	3,596	2,895	80.5	3,232	2,365	73.2	2,336	1,497	64.1
Orlando, FL	2,326	2,034	87.5	2,339	2,033	86.9	2,223	880	39.6	2,397	1,970	82.2	1,867	1,452	77.8
Philadelphia, PA	11,723	9,996	85.3	12,098	10,314	85.3	12,524	10,701	85.4	12,695	10,885	85.7	13,359	11,403	85.4
Phoenix, AZ	900	783	87.0	1,107	917	82.8	1,020	891	87.4	849	499	58.8	969	720	74.3
San Diego, CA	4,664	3,979	85.3	4,267	3,327	78.0	4,541	3,752	82.6	4,687	3,751	80.0	4,890	3,990	81.6
San Francisco, CA	4,240	3,430	80.9	3,904	2,997	76.8	2,914	1,957	67.2	2,554	1,537	60.2	3,579	2,884	80.6
San Juan, PR	3,693	3,236	87.6	4,289	3,977	92.7	5,681	5,227	92.0	5,767	5,260	91.2	8,275	7,643	92.4
Tampa-St. Petersburg, FL	3,239	2,625	81.0	2,873	2,389	83.2	3,658	2,885	78.9	3,497	2,883	82.4	3,835	3,256	84.9
Washington, DC	8,750	7,257	82.9	8,335	6,966	83.6	8,639	7,216	83.5	8,651	7,007	81.0	8,855	7,355	83.1
West Palm Beach, FL	2,581	2,160	83.7	2,277	1,836	80.6	941	577	61.3	1,912	1,593	83.3	1,913	1,636	85.5
Subtotal EMAs^a	149,014	122,728	82.4	150,333	123,662	82.3	143,579	115,919	80.7	142,558	115,717	81.2	172,754	138,237	80.0
Transitional grant area															
Austin, TX	1,415	1,268	89.6	1,420	1,275	89.8	1,620	1,371	84.6	1,587	1,387	87.4	4,417	3,798	86.0
Baton Rouge, LA	2,140	1,704	79.6	2,487	2,150	86.5	1,606	1,037	64.6	1,910	1,236	64.7	2,188	1,575	72.0
Bergen-Passaic, NJ	783	646	82.5	816	684	83.8	821	696	84.8	629	528	83.9	1,318	1,020	77.4
Charlotte, NC	1,634	1,348	82.5	1,988	1,673	84.2	2,118	1,747	82.5	2,101	1,761	83.8	2,361	1,911	80.9
Cleveland, OH	2,215	1,817	82.0	2,362	1,822	77.1	2,486	1,892	76.1	2,174	1,474	67.8	1,716	1,270	74.0
Columbus, OH	906	800	88.3	1,856	1,307	70.4	2,956	2,293	77.6	2,510	1,784	71.1	2,949	2,133	72.3
Denver, CO	2,611	2,090	80.1	2,538	2,071	81.6	3,124	2,549	81.6	3,403	2,792	82.1	3,828	3,162	82.6
Ft. Worth, TX	1,675	1,363	81.4	1,521	1,289	84.8	1,573	1,361	86.5	1,557	1,347	86.5	2,102	1,621	77.1
Hartford, CT	1,590	1,304	82.0	1,849	1,578	85.3	1,769	1,532	86.6	1,775	1,524	85.9	1,846	1,619	87.7
Indianapolis, IN	210	98	46.7	694	383	55.2	763	497	65.1	2,685	2,000	74.5	2,857	2,176	76.2
Jacksonville, FL	2,902	2,221	76.5	2,709	2,003	73.9	2,872	2,398	83.5	2,984	2,383	79.9	1,413	1,123	79.5
Jersey City, NJ	1,511	1,341	88.8	1,487	1,329	89.4	1,521	1,381	90.8	1,545	1,410	91.3	1,503	1,378	91.7
Kansas City, MO	884	664	75.1	939	778	82.9	1,121	965	86.1	646	262	40.6	1,385	1,036	74.8
Las Vegas, NV	477	274	57.4	450	302	67.1	644	336	52.2	837	424	50.7	1,242	732	58.9
Memphis, TN	2,782	2,413	86.7	2,301	2,016	87.6	2,118	1,866	88.1	1,996	1,728	86.6	3,349	2,800	83.6
Middlesex, NJ	883	771	87.3	797	692	86.8	743	644	86.7	703	519	73.8	793	689	86.9
Minneapolis-St. Paul, MN	2,053	1,618	78.8	1,918	1,454	75.8	2,343	1,952	83.3	1,981	1,511	76.3	2,084	1,710	82.1
Nashville, TN	1,365	1,145	83.9	1,229	1,035	84.2	1,118	922	82.5	1,865	1,521	81.6	4,055	3,362	82.9
Norfolk, VA	1,265	953	75.3	1,208	912	75.5	1,313	874	66.6	1,067	458	42.9	885	526	59.4

Table 12c. Retention in care among Ryan White HIV/AIDS Program clients, by year and eligible metropolitan area and transitional grant area, 2011–2015—United States and 3 territories (cont.)

	2011			2012			2013			2014			2015		
	Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained	
		No.	%		No.	%		No.	%		No.	%		No.	%
Transitional grant area															
Oakland, CA	2,806	2,319	82.6	2,791	2,306	82.6	2,315	1,310	56.6	1,808	1,013	56.0	1,129	800	70.9
Orange County, CA	1,535	1,315	85.7	1,482	1,302	87.9	1,297	1,165	89.8	1,106	789	71.3	1,097	931	84.9
Portland, OR	1,340	1,262	94.2	1,377	1,314	95.4	1,415	1,182	83.5	1,199	993	82.8	2,347	1,940	82.7
Riverside-San Bernardino, CA	2,399	2,038	85.0	2,203	1,723	78.2	1,446	859	59.4	738	380	51.5	803	601	74.8
Sacramento, CA	2,105	1,816	86.3	2,271	1,959	86.3	2,209	1,911	86.5	2,542	1,904	74.9	2,591	2,198	84.8
San Antonio, TX	1,208	977	80.9	1,420	1,169	82.3	1,505	1,264	84.0	1,444	785	54.4	3,138	2,630	83.8
San Jose, CA	1,088	882	81.1	1,031	771	74.8	698	546	78.2	627	280	44.7	566	498	88.0
Seattle, WA	1,716	1,453	84.7	1,588	1,024	64.5	1,215	493	40.6	1,352	1,118	82.7	2,172	1,581	72.8
St. Louis, MO	1,433	1,050	73.3	1,348	898	66.6	1,701	1,322	77.7	1,676	988	59.0	3,389	2,774	81.9
Subtotal TGAs^a	44,686	36,766	82.3	45,672	36,904	80.8	46,246	36,220	78.3	45,892	33,939	74.0	58,004	46,315	79.9
Total all EMAs and TGAs^a	192,187	158,247	82.3	193,538	158,525	81.9	188,423	151,067	80.2	185,867	147,818	79.5	226,814	181,478	80.0

Abbreviations: EMA, eligible metropolitan area; TGA, transitional grant area.

Note. EMA/TGA delineations are based on provider location.

Data shown for individual EMAs and TGAs are not mutually exclusive; clients may have received services from providers in multiple EMAs and/or TGAs.

Retention in care was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit by September 1 of the measurement year, with a second visit at least 90 days after.

^a The EMA/TGA subtotals and total were calculated independently of the values for each of the EMAs/TGAs and include deduplicated counts of clients receiving services in the EMAs/TGAs. Therefore, the values in each column do not sum to the column subtotals and total.

Table 13a. Viral suppression among Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2011–2015—United States and 3 territories

	2011			2012			2013			2014			2015		
	Total No.	Viral suppression		Total No.	Viral suppression		Total No.	Viral suppression		Total No.	Viral suppression		Total No.	Viral suppression	
		No.	%		No.	%		No.	%		No.	%		No.	%
Age group (yr)															
<13	1,186	827	69.7	1,099	854	77.7	1,040	834	80.2	1,021	856	83.8	1,115	938	84.1
13–14	537	365	68.0	427	310	72.6	344	257	74.7	319	265	83.1	360	286	79.4
15–19	3,114	1,622	52.1	2,771	1,519	54.8	2,470	1,488	60.2	2,329	1,497	64.3	2,361	1,627	68.9
20–24	12,503	6,186	49.5	13,647	7,126	52.2	14,207	8,474	59.7	13,591	8,726	64.2	14,291	9,754	68.3
25–29	19,355	11,421	59.0	21,316	13,282	62.3	23,191	15,682	67.6	24,238	17,167	70.8	28,547	21,001	73.6
30–34	24,377	16,068	65.9	25,675	17,669	68.8	26,644	19,397	72.8	26,329	20,034	76.1	30,964	24,041	77.6
35–39	27,814	19,538	70.3	28,266	20,528	72.6	28,507	21,679	76.1	28,366	22,286	78.6	33,595	27,045	80.5
40–44	39,955	29,296	73.3	39,190	29,517	75.3	36,814	29,003	78.8	34,226	27,803	81.2	37,409	30,957	82.8
45–49	49,863	37,844	75.9	50,543	39,315	77.8	48,146	38,876	80.8	44,591	37,160	83.3	50,514	42,877	84.9
50–54	40,781	31,711	77.8	44,484	35,603	80.0	46,029	38,296	83.2	47,013	40,236	85.6	57,393	49,746	86.7
55–59	25,695	20,637	80.3	28,995	24,005	82.8	30,441	26,050	85.6	32,309	28,364	87.8	42,217	37,551	89.0
60–64	12,678	10,628	83.8	14,787	12,637	85.5	16,089	14,179	88.1	18,002	16,199	90.0	24,388	22,111	90.7
≥65	7,336	6,347	86.5	8,839	7,782	88.0	9,745	8,830	90.6	11,369	10,458	92.0	16,931	15,688	92.7
Race/ethnicity															
American Indian/Alaska Native	1,174	875	74.5	1,210	923	76.3	1,263	986	78.1	1,192	989	83.0	1,410	1,156	82.0
Asian	2,825	2,344	83.0	3,300	2,721	82.5	3,320	2,908	87.6	3,424	3,050	89.1	4,485	4,063	90.6
Black/African American	124,332	83,370	67.1	130,129	90,972	69.9	132,115	97,658	73.9	132,079	101,827	77.1	160,675	127,649	79.5
Hispanic/Latino ^a	58,857	44,738	76.0	65,068	50,689	77.9	67,673	55,084	81.4	69,183	58,086	84.0	80,694	69,142	85.7
Native Hawaiian/Pacific Islander	593	462	77.9	450	356	79.1	427	328	76.8	392	317	80.9	474	397	83.8
White	69,810	55,167	79.0	72,663	59,144	81.4	71,841	60,556	84.3	70,112	60,734	86.6	86,305	76,214	88.3
Multiple races	3,111	2,264	72.8	3,794	2,826	74.5	4,548	3,567	78.4	5,343	4,425	82.8	4,587	3,775	82.3
Gender															
Male	184,918	136,471	73.8	197,929	150,129	75.9	200,207	158,779	79.3	200,093	164,193	82.1	241,578	202,692	83.9
Female	78,055	54,575	69.9	79,567	58,259	73.2	80,897	62,420	77.2	80,865	64,837	80.2	94,477	77,800	82.4
Transgender MTF	1,937	1,264	65.3	2,313	1,584	68.5	2,353	1,693	72.0	2,512	1,856	73.9	3,290	2,532	77.0
Transgender FTM	76	46	60.5	78	60	76.9	64	52	81.3	82	59	72.0	208	172	82.7
Transgender unknown	169	112	66.3	128	97	75.8	121	86	71.1	125	98	78.4	4	3	75.0
Transmission risk category															
Male client															
Male-to-male sexual contact	102,256	76,853	75.2	112,638	86,525	76.8	116,531	93,518	80.3	118,918	98,633	82.9	146,480	124,097	84.7
Injection drug use	14,374	10,375	72.2	13,961	10,527	75.4	14,372	11,383	79.2	12,835	10,498	81.8	14,738	12,350	83.8
Male-to-male sexual contact and injection drug use	6,004	4,416	73.6	6,278	4,637	73.9	5,711	4,415	77.3	5,976	4,766	79.8	6,667	5,469	82.0
Heterosexual contact ^b	42,094	30,413	72.3	45,315	33,814	74.6	46,274	36,181	78.2	47,853	38,869	81.2	58,258	48,387	83.1
Perinatal infection	2,529	1,505	59.5	2,439	1,500	61.5	2,484	1,591	64.1	2,438	1,679	68.9	2,679	1,864	69.6
Other ^c	1,057	836	79.1	1,163	950	81.7	1,305	1,121	85.9	1,104	964	87.3	1,417	1,270	89.6
Female client															
Injection drug use	7,934	5,467	68.9	7,343	5,382	73.3	7,690	5,928	77.1	6,967	5,554	79.7	7,890	6,398	81.1
Heterosexual contact ^b	59,501	41,967	70.5	61,923	45,574	73.6	64,079	49,818	77.7	65,380	52,855	80.8	77,676	64,455	83.0
Perinatal infection	3,067	1,777	57.9	3,001	1,827	60.9	3,041	1,955	64.3	3,112	2,116	68.0	3,469	2,422	69.8
Other ^c	743	582	78.3	831	656	78.9	965	824	85.4	875	740	84.6	1,008	876	86.9
Transgender client															
Sexual contact ^d	1,801	1,182	65.6	2,060	1,421	69.0	2,147	1,552	72.3	2,327	1,731	74.4	2,968	2,317	78.1
Injection drug use	24	18	75.0	34	25	73.5	30	22	73.3	27	20	74.1	49	32	65.3
Sexual contact ^d and injection drug use	135	88	65.2	143	101	70.6	120	83	69.2	125	90	72.0	153	120	78.4
Perinatal infection	3	1	33.3	2	2	100.0	4	1	25.0	8	4	50.0	12	7	58.3
Other ^c	4	2	50.0	6	5	83.3	10	7	70.0	7	6	85.7	9	4	44.4

Table 13a. Viral suppression among Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2011–2015—United States and 3 territories (cont.)

	2011			2012			2013			2014			2015		
	Total No.	Viral suppression		Total No.	Viral suppression		Total No.	Viral suppression		Total No.	Viral suppression		Total No.	Viral suppression	
		No.	%		No.	%		No.	%		No.	%		No.	%
Poverty level^a															
0–100%	164,839	115,744	70.2	174,430	126,156	72.3	184,640	139,850	75.7	—	—	—	—	—	—
101–200%	51,487	40,432	78.5	56,119	44,928	80.1	59,759	50,161	83.9	—	—	—	—	—	—
201–300%	14,588	11,874	81.4	16,426	13,499	82.2	18,198	15,632	85.9	—	—	—	—	—	—
>300%	11,491	8,709	75.8	12,683	10,348	81.6	11,793	10,360	87.9	—	—	—	—	—	—
0–100%	—	—	—	—	—	—	—	—	—	176,449	139,172	78.9	219,389	176,888	80.6
101–138%	—	—	—	—	—	—	—	—	—	32,830	27,881	84.9	39,110	34,058	87.1
139–250%	—	—	—	—	—	—	—	—	—	39,535	34,563	87.4	47,470	42,130	88.8
251–400%	—	—	—	—	—	—	—	—	—	14,462	12,617	87.2	18,313	16,595	90.6
>400%	—	—	—	—	—	—	—	—	—	8,535	7,279	85.3	8,287	7,619	91.9
Health care coverage^b															
Private only	29,070	23,267	80.0	32,915	27,220	82.7	32,774	28,112	85.8	—	—	—	—	—	—
Medicare only	20,554	16,488	80.2	20,988	17,169	81.8	21,149	17,811	84.2	—	—	—	—	—	—
Medicaid only	64,212	43,324	67.5	63,598	45,080	70.9	63,294	47,178	74.5	—	—	—	—	—	—
Other public	18,891	14,086	74.6	26,700	20,246	75.8	25,763	20,445	79.4	—	—	—	—	—	—
Other private	9,155	6,917	75.6	5,241	4,011	76.5	3,346	2,670	79.8	—	—	—	—	—	—
No coverage	31,583	24,214	76.7	38,395	30,681	79.9	40,769	34,007	83.4	—	—	—	—	—	—
Multiple coverages	80,748	56,270	69.7	85,261	60,661	71.2	91,184	68,718	75.4	—	—	—	—	—	—
Private employer	—	—	—	—	—	—	—	—	—	17,865	15,768	88.3	31,075	27,617	88.9
Private individual	—	—	—	—	—	—	—	—	—	14,696	12,909	87.8	23,834	21,271	89.3
Medicare	—	—	—	—	—	—	—	—	—	24,566	21,474	87.4	34,127	30,116	88.3
Medicaid	—	—	—	—	—	—	—	—	—	88,553	69,748	78.8	106,911	85,690	80.2
Medicare and Medicaid	—	—	—	—	—	—	—	—	—	18,300	15,722	85.9	24,471	21,399	87.5
Veterans Administration	—	—	—	—	—	—	—	—	—	419	375	89.5	436	384	88.1
Indian Health Service	—	—	—	—	—	—	—	—	—	69	56	81.2	149	125	83.9
Other plan	—	—	—	—	—	—	—	—	—	11,259	9,408	83.6	6,857	5,948	86.7
No coverage	—	—	—	—	—	—	—	—	—	83,454	64,573	77.4	73,120	56,915	77.8
Multiple coverages	—	—	—	—	—	—	—	—	—	19,956	17,218	86.3	36,210	31,748	87.7
Housing status															
Stable	205,573	152,509	74.2	221,603	169,222	76.4	229,596	183,930	80.1	233,438	193,210	82.8	288,018	243,742	84.6
Temporary	33,380	22,559	67.6	33,510	23,431	69.9	34,219	25,155	73.5	34,012	26,189	77.0	32,457	25,458	78.4
Unstable	7,828	4,812	61.5	7,379	4,421	59.9	9,341	6,007	64.3	10,621	7,124	67.1	13,996	9,699	69.3
Total^f	265,195	192,491	72.6	280,045	210,152	75.0	283,669	223,046	78.6	283,811	231,140	81.4	340,085	283,622	83.4

Viral suppression was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit during the measurement year and whose most recent viral load test result was <200 copies/mL.

Abbreviations: MTF, male-to-female; FTM, female-to-male.

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia and blood transfusion.

^d Includes any sexual transmission risk category reported by transgender clients.

^e Data collected in 2014–2015 used different categories than previous years. See Technical Notes for additional details.

^f Because column totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 13b. Viral Suppression among Ryan White HIV/AIDS Program clients (non-ADAP), by year and state, 2011–2015—United States and 3 territories

State	2011			2012			2013			2014			2015		
	Total No.	Viral suppression		Total No.	Viral suppression		Total No.	Viral suppression		Total No.	Viral suppression		Total No.	Viral suppression	
		No.	%		No.	%		No.	%		No.	%		No.	%
Alabama	3,974	2,805	70.6	3,864	2,820	73.0	4,179	3,104	74.3	3,885	2,846	73.3	4,975	3,987	80.1
Alaska	300	212	70.7	284	208	73.2	299	235	78.6	316	263	83.2	338	289	85.5
Arizona	1,533	1,288	84.0	1,826	1,438	78.8	2,163	1,884	87.1	2,065	1,785	86.4	2,280	2,046	89.7
Arkansas	623	393	63.1	1,049	664	63.3	1,009	791	78.4	695	570	82.0	658	499	75.8
California	35,408	27,507	77.7	38,248	29,818	78.0	30,443	24,955	82.0	26,109	21,914	83.9	33,995	28,601	84.1
Colorado	2,999	2,390	79.7	2,501	1,911	76.4	3,498	2,886	82.5	3,619	3,101	85.7	3,902	3,387	86.8
Connecticut	3,929	2,828	72.0	4,398	3,444	78.3	3,713	3,028	81.6	3,521	3,013	85.6	3,755	3,247	86.5
Delaware	1,553	1,162	74.8	1,564	1,210	77.4	1,552	1,239	79.8	1,527	1,276	83.6	1,582	1,337	84.5
District of Columbia	5,889	4,543	77.1	5,496	4,149	75.5	5,659	4,354	76.9	4,926	4,096	83.2	5,049	4,326	85.7
Florida	22,789	15,424	67.7	25,024	18,016	72.0	24,842	19,313	77.7	27,644	22,439	81.2	30,401	24,988	82.2
Georgia	15,887	11,651	73.3	15,613	11,409	73.1	17,543	13,222	75.4	17,725	13,846	78.1	18,699	14,925	79.8
Hawaii	383	273	71.3	355	253	71.3	293	221	75.4	497	424	85.3	581	520	89.5
Idaho	207	169	81.6	245	213	86.9	241	210	87.1	190	173	91.1	649	607	93.5
Illinois	11,368	8,401	73.9	12,854	10,085	78.5	13,433	10,718	79.8	12,964	10,676	82.4	14,651	12,056	82.3
Indiana	202	114	56.4	613	393	64.1	721	501	69.5	2,204	1,890	85.8	2,689	2,333	86.8
Iowa	920	724	78.7	635	521	82.1	666	556	83.5	501	458	91.4	1,148	1,026	89.4
Kansas	768	590	76.8	909	715	78.7	533	423	79.4	436	352	80.7	758	632	83.4
Kentucky	2,929	2,169	74.1	2,919	2,210	75.7	2,694	2,142	79.5	2,409	2,030	84.3	3,437	2,899	84.4
Louisiana	5,787	3,108	53.7	6,026	3,688	61.2	5,615	3,566	63.5	5,235	3,701	70.7	6,638	5,060	76.2
Maine	316	260	82.3	478	410	85.8	516	463	89.7	504	456	90.5	492	455	92.5
Maryland	7,414	5,179	69.9	7,386	5,465	74.0	8,583	6,757	78.7	7,389	5,923	80.2	10,750	8,992	83.7
Massachusetts	4,231	3,492	82.5	4,867	4,096	84.2	6,641	5,662	85.3	6,750	5,979	88.6	7,062	6,352	90.0
Michigan	5,322	3,816	71.7	5,745	4,289	74.7	4,871	3,924	80.6	4,627	3,865	83.5	6,526	5,520	84.6
Minnesota	2,138	1,704	79.7	2,096	1,706	81.4	2,419	2,084	86.2	1,979	1,741	88.0	2,003	1,762	88.0
Mississippi	1,261	784	62.2	1,582	935	59.1	1,552	1,080	69.6	1,461	1,081	74.0	2,656	2,089	78.7
Missouri	1,499	905	60.4	1,694	1,206	71.2	2,199	1,687	76.7	1,746	1,384	79.3	4,137	3,517	85.0
Montana	226	197	87.2	222	205	92.3	190	169	89.0	202	188	93.1	222	199	89.6
Nebraska	500	385	77.0	492	380	77.2	469	379	80.8	416	354	85.1	846	755	89.2
Nevada	974	712	73.1	1,047	773	73.8	1,187	811	68.3	1,282	859	67.0	1,836	1,345	73.3
New Hampshire	448	375	83.7	287	250	87.1	408	365	89.5	147	124	84.4	627	571	91.1
New Jersey	9,720	6,254	64.3	10,360	7,439	71.8	10,438	7,941	76.1	9,032	7,247	80.2	10,029	8,248	82.2
New Mexico	926	726	78.4	990	805	81.3	1,603	1,393	86.9	1,651	1,481	89.7	1,659	1,511	91.1
New York	29,496	20,436	69.3	29,404	21,886	74.4	26,905	21,141	78.6	29,341	23,456	79.9	31,884	26,790	84.0
North Carolina	9,797	7,321	74.7	11,182	8,543	76.4	10,311	8,070	78.3	10,072	8,176	81.2	13,023	11,160	85.7
North Dakota	39	38	97.4	57	48	84.2	70	62	88.6	70	67	95.7	73	67	91.8
Ohio	3,728	2,671	71.7	4,769	3,443	72.2	7,050	5,461	77.5	6,870	5,554	80.8	7,024	5,911	84.2
Oklahoma	1,323	971	73.4	1,540	1,113	72.3	1,918	1,502	78.3	1,931	1,579	81.8	1,980	1,660	83.8
Oregon	1,355	1,044	77.1	1,330	1,067	80.2	1,491	1,232	82.6	1,140	965	84.7	1,181	1,018	86.2
Pennsylvania	14,619	11,031	75.5	15,910	12,411	78.0	17,120	13,900	81.2	16,014	13,475	84.2	18,304	15,880	86.8
Rhode Island	1,311	1,058	80.7	1,392	1,152	82.8	1,520	1,317	86.6	1,462	1,291	88.3	1,565	1,408	90.0
South Carolina	7,464	5,560	74.5	8,270	6,363	76.9	8,730	6,943	79.5	8,762	7,162	81.7	9,272	7,778	83.9
South Dakota	197	154	78.2	210	166	79.1	178	152	85.4	222	189	85.1	233	207	88.8
Tennessee	6,043	4,228	70.0	4,006	2,841	70.9	3,814	2,817	73.9	4,684	3,678	78.5	8,600	7,042	81.9
Texas	19,147	13,371	69.8	20,554	14,505	70.6	22,076	16,335	74.0	21,871	17,068	78.0	30,826	24,411	79.2

Table 13b. Viral Suppression among Ryan White HIV/AIDS Program clients (non-ADAP), by year and state, 2011–2015—United States and 3 territories (cont.)

State	2011			2012			2013			2014			2015		
	Total No.	Viral suppression		Total No.	Viral suppression		Total No.	Viral suppression		Total No.	Viral suppression		Total No.	Viral suppression	
		No.	%		No.	%		No.	%		No.	%		No.	%
Utah	428	293	68.5	551	399	72.4	618	482	78.0	534	423	79.2	1,430	1,264	88.4
Vermont	373	317	85.0	391	340	87.0	421	385	91.5	428	402	93.9	418	396	94.7
Virginia	4,958	3,887	78.4	5,236	4,206	80.3	6,022	4,994	82.9	5,431	4,673	86.0	5,220	4,510	86.4
Washington	2,270	2,005	88.3	2,452	1,994	81.3	2,073	1,738	83.8	2,019	1,782	88.3	2,979	2,640	88.6
West Virginia	675	543	80.4	675	570	84.4	719	612	85.1	692	600	86.7	690	612	88.7
Wisconsin	1,243	905	72.8	1,437	1,104	76.8	1,809	1,473	81.4	2,184	1,869	85.6	2,428	2,113	87.0
Wyoming	95	65	68.4	128	103	80.5	135	111	82.2	120	101	84.2	54	44	81.5
Subtotal	256,984	186,438	72.5	271,163	203,378	75.0	273,152	214,790	78.6	267,501	218,045	81.5	322,214	268,992	83.5
Territories															
Guam	17	8	47.1	19	12	63.2	22	13	59.1	19	10	52.6	31	12	38.7
Puerto Rico	5,919	4,358	73.6	7,147	5,433	76.0	8,681	6,790	78.2	8,833	7,267	82.3	9,691	8,169	84.3
U.S. Virgin Islands	186	113	60.8	189	127	67.2	179	131	73.2	215	161	74.9	199	146	73.4
Subtotal	6,122	4,479	73.2	7,355	5,572	75.8	8,882	6,934	78.1	9,067	7,438	82.0	9,921	8,327	83.9
Total^a	265,195	192,491	72.6	280,045	210,152	75.0	283,669	223,046	78.6	283,811	231,140	81.4	340,085	283,622	83.4

Note. Data are based on provider location. Clients receiving services in multiple states were not included in state-specific totals.

Viral suppression was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit during the measurement year and whose most recent viral load test result was <200 copies/mL.

^a Because column totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 13c. Viral suppression among Ryan White HIV/AIDS Program clients, by year and eligible metropolitan area and transitional grant area, 2011–2015—United States and 3 territories

	2011			2012			2013			2014			2015		
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression		
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Eligible metropolitan area															
Atlanta, GA	8,806	6,701	76.1	8,738	6,481	74.2	10,447	7,972	76.3	11,081	8,613	77.7	11,861	9,407	79.3
Baltimore, MD	6,365	4,409	69.3	6,276	4,653	74.1	7,253	5,717	78.8	5,742	4,604	80.2	9,040	7,606	84.1
Boston, MA	3,924	3,229	82.3	4,526	3,805	84.1	5,276	4,508	85.4	5,392	4,777	88.6	5,698	5,105	89.6
Chicago, IL	10,436	7,712	73.9	11,291	8,883	78.7	11,947	9,487	79.4	12,150	9,956	81.9	14,255	11,708	82.1
Dallas, TX	3,850	2,799	72.7	4,621	3,344	72.4	4,643	3,500	75.4	4,700	3,655	77.8	6,603	5,122	77.6
Detroit, MI	3,652	2,437	66.7	3,772	2,616	69.4	2,455	1,820	74.1	2,254	1,729	76.7	4,204	3,400	80.9
Ft. Lauderdale, FL	3,412	2,236	65.5	5,569	4,068	73.1	4,549	3,648	80.2	5,097	4,317	84.7	7,249	5,974	82.4
Houston, TX	6,558	4,556	69.5	7,080	4,882	69.0	7,287	5,338	73.3	7,799	6,031	77.3	10,421	8,141	78.1
Los Angeles, CA	15,939	12,010	75.4	17,752	13,237	74.6	11,914	9,536	80.0	10,067	8,322	82.7	17,664	14,271	80.8
Miami, FL	7,387	4,851	65.7	7,175	5,018	69.9	6,617	4,924	74.4	7,511	6,000	79.9	7,111	5,879	82.7
Nassau Suffolk, NY	1,135	726	64.0	904	726	80.3	1,097	883	80.5	1,336	1,087	81.4	1,318	1,166	88.5
New Haven, CT	1,524	1,128	74.0	2,064	1,671	81.0	1,357	1,124	82.8	1,335	1,199	89.8	1,565	1,390	88.8
New Orleans, LA	2,923	1,573	53.8	2,771	1,575	56.8	2,605	1,536	59.0	2,767	1,976	71.4	3,691	2,890	78.3
New York, NY	24,341	16,516	67.9	24,400	17,685	72.5	22,509	17,470	77.6	24,005	19,232	80.1	28,554	23,781	83.3
Newark, NJ	3,923	1,981	50.5	4,275	2,894	67.7	4,038	2,911	72.1	3,456	2,598	75.2	2,672	2,075	77.7
Orlando, FL	2,139	1,249	58.4	2,440	1,772	72.6	2,213	1,803	81.5	2,570	2,056	80.0	1,955	1,639	83.8
Philadelphia, PA	11,839	8,874	75.0	12,416	9,541	76.8	12,970	10,301	79.4	13,226	10,922	82.6	13,742	11,733	85.4
Phoenix, AZ	301	250	83.1	534	324	60.7	723	632	87.4	936	748	79.9	1,035	885	85.5
San Diego, CA	3,342	2,738	81.9	4,208	3,482	82.8	4,699	4,037	85.9	4,628	4,032	87.1	4,948	4,442	89.8
San Francisco, CA	3,586	2,754	76.8	3,733	2,920	78.2	2,561	2,072	80.9	2,370	1,912	80.7	3,679	3,108	84.5
San Juan, PR	3,516	2,524	71.8	4,306	3,242	75.3	5,791	4,492	77.6	5,881	4,740	80.6	8,409	7,070	84.1
Tampa-St. Petersburg, FL	3,314	2,396	72.3	3,336	2,516	75.4	3,741	2,906	77.7	3,718	2,967	79.8	4,347	3,441	79.2
Washington, DC	9,013	7,040	78.1	8,790	6,820	77.6	8,896	7,035	79.1	8,870	7,395	83.4	9,117	7,729	84.8
West Palm Beach, FL	112	67	59.8	500	355	71.0	141	141	100.0	1,902	1,538	80.9	1,918	1,598	83.3
Subtotal EMAs^a	140,799	100,354	71.3	150,591	111,853	74.3	145,555	113,656	78.1	147,192	119,165	81.0	178,006	147,101	82.6
Transitional grant area															
Austin, TX	1,488	990	66.5	1,544	1,063	68.9	1,723	1,288	74.8	1,727	1,346	77.9	4,658	3,795	81.5
Baton Rouge, LA	1,738	945	54.4	2,387	1,633	68.4	1,692	1,207	71.3	2,057	1,570	76.3	2,254	1,594	70.7
Bergen-Passaic, NJ	694	442	63.7	839	521	62.1	872	586	67.2	654	527	80.6	1,300	1,016	78.2
Charlotte, NC	1,650	1,103	66.9	1,944	1,359	69.9	2,236	1,642	73.4	2,333	1,905	81.7	2,583	2,146	83.1
Cleveland, OH	1,589	1,111	69.9	2,397	1,771	73.9	2,675	2,117	79.1	2,358	1,922	81.5	1,867	1,597	85.5
Columbus, OH	939	728	77.5	1,016	758	74.6	3,025	2,407	79.6	2,643	2,209	83.6	3,136	2,698	86.0
Denver, CO	2,715	2,158	79.5	2,405	1,823	75.8	3,276	2,703	82.5	3,588	3,055	85.1	3,743	3,216	85.9
Ft. Worth, TX	1,493	1,074	71.9	1,601	1,206	75.3	1,640	1,284	78.3	1,665	1,331	79.9	2,227	1,784	80.1
Hartford, CT	1,536	1,066	69.4	1,805	1,382	76.6	1,808	1,459	80.7	1,816	1,561	86.0	1,898	1,629	85.8
Indianapolis, IN	257	151	58.8	679	447	65.8	778	543	69.8	2,420	2,068	85.5	2,960	2,553	86.3
Jacksonville, FL	2,765	1,886	68.2	2,513	1,741	69.3	2,761	1,990	72.1	3,149	2,419	76.8	1,493	1,207	80.8
Jersey City, NJ	1,568	1,114	71.1	1,547	1,114	72.0	1,561	1,249	80.0	1,608	1,368	85.1	1,560	1,315	84.3
Kansas City, MO	885	577	65.2	925	694	75.0	1,196	932	77.9	682	566	83.0	1,490	1,247	83.7
Las Vegas, NV	500	321	64.2	494	328	66.4	785	461	58.7	998	587	58.8	1,563	1,102	70.5
Memphis, TN	2,852	1,862	65.3	2,355	1,525	64.8	2,210	1,531	69.3	2,092	1,464	70.0	3,528	2,625	74.4
Middlesex, NJ	912	663	72.7	832	627	75.4	799	651	81.5	732	599	81.8	827	722	87.3
Minneapolis-St. Paul, MN	2,146	1,711	79.7	2,103	1,712	81.4	2,411	2,077	86.2	2,037	1,786	87.7	2,123	1,861	87.7
Nashville, TN	1,473	1,051	71.4	1,316	1,021	77.6	1,195	941	78.7	1,872	1,553	83.0	4,302	3,654	84.9
Norfolk, VA	1,206	882	73.1	1,202	892	74.2	1,406	1,069	76.0	1,192	902	75.7	1,050	796	75.8

Table 13c. Viral suppression among Ryan White HIV/AIDS Program clients, by year and eligible metropolitan area and transitional grant area, 2011–2015—United States and 3 territories (cont.)

	2011			2012			2013			2014			2015		
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression		
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Transitional grant area															
Oakland, CA	2,207	1,650	74.8	2,504	1,989	79.4	1,556	1,273	81.8	1,172	990	84.5	876	719	82.1
Orange County, CA	1,579	1,267	80.2	1,554	1,284	82.6	1,360	1,147	84.3	1,119	958	85.6	1,143	1,013	88.6
Portland, OR	1,371	1,056	77.0	1,339	1,074	80.2	1,501	1,242	82.7	1,277	1,078	84.4	2,514	2,169	86.3
Riverside-San Bernardino, CA	2,453	1,981	80.8	2,101	1,696	80.7	1,460	1,220	83.6	782	641	82.0	831	687	82.7
Sacramento, CA	2,175	1,670	76.8	2,304	1,819	79.0	2,270	1,820	80.2	2,360	1,921	81.4	2,758	2,342	84.9
San Antonio, TX	1,326	885	66.7	1,238	872	70.4	1,579	1,129	71.5	1,536	1,158	75.4	3,311	2,616	79.0
San Jose, CA	1,133	962	84.9	1,068	906	84.8	734	606	82.6	687	572	83.3	603	523	86.7
Seattle, WA	1,758	1,561	88.8	1,796	1,443	80.4	1,259	1,037	82.4	1,395	1,223	87.7	2,360	2,090	88.6
St. Louis, MO	1,122	680	60.6	1,392	1,001	71.9	1,847	1,431	77.5	1,897	1,491	78.6	3,675	3,073	83.6
Subtotal TGAs^a	43,300	31,386	72.5	44,808	33,413	74.6	47,421	36,900	77.8	47,265	38,294	81.0	61,014	50,415	82.6
Total all EMAs and TGAs^a	182,641	130,715	71.6	192,954	143,406	74.3	191,533	149,458	78.0	191,761	155,255	81.0	234,850	194,215	82.7

Abbreviations: EMA, eligible metropolitan area; TGA, transitional grant area.

Note. EMA/TGA delineations are based on provider location.

Data shown for individual EMAs and TGAs are not mutually exclusive; clients may have received services from providers in multiple EMAs and/or TGAs.

Viral suppression was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit during the measurement year and whose most recent viral load test result was <200 copies/mL.

^a The EMA/TGA subtotals and total were calculated independently of the values for each of the EMAs/TGAs and include deduplicated counts of clients receiving services in the EMAs/TGAs. Therefore, the values in each column do not sum to the column subtotals and total.

Table 14a. Retention in care among women (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b			
	Retained			Retained			Retained			Retained			Retained			Retained			Retained			Retained			
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	
Age group (yr)																									
13–14	0	—	—	6	6	100.0	135	126	93.3	28	28	100.0	0	—	—	20	16	80.0	5	5	100.0	195	182	93.3	
15–19	0	—	—	8	7	87.5	645	558	86.5	164	144	87.8	1	1	100.0	75	61	81.3	20	19	95.0	916	790	86.2	
20–24	8	6	75.0	20	17	85.0	1,840	1,432	77.8	516	401	77.7	3	3	100.0	330	240	72.7	52	43	82.7	2,779	2,147	77.3	
25–29	18	15	83.3	45	37	82.2	3,162	2,380	75.3	847	677	79.9	9	9	100.0	735	557	75.8	79	62	78.5	4,910	3,747	76.3	
30–34	36	24	66.7	130	102	78.5	4,236	3,255	76.8	1,324	1,115	84.2	9	6	66.7	1,027	794	77.3	107	89	83.2	6,894	5,398	78.3	
35–39	40	33	82.5	157	130	82.8	5,849	4,641	79.4	1,970	1,662	84.4	13	10	76.9	1,471	1,139	77.4	131	103	78.6	9,668	7,740	80.1	
40–44	42	31	73.8	159	130	81.8	7,019	5,664	80.7	2,469	2,128	86.2	11	9	81.8	1,709	1,332	77.9	138	104	75.4	11,589	9,426	81.3	
45–49	53	41	77.4	110	98	89.1	8,699	7,227	83.1	2,855	2,465	86.3	10	9	90.0	2,206	1,781	80.7	177	158	89.3	14,152	11,812	83.5	
50–54	57	48	84.2	82	73	89.0	9,379	7,925	84.5	3,220	2,847	88.4	16	12	75.0	2,499	2,063	82.6	210	184	87.6	15,508	13,179	85.0	
55–59	50	38	76.0	69	62	89.9	7,377	6,265	84.9	2,449	2,177	88.9	8	7	87.5	1,855	1,524	82.2	157	140	89.2	12,003	10,241	85.3	
60–64	26	23	88.5	42	38	90.5	4,385	3,737	85.2	1,454	1,304	89.7	10	10	100.0	985	817	82.9	89	76	85.4	7,011	6,019	85.9	
≥65	19	15	79.0	54	42	77.8	3,031	2,602	85.9	1,339	1,194	89.2	1	1	100.0	695	594	85.5	52	45	86.5	5,200	4,500	86.5	
Transmission risk category																									
Injection drug use	63	51	81.0	17	10	58.8	3,579	2,998	83.8	1,467	1,262	86.0	9	9	100.0	2,311	1,852	80.1	175	147	84.0	7,647	6,346	83.0	
Heterosexual contact ^c	256	197	77.0	730	624	85.5	46,889	38,640	82.4	15,763	13,732	87.1	65	52	80.0	10,331	8,313	80.5	920	779	84.7	75,145	62,460	83.1	
Perinatal infection	4	4	100.0	20	17	85.0	1,802	1,519	84.3	630	524	83.2	3	3	100.0	281	222	79.0	65	58	89.2	2,813	2,351	83.6	
Other ^d	2	2	100.0	43	33	76.7	508	424	83.5	217	186	85.7	1	1	100.0	179	142	79.3	16	12	75.0	974	806	82.8	
HHS region^e																									
Region 1	7	6	85.7	54	49	90.7	1,704	1,449	85.0	1,544	1,341	86.9	1	1	100.0	980	812	82.9	43	35	81.4	4,350	3,705	85.2	
Region 2	18	14	77.8	139	125	89.9	7,745	6,544	84.5	7,252	6,501	89.6	8	8	100.0	1,395	1,171	83.9	149	133	89.3	16,765	14,544	86.8	
Region 3	18	15	83.3	72	65	90.3	9,824	8,251	84.0	1,350	1,209	89.6	6	6	100.0	1,595	1,266	79.4	289	251	86.9	13,181	11,083	84.1	
Region 4	64	56	87.5	124	111	89.5	20,249	17,042	84.2	2,224	1,923	86.5	7	5	71.4	4,017	3,358	83.6	290	248	85.5	26,980	22,747	84.3	
Region 5	42	37	88.1	86	71	82.6	5,306	4,191	79.0	860	733	85.2	8	8	100.0	1,306	1,006	77.0	133	113	85.0	7,892	6,244	79.1	
Region 6	42	33	78.6	97	79	81.4	6,487	4,887	75.3	2,132	1,784	83.7	3	3	100.0	1,533	1,155	75.3	85	66	77.7	10,380	8,008	77.2	
Region 7	13	10	76.9	22	16	72.7	971	811	83.5	92	82	89.1	1	1	100.0	445	349	78.4	25	20	80.0	1,569	1,289	82.2	
Region 8	21	15	71.4	34	31	91.2	371	305	82.2	240	206	85.8	1	1	100.0	380	295	77.6	17	12	70.6	1,066	866	81.2	
Region 9	44	30	68.2	195	145	74.4	1,886	1,349	71.5	2,454	1,949	79.4	48	39	81.3	1,334	1,044	78.3	83	66	79.5	6,057	4,633	76.5	
Region 10	73	52	71.2	38	33	86.8	279	220	78.9	125	100	80.0	6	4	66.7	289	211	73.0	31	25	80.7	852	650	76.3	
Poverty level																									
0–100%	274	215	78.5	546	460	84.3	40,386	33,198	82.2	15,026	13,060	86.9	68	59	86.8	9,080	7,254	79.9	964	810	84.0	66,521	55,173	82.9	
101–138%	29	26	89.7	104	89	85.6	5,824	4,861	83.5	1,621	1,412	87.1	7	5	71.4	1,542	1,291	83.7	97	85	87.6	9,258	7,788	84.1	
139–250%	26	20	76.9	134	117	87.3	5,922	4,927	83.2	1,424	1,211	85.0	11	8	72.7	1,678	1,382	82.4	113	97	85.8	9,356	7,794	83.3	
251–400%	10	9	90.0	51	41	80.4	1,875	1,532	81.7	320	273	85.3	3	3	100.0	667	528	79.2	23	21	91.3	2,960	2,415	81.6	
>400%	2	1	50.0	19	15	79.0	428	355	82.9	108	90	83.3	1	1	100.0	285	220	77.2	6	6	100.0	852	691	81.1	

Table 14a. Retention in care among women (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories (cont.)

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Total No.	Retained		Total No.	Retained		Total No.	Retained		T otal No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained	
		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%
Health care coverage																								
Private employer	10	10	100.0	95	77	81.1	4,151	3,405	82.0	719	597	83.0	6	6	100.0	1,302	1,018	78.2	59	53	89.8	6,350	5,173	81.5
Private individual	17	14	82.4	86	71	82.6	2,972	2,380	80.1	622	495	79.6	5	4	80.0	864	675	78.1	49	35	71.4	4,619	3,675	79.6
Medicare	20	14	70.0	47	38	80.9	5,277	4,389	83.2	1,014	901	88.9	4	4	100.0	1,499	1,258	83.9	90	79	87.8	7,970	6,697	84.0
Medicaid	154	124	80.5	345	289	83.8	22,463	18,235	81.2	8,754	7,594	86.8	38	32	84.2	4,868	3,842	78.9	504	426	84.5	37,200	30,596	82.3
Medicare and Medicaid	31	23	74.2	17	17	100.0	4,593	4,031	87.8	1,234	1,078	87.4	1	1	100.0	1,442	1,224	84.9	142	123	86.6	7,466	6,500	87.1
Veterans Administration	1	1	100.0	1	1	100.0	65	51	78.5	8	7	87.5	0	—	—	21	15	71.4	0	—	—	96	75	78.1
Indian Health Service	31	18	58.1	0	—	—	14	12	85.7	2	1	50.0	0	—	—	6	4	66.7	1	1	100.0	54	36	66.7
Other plan	4	3	75.0	12	9	75.0	844	714	84.6	427	378	88.5	4	1	25.0	206	156	75.7	19	15	79.0	1,524	1,282	84.1
No coverage	26	22	84.6	165	142	86.1	9,317	7,490	80.4	3,907	3,392	86.8	11	11	100.0	1,727	1,360	78.8	142	120	84.5	15,442	12,622	81.7
Multiple coverages	51	43	84.3	103	91	88.4	5,534	4,753	85.9	1,821	1,615	88.7	20	17	85.0	1,578	1,312	83.1	207	174	84.1	9,325	8,014	85.9
Housing status																								
Stable	272	215	79.0	765	656	85.8	48,653	40,298	82.8	16,451	14,342	87.2	78	66	84.6	11,702	9,497	81.2	980	834	85.1	79,118	66,054	83.5
Temporary	32	27	84.4	72	53	73.6	4,308	3,430	79.6	1,569	1,320	84.1	7	6	85.7	1,175	908	77.3	148	124	83.8	7,363	5,895	80.1
Unstable	36	26	72.2	27	22	81.5	1,908	1,471	77.1	494	395	80.0	5	4	80.0	478	350	73.2	74	59	79.7	3,028	2,332	77.0
Total^b	349	274	78.5	882	742	84.1	55,757	45,812	82.2	18,635	16,142	86.6	91	77	84.6	13,607	10,918	80.2	1,217	1,028	84.5	90,825	75,181	82.8

Retention in care was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit by September 1 of the measurement year, with a second visit at least 90 days after.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

Table 14b. Viral suppression among women (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b			
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	
Age group (yr)																									
13–14	0	—	—	6	6	100.0	140	103	73.6	26	22	84.6	0	—	—	17	16	94.1	5	3	60.0	195	151	77.4	
15–19	0	—	—	8	7	87.5	676	450	66.6	170	138	81.2	1	0	0.0	86	70	81.4	21	18	85.7	964	683	70.9	
20–24	9	7	77.8	24	19	79.2	1,969	1,217	61.8	538	366	68.0	3	1	33.3	375	281	74.9	55	34	61.8	2,984	1,932	64.8	
25–29	19	13	68.4	49	40	81.6	3,364	2,275	67.6	879	648	73.7	10	6	60.0	793	570	71.9	86	63	73.3	5,219	3,630	69.6	
30–34	39	23	59.0	135	120	88.9	4,512	3,269	72.5	1,382	1,108	80.2	10	7	70.0	1,121	855	76.3	111	81	73.0	7,335	5,480	74.7	
35–39	45	32	71.1	162	155	95.7	6,113	4,686	76.7	2,045	1,673	81.8	15	9	60.0	1,549	1,248	80.6	133	113	85.0	10,100	7,945	78.7	
40–44	44	29	65.9	164	155	94.5	7,343	5,855	79.7	2,532	2,130	84.1	12	9	75.0	1,783	1,473	82.6	139	110	79.1	12,056	9,796	81.3	
45–49	59	47	79.7	120	111	92.5	8,977	7,373	82.1	2,897	2,467	85.2	11	8	72.7	2,307	1,987	86.1	185	143	77.3	14,600	12,173	83.4	
50–54	62	52	83.9	85	77	90.6	9,624	8,099	84.2	3,225	2,818	87.4	16	14	87.5	2,565	2,256	88.0	213	186	87.3	15,833	13,539	85.5	
55–59	51	49	96.1	71	67	94.4	7,528	6,535	86.8	2,464	2,200	89.3	8	7	87.5	1,894	1,727	91.2	158	140	88.6	12,211	10,757	88.1	
60–64	25	19	76.0	42	39	92.9	4,454	3,933	88.3	1,458	1,328	91.1	11	11	100.0	1,007	937	93.1	86	77	89.5	7,101	6,360	89.6	
≥65	22	22	100.0	54	49	90.7	3,066	2,772	90.4	1,325	1,231	92.9	3	3	100.0	701	670	95.6	55	53	96.4	5,237	4,810	91.9	
Transmission risk category																									
Injection drug use	70	59	84.3	18	14	77.8	3,692	2,986	80.9	1,475	1,200	81.4	9	7	77.8	2,416	1,959	81.1	179	148	82.7	7,890	6,398	81.1	
Heterosexual contact ^c	273	209	76.6	764	708	92.7	48,617	39,445	81.1	16,046	13,824	86.2	74	55	74.3	10,782	9,285	86.1	938	775	82.6	77,676	64,455	83.0	
Perinatal infection	4	2	50.0	20	18	90.0	1,839	1,169	63.6	627	428	68.3	3	0	0.0	284	232	81.7	67	45	67.2	2,852	1,899	66.6	
Other ^d	3	2	66.7	42	39	92.9	525	448	85.3	226	197	87.2	1	1	100.0	181	163	90.1	20	17	85.0	1,004	873	87.0	
HHS region^e																									
Region 1	9	5	55.6	55	53	96.4	1,767	1,517	85.9	1,589	1,378	86.7	1	1	100.0	992	869	87.6	44	39	88.6	4,474	3,872	86.5	
Region 2	20	16	80.0	141	134	95.0	8,042	6,452	80.2	7,331	6,150	83.9	10	9	90.0	1,447	1,278	88.3	148	125	84.5	17,205	14,217	82.6	
Region 3	18	14	77.8	76	69	90.8	10,138	8,472	83.6	1,376	1,209	87.9	6	6	100.0	1,688	1,480	87.7	292	248	84.9	13,619	11,520	84.6	
Region 4	70	56	80.0	130	121	93.1	20,915	16,813	80.4	2,275	2,003	88.0	7	5	71.4	4,200	3,561	84.8	298	241	80.9	27,901	22,805	81.7	
Region 5	44	35	79.6	90	84	93.3	5,466	4,415	80.8	906	791	87.3	8	7	87.5	1,380	1,184	85.8	139	109	78.4	8,173	6,744	82.5	
Region 6	47	32	68.1	104	94	90.4	6,856	5,138	74.9	2,231	1,835	82.3	4	4	100.0	1,613	1,278	79.2	89	64	71.9	10,945	8,446	77.2	
Region 7	12	9	75.0	22	21	95.5	1,036	859	82.9	102	84	82.4	1	1	100.0	497	426	85.7	31	22	71.0	1,701	1,422	83.6	
Region 8	24	19	79.2	34	32	94.1	375	321	85.6	243	203	83.5	1	1	100.0	394	340	86.3	17	13	76.5	1,091	931	85.3	
Region 9	44	34	77.3	205	182	88.8	1,875	1,520	81.1	2,384	2,051	86.0	54	34	63.0	1,349	1,136	84.2	82	71	86.6	6,008	5,039	83.9	
Region 10	80	67	83.8	42	36	85.7	299	263	88.0	135	122	90.4	6	5	83.3	302	260	86.1	34	31	91.2	912	796	87.3	
Poverty level																									
0–100%	295	222	75.3	571	516	90.4	41,936	32,981	78.7	15,269	12,853	84.2	74	52	70.3	9,500	7,828	82.4	978	780	79.8	68,797	55,374	80.5	
101–138%	32	27	84.4	105	98	93.3	6,010	5,102	84.9	1,639	1,455	88.8	9	7	77.8	1,610	1,432	88.9	101	91	90.1	9,540	8,242	86.4	
139–250%	26	24	92.3	138	129	93.5	6,117	5,300	86.6	1,464	1,333	91.1	12	12	100.0	1,753	1,614	92.1	121	111	91.7	9,678	8,562	88.5	
251–400%	12	12	100.0	56	53	94.6	1,932	1,719	89.0	326	290	89.0	3	2	66.7	692	639	92.3	25	22	88.0	3,059	2,749	89.9	
>400%	1	1	100.0	22	22	100.0	451	402	89.1	111	100	90.1	2	2	100.0	291	282	96.9	6	6	100.0	888	819	92.2	

Table 14b. Viral suppression among women (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories (cont.)

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression		
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Health care coverage																								
Private employer	13	12	92.3	98	96	98.0	4,328	3,754	86.7	754	682	90.5	6	5	83.3	1,372	1,256	91.6	61	53	86.9	6,643	5,869	88.4
Private individual	16	14	87.5	91	85	93.4	3,082	2,675	86.8	641	573	89.4	5	5	100.0	894	809	90.5	52	44	84.6	4,785	4,209	88.0
Medicare	22	19	86.4	45	42	93.3	5,414	4,593	84.8	1,025	934	91.1	5	5	100.0	1,545	1,411	91.3	94	78	83.0	8,170	7,100	86.9
Medicaid	166	120	72.3	355	324	91.3	23,237	17,919	77.1	8,896	7,348	82.6	43	31	72.1	5,085	4,138	81.4	511	404	79.1	38,373	30,344	79.1
Medicare and Medicaid	30	25	83.3	17	15	88.2	4,666	3,974	85.2	1,238	1,076	86.9	3	3	100.0	1,491	1,329	89.1	143	126	88.1	7,595	6,553	86.3
Veterans Administration	1	1	100.0	1	1	100.0	63	55	87.3	8	8	100.0	0	—	—	21	19	90.5	0	—	—	94	84	89.4
Indian Health Service	32	24	75.0	0	—	—	16	15	93.8	2	2	100.0	0	—	—	6	6	100.0	1	1	100.0	57	48	84.2
Other plan	3	3	100.0	17	17	100.0	868	740	85.3	428	380	88.8	5	0	0.0	210	178	84.8	21	16	76.2	1,560	1,340	85.9
No coverage	35	25	71.4	179	159	88.8	9,929	7,625	76.8	3,991	3,417	85.6	12	9	75.0	1,851	1,424	76.9	152	120	79.0	16,287	12,895	79.2
Multiple coverages	53	46	86.8	108	99	91.7	5,656	4,797	84.8	1,851	1,623	87.7	20	16	80.0	1,637	1,446	88.3	208	175	84.1	9,544	8,212	86.0
Housing status																								
Stable	290	238	82.1	801	740	92.4	50,301	41,040	81.6	16,743	14,347	85.7	85	65	76.5	12,198	10,554	86.5	1,007	830	82.4	81,642	67,991	83.3
Temporary	35	21	60.0	73	66	90.4	4,557	3,408	74.8	1,614	1,340	83.0	8	7	87.5	1,248	996	79.8	149	122	81.9	7,737	6,005	77.6
Unstable	40	24	60.0	29	23	79.3	2,045	1,418	69.3	485	365	75.3	7	3	42.9	521	342	65.6	75	56	74.7	3,207	2,235	69.7
Total^b	375	293	78.1	920	845	91.9	57,766	46,567	80.6	18,941	16,129	85.2	100	75	75.0	14,198	12,090	85.2	1,247	1,021	81.9	93,835	77,256	82.3

Viral suppression was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit during the measurement year and whose most recent viral load test result was <200 copies/mL.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia and blood transfusion.

^e See Technical Notes for the states/territories in each region.

Table 15a. Retention in care among men (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories (cont.)

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Retained			Retained			Retained			Retained			Retained			Retained			Retained			Retained		
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Health care coverage																								
Private employer	95	61	64.2	325	260	80.0	8,355	6,586	78.8	3,503	2,790	79.7	42	32	76.2	10,111	8,064	79.8	239	184	77.0	22,735	18,024	79.3
Private individual	73	44	60.3	350	284	81.1	6,552	4,946	75.5	3,317	2,403	72.4	31	26	83.9	7,504	5,742	76.5	212	155	73.1	18,083	13,633	75.4
Medicare	99	84	84.9	142	121	85.2	10,735	8,899	82.9	3,714	3,184	85.7	23	18	78.3	10,077	8,372	83.1	268	224	83.6	25,114	20,939	83.4
Medicaid	269	208	77.3	1,000	799	79.9	28,525	22,282	78.1	18,800	15,713	83.6	110	83	75.5	13,764	10,734	78.0	898	725	80.7	63,592	50,709	79.7
Medicare and Medicaid	85	74	87.1	137	115	83.9	7,059	5,947	84.3	3,224	2,667	82.7	20	17	85.0	5,634	4,775	84.8	323	270	83.6	16,509	13,885	84.1
Veterans Administration	1	0	0.0	0	—	—	104	76	73.1	30	21	70.0	0	—	—	163	119	73.0	7	7	100.0	305	223	73.1
Indian Health Service	55	37	67.3	0	—	—	9	7	77.8	5	2	40.0	0	—	—	6	6	100.0	1	1	100.0	76	53	69.7
Other plan	19	11	57.9	126	99	78.6	1,600	1,273	79.6	1,915	1,613	84.2	6	3	50.0	1,244	934	75.1	53	40	75.5	5,001	3,999	80.0
No coverage	105	74	70.5	736	583	79.2	22,486	16,832	74.9	18,197	14,942	82.1	48	34	70.8	9,714	7,429	76.5	438	348	79.5	52,304	40,560	77.6
Multiple coverages	134	95	70.9	450	392	87.1	8,651	7,286	84.2	5,614	4,821	85.9	51	37	72.6	9,575	7,816	81.6	614	506	82.4	25,173	21,014	83.5
Housing status																								
Stable	752	569	75.7	2,812	2,281	81.1	78,995	63,040	79.8	49,656	41,227	83.0	275	213	77.5	58,612	47,174	80.5	2,333	1,923	82.4	194,294	156,998	80.8
Temporary	101	73	72.3	344	286	83.1	9,399	6,984	74.3	6,555	5,311	81.0	32	21	65.6	5,672	4,281	75.5	445	336	75.5	22,740	17,393	76.5
Unstable	67	37	55.2	76	57	75.0	5,078	3,658	72.0	1,914	1,445	75.5	19	12	63.2	2,382	1,669	70.1	262	200	76.3	9,843	7,098	72.1
Total^b	944	693	73.4	3,300	2,671	80.9	95,175	74,771	78.6	58,796	48,440	82.4	332	250	75.3	68,456	54,402	79.5	3,077	2,475	80.4	231,227	184,424	79.8

Retention in care was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit by September 1 of the measurement year, with a second visit at least 90 days after.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia and blood transfusion.

^e See Technical Notes for the states/territories in each region.

Table 15b. Viral suppression among men (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b			
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	
Age group (yr)																									
13–14	3	3	100.0	0	—	—	108	84	77.8	26	22	84.6	1	1	100.0	18	17	94.4	5	5	100.0	163	134	82.2	
15–19	3	1	33.3	18	14	77.8	944	614	65.0	254	193	76.0	2	2	100.0	119	87	73.1	21	12	57.1	1,365	926	67.8	
20–24	35	22	62.9	170	139	81.8	6,655	4,427	66.5	2,424	1,758	72.5	11	7	63.6	1,474	1,100	74.6	228	167	73.3	11,047	7,657	69.3	
25–29	92	69	75.0	368	317	86.1	12,315	8,654	70.3	5,214	4,130	79.2	33	27	81.8	4,137	3,319	80.2	386	301	78.0	22,678	16,927	74.6	
30–34	86	66	76.7	397	346	87.2	10,241	7,516	73.4	6,485	5,373	82.9	49	40	81.6	5,339	4,445	83.3	311	249	80.1	23,037	18,129	78.7	
35–39	108	87	80.6	431	388	90.0	8,576	6,532	76.2	7,380	6,260	84.8	47	41	87.2	5,963	4,991	83.7	316	261	82.6	22,936	18,651	81.3	
40–44	119	102	85.7	597	551	92.3	8,763	6,834	78.0	7,785	6,698	86.0	42	36	85.7	7,099	6,162	86.8	298	235	78.9	24,846	20,746	83.5	
45–49	182	152	83.5	575	526	91.5	12,510	10,153	81.2	9,775	8,535	87.3	54	49	90.7	11,617	10,283	88.5	483	404	83.6	35,374	30,258	85.5	
50–54	176	154	87.5	403	378	93.8	15,596	12,913	82.8	9,318	8,225	88.3	51	48	94.1	14,895	13,524	90.8	529	459	86.8	41,135	35,848	87.2	
55–59	123	111	90.2	246	231	93.9	12,475	10,665	85.5	6,012	5,410	90.0	37	33	89.2	10,437	9,738	93.3	320	293	91.6	29,748	26,572	89.3	
60–64	57	55	96.5	146	138	94.5	7,283	6,382	87.6	3,346	3,072	91.8	9	8	88.9	6,039	5,741	95.1	200	171	85.5	17,147	15,631	91.2	
≥65	26	26	100.0	109	100	91.7	4,619	4,164	90.2	2,425	2,249	92.7	9	9	100.0	4,292	4,135	96.3	116	106	91.4	11,632	10,822	93.0	
Transmission risk category																									
Male-to-male sexual contact	650	554	85.2	2,151	1,948	90.6	51,136	39,722	77.7	36,470	31,587	86.6	257	225	87.6	52,991	47,682	90.0	2,121	1,769	83.4	146,480	124,097	84.7	
Injection drug use	64	56	87.5	89	77	86.5	6,275	5,217	83.1	4,360	3,627	83.2	8	8	100.0	3,714	3,180	85.6	174	140	80.5	14,738	12,350	83.8	
Male-to-male sexual contact and injection drug use	83	69	83.1	55	47	85.5	1,520	1,188	78.2	1,234	1,005	81.4	5	4	80.0	3,570	2,994	83.9	185	151	81.6	6,667	5,469	82.0	
Heterosexual contact ^c	152	120	79.0	858	783	91.3	33,912	27,261	80.4	15,200	13,135	86.4	46	39	84.8	7,380	6,459	87.5	568	464	81.7	58,258	48,387	83.1	
Perinatal infection	4	3	75.0	13	12	92.3	1,402	895	63.8	505	340	67.3	4	2	50.0	240	191	79.6	52	36	69.2	2,228	1,485	66.7	
Other ^a	12	11	91.7	51	48	94.1	455	392	86.2	304	273	89.8	4	4	100.0	556	510	91.7	20	19	95.0	1,415	1,269	89.7	
HHS region^e																									
Region 1	23	16	69.6	153	140	91.5	1,914	1,659	86.7	2,539	2,264	89.2	12	11	91.7	4,463	4,160	93.2	127	115	90.6	9,271	8,398	90.6	
Region 2	54	46	85.2	623	572	91.8	11,348	9,097	80.2	15,699	13,372	85.2	35	33	94.3	5,287	4,780	90.4	324	270	83.3	33,656	28,408	84.4	
Region 3	26	22	84.6	248	227	91.5	16,321	13,628	83.5	2,929	2,598	88.7	23	18	78.3	7,184	6,633	92.3	480	403	84.0	27,289	23,595	86.5	
Region 4	145	134	92.4	360	327	90.8	35,626	27,748	77.9	8,048	7,068	87.8	25	22	88.0	17,232	15,353	89.1	621	515	82.9	62,080	51,188	82.5	
Region 5	77	67	87.0	294	263	89.5	12,669	10,111	79.8	3,976	3,511	88.3	14	13	92.9	8,504	7,658	90.1	491	414	84.3	26,553	22,495	84.7	
Region 6	182	144	79.1	339	298	87.9	11,660	8,664	74.3	9,728	8,199	84.3	24	21	87.5	8,103	6,771	83.6	266	215	80.8	30,325	24,330	80.2	
Region 7	22	19	86.4	70	61	87.1	1,940	1,592	82.1	430	386	89.8	5	5	100.0	2,532	2,281	90.1	77	70	90.9	5,076	4,414	87.0	
Region 8	64	54	84.4	62	61	98.4	553	454	82.1	1,066	915	85.8	6	5	83.3	2,932	2,634	89.8	58	43	74.1	4,749	4,172	87.9	
Region 9	258	210	81.4	1,152	1,035	89.8	5,244	3,904	74.5	14,049	11,931	84.9	184	157	85.3	10,624	9,275	87.3	296	243	82.1	31,882	26,815	84.1	
Region 10	137	119	86.9	103	94	91.3	561	466	83.1	683	610	89.3	15	14	93.3	2,480	2,239	90.3	138	114	82.6	4,178	3,712	88.9	
Poverty level																									
0–100%	633	507	80.1	1,883	1,674	88.9	67,461	51,488	76.3	39,100	32,807	83.9	183	154	84.2	34,815	29,768	85.5	2,163	1,752	81.0	146,838	118,652	80.8	
101–138%	117	104	88.9	449	415	92.4	10,876	9,039	83.1	7,465	6,660	89.2	41	37	90.2	9,673	8,764	90.6	356	308	86.5	29,076	25,409	87.4	
139–250%	148	135	91.2	639	584	91.4	13,042	10,980	84.2	9,045	8,134	89.9	66	60	90.9	13,712	12,670	92.4	453	390	86.1	37,332	33,160	88.8	
251–400%	59	55	93.2	256	239	93.4	4,914	4,261	86.7	2,935	2,650	90.3	28	28	100.0	6,621	6,215	93.9	141	123	87.2	15,051	13,659	90.8	
>400%	30	27	90.0	148	135	91.2	1,502	1,317	87.7	1,237	1,108	89.6	18	15	83.3	4,252	4,001	94.1	50	47	94.0	7,284	6,693	91.9	

Table 15b. Viral suppression among men (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories (cont.)

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression		
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Health care coverage																								
Private employer	95	90	94.7	352	319	90.6	8,901	7,501	84.3	3,678	3,261	88.7	44	39	88.6	10,656	9,914	93.0	246	213	86.6	24,044	21,398	89.0
Private individual	81	71	87.7	363	342	94.2	6,841	5,858	85.6	3,427	3,129	91.3	32	31	96.9	7,778	7,176	92.3	226	191	84.5	18,798	16,840	89.6
Medicare	101	90	89.1	146	133	91.1	11,023	9,397	85.3	3,779	3,396	89.9	23	22	95.7	10,326	9,503	92.0	280	250	89.3	25,736	22,844	88.8
Medicaid	293	243	82.9	1,041	937	90.0	29,819	22,895	76.8	19,196	16,012	83.4	111	98	88.3	14,418	12,318	85.4	934	753	80.6	66,071	53,466	80.9
Medicare and Medicaid	87	79	90.8	127	116	91.3	7,137	6,064	85.0	3,162	2,811	88.9	20	18	90.0	5,762	5,261	91.3	330	288	87.3	16,653	14,662	88.0
Veterans Administration	1	0	0.0	1	0	0.0	115	96	83.5	33	29	87.9	0	—	—	177	161	91.0	7	6	85.7	334	292	87.4
Indian Health Service	62	51	82.3	0	—	—	12	10	83.3	6	6	100.0	0	—	—	8	6	75.0	1	1	100.0	89	74	83.2
Other plan	19	15	79.0	137	118	86.1	1,663	1,367	82.2	1,975	1,770	89.6	6	4	66.7	1,318	1,183	89.8	54	42	77.8	5,212	4,537	87.1
No coverage	123	87	70.7	798	697	87.3	24,551	17,419	71.0	18,979	15,972	84.2	49	37	75.5	10,409	8,323	80.0	479	353	73.7	55,897	43,325	77.5
Multiple coverages	142	119	83.8	462	434	93.9	8,989	7,493	83.4	5,818	5,213	89.6	55	49	89.1	9,964	9,162	92.0	634	546	86.1	26,151	23,090	88.3
Housing status																								
Stable	803	697	86.8	2,922	2,659	91.0	82,932	66,550	80.3	50,930	44,291	87.0	282	246	87.2	61,067	55,092	90.2	2,438	2,087	85.6	202,220	172,358	85.2
Temporary	112	82	73.2	380	334	87.9	10,081	7,405	73.5	6,885	5,727	83.2	33	31	93.9	6,007	4,966	82.7	467	351	75.2	24,142	19,044	78.9
Unstable	74	50	67.6	85	67	78.8	5,402	3,650	67.6	2,008	1,394	69.4	22	17	77.3	2,554	1,855	72.6	272	197	72.4	10,461	7,259	69.4
Total^b	1,010	848	84.0	3,460	3,128	90.4	100,085	78,938	78.9	60,444	51,925	85.9	345	301	87.3	71,429	63,542	89.0	3,213	2,663	82.9	241,108	202,301	83.9

Viral suppression was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit during the measurement year and whose most recent viral load test result was <200 copies/mL.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia and blood transfusion.

^e See Technical Notes for the states/territories in each region.

Table 16a. Retention in care among transgender adults and adolescents (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories (cont.)

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b			
	Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		
		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%	No.
Health care coverage																									
Private employer	0	—	—	2	1	50.0	52	37	71.2	34	29	85.3	0	—	—	49	32	65.3	1	0	0.0	138	99	71.7	
Private individual	0	—	—	5	3	60.0	79	54	68.4	36	24	66.7	0	—	—	35	27	77.1	6	5	83.3	165	116	70.3	
Medicare	2	1	50.0	4	4	100.0	105	85	81.0	15	11	73.3	2	0	0.0	42	34	81.0	6	5	83.3	179	142	79.3	
Medicaid	6	4	66.7	25	17	68.0	801	619	77.3	465	364	78.3	9	6	66.7	148	116	78.4	34	28	82.4	1,507	1,172	77.8	
Medicare and Medicaid	2	2	100.0	4	4	100.0	107	92	86.0	43	40	93.0	2	2	100.0	19	18	94.7	3	3	100.0	183	164	89.6	
Veterans Administration	0	—	—	0	—	—	0	—	—	1	0	0.0	0	—	—	1	1	100.0	0	—	—	2	1	50.0	
Indian Health Service	1	0	0.0	0	—	—	1	1	100.0	0	—	—	0	—	—	0	—	—	0	—	—	2	1	50.0	
Other plan	1	0	0.0	2	1	50.0	19	17	89.5	50	41	82.0	0	—	—	4	3	75.0	1	1	100.0	77	63	81.8	
No coverage	1	1	100.0	12	11	91.7	341	249	73.0	304	250	82.2	1	0	0.0	56	42	75.0	6	3	50.0	728	560	76.9	
Multiple coverages	3	2	66.7	7	4	57.1	153	132	86.3	107	99	92.5	5	4	80.0	54	48	88.9	16	16	100.0	351	310	88.3	
Housing status																									
Stable	16	9	56.3	54	41	75.9	1,263	999	79.1	834	692	83.0	13	8	61.5	321	256	79.8	44	39	88.6	2,578	2,073	80.4	
Temporary	0	—	—	6	4	66.7	237	178	75.1	153	118	77.1	3	1	33.3	48	36	75.0	17	13	76.5	469	354	75.5	
Unstable	0	—	—	1	0	0.0	141	93	66.0	64	46	71.9	3	3	100.0	29	22	75.9	13	10	76.9	253	176	69.6	
Total^b	17	10	58.8	62	46	74.2	1,683	1,302	77.4	1,065	864	81.1	20	12	60.0	410	322	78.5	74	62	83.8	3,373	2,653	78.7	

Retention in care was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit by September 1 of the measurement year, with a second visit at least 90 days after.
Abbreviations: MTF, male-to-female; FTM, female-to-male.

* To ensure confidentiality, data have been suppressed.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c Includes any sexual transmission risk category reported by transgender clients.

^d Includes hemophilia and blood transfusion.

^e See Technical Notes for the states/territories in each region.

Table 16b. Viral suppression among transgender adults and adolescents (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression					
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Gender																								
Transgender MTF	19	12	63.2	60	49	81.7	1,670	1,209	72.4	1,024	856	83.6	18	12	66.7	386	318	82.4	79	53	67.1	3,290	2,532	77.0
Transgender FTM	1	0	0.0	1	1	100.0	87	73	83.9	55	44	80.0	4	4	100.0	51	41	80.4	3	3	100.0	208	172	82.7
Transgender unknown	0	—	—	0	—	—	3	3	100.0	1	0	0.0	0	—	—	0	—	—	0	—	—	4	3	75.0
Age group (yr)																								
13–14	*	—	—	*	—	—	*	—	—	*	—	—	*	—	—	*	—	—	*	—	—	*	—	—
15–19	0	—	—	1	0	0.0	16	9	56.3	7	5	71.4	0	—	—	2	2	100.0	2	0	0.0	29	17	58.6
20–24	0	—	—	6	3	50.0	144	89	61.8	43	28	65.1	0	—	—	20	10	50.0	6	4	66.7	221	134	60.6
25–29	3	1	33.3	10	9	90.0	367	236	64.3	126	93	73.8	4	2	50.0	57	43	75.4	14	11	78.6	589	399	67.7
30–34	5	1	20.0	6	6	100.0	302	215	71.2	153	120	78.4	3	3	100.0	45	29	64.4	18	12	66.7	541	391	72.3
35–39	2	2	100.0	8	3	37.5	257	194	75.5	168	146	86.9	3	1	33.3	49	44	89.8	10	6	60.0	501	400	79.8
40–44	2	1	50.0	7	6	85.7	162	125	77.2	193	165	85.5	4	2	50.0	59	54	91.5	10	9	90.0	442	367	83.0
45–49	4	3	75.0	11	11	100.0	180	147	81.7	180	157	87.2	4	4	100.0	73	59	80.8	10	8	80.0	467	394	84.4
50–54	2	2	100.0	6	6	100.0	162	129	79.6	113	100	88.5	1	1	100.0	55	48	87.3	7	3	42.9	350	293	83.7
55–59	0	—	—	4	4	100.0	95	80	84.2	62	52	83.9	3	3	100.0	44	39	88.6	4	2	50.0	213	181	85.0
60–64	1	1	100.0	2	2	100.0	54	43	79.6	25	24	96.0	0	—	—	23	22	95.7	0	—	—	106	92	86.8
≥65	1	1	100.0	0	—	—	20	17	85.0	10	10	100.0	0	—	—	10	9	90.0	1	1	100.0	42	38	90.5
Transmission risk category																								
Sexual contact ^c	16	9	56.3	51	42	82.4	1,530	1,120	73.2	916	777	84.8	16	11	68.8	336	286	85.1	66	45	68.2	2,964	2,315	78.1
Injection drug use	2	2	100.0	0	—	—	13	5	38.5	15	11	73.3	1	1	100.0	15	12	80.0	2	1	50.0	49	32	65.3
Sexual contact ^c and injection drug use	0	—	—	4	4	100.0	66	53	80.3	48	38	79.2	1	1	100.0	31	22	71.0	3	2	66.7	153	120	78.4
Perinatal infection	0	—	—	1	0	0.0	5	5	100.0	1	0	0.0	0	—	—	3	0	0.0	2	2	100.0	12	7	58.3
Other ^d	0	—	—	0	—	—	7	3	42.9	4	1	25.0	0	—	—	2	2	100.0	0	—	—	13	6	46.2
HHS region^e																								
Region 1	0	—	—	7	7	100.0	35	32	91.4	50	46	92.0	1	1	100.0	28	27	96.4	5	5	100.0	128	119	93.0
Region 2	5	3	60.0	14	12	85.7	341	254	74.5	317	255	80.4	3	2	66.7	58	48	82.8	22	15	68.2	781	606	77.6
Region 3	1	0	0.0	5	4	80.0	341	253	74.2	86	71	82.6	1	1	100.0	28	23	82.1	10	6	60.0	476	361	75.8
Region 4	3	3	100.0	4	4	100.0	433	323	74.6	72	66	91.7	1	0	0.0	84	70	83.3	5	4	80.0	602	470	78.1
Region 5	1	1	100.0	5	4	80.0	218	149	68.4	88	72	81.8	1	1	100.0	104	84	80.8	14	9	64.3	441	325	73.7
Region 6	3	1	33.3	0	—	—	151	104	68.9	79	58	73.4	0	—	—	29	22	75.9	1	0	0.0	263	185	70.3
Region 7	0	—	—	0	—	—	52	41	78.9	9	9	100.0	0	—	—	13	12	92.3	1	1	100.0	75	63	84.0
Region 8	1	1	100.0	0	—	—	6	3	50.0	14	13	92.9	0	—	—	3	2	66.7	1	0	0.0	25	19	76.0
Region 9	4	2	50.0	22	15	68.2	148	104	70.3	332	283	85.2	14	10	71.4	65	53	81.5	13	10	76.9	600	479	79.8
Region 10	2	1	50.0	3	3	100.0	9	6	66.7	19	16	84.2	1	1	100.0	16	13	81.3	3	2	66.7	54	43	79.6
Poverty level																								
0–100%	12	5	41.7	42	35	83.3	1,448	1,044	72.1	810	664	82.0	15	10	66.7	270	210	77.8	72	49	68.1	2,701	2,038	75.5
101–138%	2	2	100.0	7	4	57.1	119	90	75.6	122	105	86.1	2	1	50.0	80	70	87.5	2	0	0.0	335	273	81.5
139–250%	1	0	0.0	6	6	100.0	107	89	83.2	94	80	85.1	2	2	100.0	33	31	93.9	5	5	100.0	251	216	86.1
251–400%	3	3	100.0	4	3	75.0	36	27	75.0	26	26	100.0	2	2	100.0	20	19	95.0	2	2	100.0	96	85	88.5
>400%	0	—	—	2	2	100.0	15	13	86.7	19	17	89.5	0	—	—	21	19	90.5	0	—	—	58	52	89.7

Table 16b. Viral suppression among transgender adults and adolescents (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories (cont.)

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression		
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Health care coverage																								
Private employer	0	—	—	2	2	100.0	54	42	77.8	37	33	89.2	0	—	—	50	41	82.0	3	1	33.3	146	119	81.5
Private individual	0	—	—	5	5	100.0	79	68	86.1	36	34	94.4	0	—	—	33	31	93.9	6	5	83.3	162	145	89.5
Medicare	2	2	100.0	4	4	100.0	103	83	80.6	15	10	66.7	3	1	33.3	46	35	76.1	6	4	66.7	181	140	77.4
Medicaid	7	3	42.9	23	18	78.3	830	586	70.6	466	379	81.3	9	7	77.8	157	125	79.6	38	26	68.4	1,551	1,159	74.7
Medicare and Medicaid	2	2	100.0	4	4	100.0	113	85	75.2	44	42	95.5	2	2	100.0	24	21	87.5	3	2	66.7	195	161	82.6
Veterans Administration	0	—	—	0	—	—	0	—	—	0	—	—	0	—	—	1	1	100.0	0	—	—	1	1	100.0
Indian Health Service	1	1	100.0	0	—	—	1	1	100.0	0	—	—	0	—	—	0	—	—	0	—	—	2	2	100.0
Other plan	1	0	0.0	2	2	100.0	19	15	79.0	52	45	86.5	0	—	—	3	3	100.0	1	1	100.0	78	66	84.6
No coverage	2	1	50.0	14	10	71.4	379	257	67.8	313	252	80.5	2	1	50.0	61	47	77.1	5	3	60.0	781	573	73.4
Multiple coverages	3	2	66.7	6	4	66.7	158	131	82.9	112	100	89.3	5	4	80.0	60	54	90.0	18	13	72.2	368	314	85.3
Housing status																								
Stable	17	11	64.7	53	44	83.0	1,303	994	76.3	839	724	86.3	15	11	73.3	344	293	85.2	46	32	69.6	2,649	2,134	80.6
Temporary	0	—	—	6	4	66.7	250	164	65.6	166	123	74.1	3	2	66.7	50	34	68.0	17	13	76.5	497	342	68.8
Unstable	2	0	0.0	1	1	100.0	164	99	60.4	66	47	71.2	3	2	66.7	32	23	71.9	18	11	61.1	288	184	63.9
Total^b	20	12	60.0	61	50	82.0	1,760	1,285	73.0	1,080	900	83.3	22	16	72.7	437	359	82.2	82	56	68.3	3,502	2,707	77.3

Viral suppression was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit during the measurement year and whose most recent viral load test result was <200 copies/mL.

Abbreviations: MTF, male-to-female; FTM, female-to-male.

* To ensure confidentiality, data have been suppressed.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c Includes any sexual transmission risk category reported by transgender clients.

^d Includes hemophilia and blood transfusion.

^e See Technical Notes for the states/territories in each region.

Table 17a. Retention in care among youth and young adults (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b			
	Retained			Retained			Retained			Retained			Retained			Retained			Retained						
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	
Gender																									
Male	32	21	65.6	153	120	78.4	6,872	5,145	74.9	2,414	1,846	76.5	11	7	63.6	1,392	1,033	74.2	230	170	73.9	11,162	8,377	75.1	
Female	8	6	75.0	34	30	88.2	2,620	2,116	80.8	708	573	80.9	4	4	100.0	425	317	74.6	77	67	87.0	3,890	3,119	80.2	
Transgender	0	—	—	5	4	80.0	143	110	76.9	51	35	68.6	0	—	—	18	12	66.7	7	4	57.1	228	168	73.7	
Transmission risk category																									
Male client																									
Male-to-male sexual contact	28	18	64.3	121	96	79.3	4,963	3,704	74.6	1,768	1,345	76.1	7	4	57.1	1,021	768	75.2	180	133	73.9	8,122	6,090	75.0	
Injection drug use	0	—	—	1	1	100.0	11	2	18.2	8	1	12.5	0	—	—	10	7	70.0	1	0	0.0	33	11	33.3	
Male-to-male sexual contact and injection drug use	1	0	0.0	1	1	100.0	22	16	72.7	26	14	53.9	0	—	—	49	37	75.5	2	2	100.0	101	70	69.3	
Heterosexual contact ^c	1	1	100.0	7	7	100.0	611	413	67.6	173	122	70.5	1	0	0.0	68	41	60.3	10	5	50.0	876	592	67.6	
Perinatal infection	1	1	100.0	10	7	70.0	1,046	862	82.4	336	291	86.6	3	3	100.0	160	129	80.6	32	27	84.4	1,595	1,325	83.1	
Other ^d	0	—	—	1	1	100.0	14	12	85.7	5	5	100.0	0	—	—	5	3	60.0	0	—	—	25	21	84.0	
Female client																									
Injection drug use	0	—	—	0	—	—	7	4	57.1	11	7	63.6	0	—	—	20	14	70.0	1	0	0.0	40	25	62.5	
Heterosexual contact ^c	4	3	75.0	12	10	83.3	1,188	904	76.1	271	216	79.7	2	2	100.0	198	139	70.2	28	22	78.6	1,710	1,298	75.9	
Perinatal infection	2	2	100.0	18	16	88.9	1,338	1,151	86.0	397	326	82.1	2	2	100.0	191	152	79.6	46	43	93.5	1,999	1,696	84.8	
Other ^d	0	—	—	0	—	—	9	8	88.9	7	4	57.1	0	—	—	3	2	66.7	0	—	—	19	14	73.7	
Transgender client																									
Sexual contact ^e	0	—	—	3	2	66.7	126	99	78.6	41	29	70.7	0	—	—	11	9	81.8	7	4	57.1	189	144	76.2	
Injection drug use	0	—	—	0	—	—	0	—	—	1	1	100.0	0	—	—	0	—	—	0	—	—	1	1	100.0	
Sexual contact ^e and injection drug use	0	—	—	0	—	—	0	—	—	1	0	0.0	0	—	—	1	1	100.0	0	—	—	2	1	50.0	
Perinatal infection	0	—	—	1	1	100.0	2	2	100.0	1	1	100.0	0	—	—	3	1	33.3	0	—	—	7	5	71.4	
Other ^d	0	—	—	0	—	—	1	1	100.0	0	—	—	0	—	—	0	—	—	0	—	—	1	1	100.0	
HHS region^f																									
Region 1	0	—	—	13	8	61.5	161	136	84.5	144	113	78.5	0	—	—	93	72	77.4	16	15	93.8	429	346	80.7	
Region 2	1	1	100.0	35	32	91.4	1,046	796	76.1	859	708	82.4	1	0	0.0	141	114	80.9	26	23	88.5	2,131	1,689	79.3	
Region 3	1	1	100.0	7	6	85.7	1,349	1,070	79.3	195	157	80.5	1	0	0.0	179	126	70.4	36	33	91.7	1,774	1,396	78.7	
Region 4	7	5	71.4	26	21	80.8	3,654	2,957	80.9	397	306	77.1	3	3	100.0	473	378	79.9	63	51	81.0	4,626	3,722	80.5	
Region 5	6	4	66.7	12	11	91.7	1,303	927	71.1	178	131	73.6	3	3	100.0	276	202	73.2	48	32	66.7	1,863	1,329	71.3	
Region 6	6	3	50.0	24	21	87.5	1,217	823	67.6	637	498	78.2	0	—	—	211	160	75.8	36	25	69.4	2,131	1,530	71.8	
Region 7	2	2	100.0	6	5	83.3	227	167	73.6	30	25	83.3	0	—	—	64	40	62.5	15	12	80.0	344	251	73.0	
Region 8	2	1	50.0	5	4	80.0	40	36	90.0	64	52	81.3	1	1	100.0	61	45	73.8	8	6	75.0	182	146	80.2	
Region 9	7	3	42.9	54	40	74.1	307	184	59.9	546	371	68.0	6	4	66.7	217	142	65.4	25	18	72.0	1,166	765	65.6	
Region 10	5	5	100.0	5	3	60.0	20	16	80.0	25	18	72.0	0	—	—	43	29	67.4	4	2	50.0	103	73	70.9	
Poverty level																									
0–100%	29	19	65.5	120	100	83.3	7,210	5,426	75.3	2,382	1,836	77.1	10	8	80.0	1,216	897	73.8	227	169	74.5	11,247	8,485	75.4	
101–138%	5	3	60.0	27	25	92.6	847	685	80.9	322	253	78.6	1	1	100.0	187	150	80.2	33	29	87.9	1,431	1,151	80.4	
139–250%	4	4	100.0	26	17	65.4	1,052	863	82.0	337	270	80.1	1	0	0.0	242	182	75.2	36	30	83.3	1,705	1,371	80.4	
251–400%	0	—	—	9	6	66.7	237	190	80.2	74	53	71.6	3	2	66.7	93	67	72.0	11	10	90.9	428	329	76.9	
>400%	0	—	—	4	3	75.0	70	55	78.6	32	23	71.9	0	—	—	43	31	72.1	4	4	100.0	154	117	76.0	

Table 17a. Retention in care among youth and young adults (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories (cont.)

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Retained			Retained			Retained			Retained			Retained			Retained			Retained					
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Health care coverage																								
Private employer	4	3	75.0	21	17	81.0	890	697	78.3	222	177	79.7	3	3	100.0	311	225	72.4	29	20	69.0	1,481	1,142	77.1
Private individual	3	3	100.0	22	18	81.8	633	455	71.9	169	109	64.5	1	1	100.0	183	130	71.0	25	16	64.0	1,040	734	70.6
Medicare	0	—	—	0	—	—	72	49	68.1	16	13	81.3	0	—	—	21	14	66.7	1	0	0.0	110	76	69.1
Medicaid	16	9	56.3	62	48	77.4	4,169	3,257	78.1	1,420	1,107	78.0	2	1	50.0	612	465	76.0	134	105	78.4	6,434	5,003	77.8
Medicare and Medicaid	1	1	100.0	0	—	—	112	102	91.1	44	39	88.6	0	—	—	25	19	76.0	7	6	85.7	189	167	88.4
Veterans Administration	1	0	0.0	0	—	—	23	18	78.3	11	7	63.6	0	—	—	8	7	87.5	1	1	100.0	44	33	75.0
Indian Health Service	2	2	100.0	0	—	—	1	1	100.0	3	1	33.3	0	—	—	0	—	—	0	—	—	6	4	66.7
Other plan	0	—	—	7	5	71.4	163	119	73.0	78	65	83.3	1	0	0.0	38	27	71.1	6	5	83.3	296	224	75.7
No coverage	9	8	88.9	53	44	83.0	2,672	1,943	72.7	865	647	74.8	3	2	66.7	383	276	72.1	57	46	80.7	4,081	2,985	73.1
Multiple coverages	4	1	25.0	25	22	88.0	831	702	84.5	336	282	83.9	5	4	80.0	237	189	79.8	54	43	79.6	1,499	1,250	83.4
Housing status																								
Stable	34	24	70.6	158	127	80.4	7,867	6,151	78.2	2,545	2,003	78.7	12	9	75.0	1,499	1,121	74.8	223	180	80.7	12,401	9,655	77.9
Temporary	3	3	100.0	23	19	82.6	1,194	855	71.6	468	336	71.8	3	2	66.7	204	157	77.0	63	45	71.4	1,966	1,420	72.2
Unstable	3	0	0.0	8	7	87.5	465	308	66.2	145	102	70.3	0	—	—	87	58	66.7	28	17	60.7	739	492	66.6
Total^b	40	27	67.5	193	155	80.3	9,660	7,386	76.5	3,182	2,461	77.3	15	11	73.3	1,838	1,365	74.3	315	242	76.8	15,319	11,691	76.3

Retention in care was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit by September 1 of the measurement year, with a second visit at least 90 days after.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia and blood transfusion.

^e Includes any sexual transmission risk category reported by transgender clients.

^f See Technical Notes for the states/territories in each region.

Table 17b. Viral suppression among youth and young adults (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b			
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	
Gender																									
Male	41	26	63.4	188	153	81.4	7,707	5,125	66.5	2,704	1,973	73.0	14	10	71.4	1,611	1,204	74.7	254	184	72.4	12,575	8,717	69.3	
Female	9	7	77.8	38	32	84.2	2,785	1,770	63.6	734	526	71.7	4	1	25.0	478	367	76.8	81	55	67.9	4,143	2,766	66.8	
Transgender	0	—	—	7	3	42.9	161	99	61.5	50	33	66.0	0	—	—	22	12	54.6	8	4	50.0	251	152	60.6	
Transmission risk category																									
Male client																									
Male-to-male sexual contact	31	22	71.0	149	122	81.9	5,644	3,778	66.9	2,014	1,488	73.9	10	7	70.0	1,197	910	76.0	204	147	72.1	9,281	6,497	70.0	
Injection drug use	0	—	—	1	1	100.0	12	7	58.3	11	6	54.6	0	—	—	17	9	52.9	1	1	100.0	44	26	59.1	
Male-to-male sexual contact and injection drug use	1	0	0.0	1	0	0.0	25	14	56.0	25	16	64.0	0	—	—	58	36	62.1	2	2	100.0	112	68	60.7	
Heterosexual contact ^c	3	1	33.3	10	8	80.0	689	460	66.8	196	140	71.4	1	1	100.0	79	55	69.6	11	6	54.6	992	674	67.9	
Perinatal infection	3	2	66.7	12	11	91.7	1,081	699	64.7	330	233	70.6	3	2	66.7	163	129	79.1	32	24	75.0	1,631	1,105	67.8	
Other ^d	0	—	—	1	1	100.0	15	14	93.3	5	5	100.0	0	—	—	6	4	66.7	0	—	—	27	24	88.9	
Female client																									
Injection drug use	1	1	100.0	1	1	100.0	7	2	28.6	9	8	88.9	0	—	—	28	18	64.3	0	—	—	48	31	64.6	
Heterosexual contact ^c	4	3	75.0	15	12	80.0	1,316	826	62.8	298	221	74.2	2	1	50.0	227	163	71.8	30	20	66.7	1,898	1,250	65.9	
Perinatal infection	2	1	50.0	18	16	88.9	1,367	879	64.3	396	273	68.9	2	0	0.0	198	165	83.3	47	32	68.1	2,035	1,369	67.3	
Other ^d	0	—	—	0	—	—	9	6	66.7	7	6	85.7	0	—	—	3	3	100.0	2	1	50.0	21	16	76.2	
Transgender client																									
Sexual contact ^e	0	—	—	5	3	60.0	143	87	60.8	40	26	65.0	0	—	—	14	9	64.3	6	3	50.0	209	129	61.7	
Injection drug use	0	—	—	0	—	—	1	0	0.0	1	1	100.0	0	—	—	0	—	—	0	—	—	2	1	50.0	
Sexual contact ^e and injection drug use	0	—	—	0	—	—	0	—	—	1	1	100.0	0	—	—	1	0	0.0	0	—	—	2	1	50.0	
Perinatal infection	0	—	—	1	0	0.0	2	2	100.0	1	0	0.0	0	—	—	3	0	0.0	0	—	—	7	2	28.6	
Other ^d	0	—	—	0	—	—	1	0	0.0	0	—	—	0	—	—	0	—	—	0	—	—	1	0	0.0	
HHS region^f																									
Region 1	1	0	0.0	14	12	85.7	175	115	65.7	152	121	79.6	0	—	—	107	90	84.1	18	15	83.3	469	354	75.5	
Region 2	1	1	100.0	42	35	83.3	1,132	762	67.3	920	665	72.3	2	1	50.0	164	123	75.0	28	22	78.6	2,313	1,624	70.2	
Region 3	1	1	100.0	9	9	100.0	1,456	1,001	68.8	215	171	79.5	1	1	100.0	208	168	80.8	37	28	75.7	1,931	1,383	71.6	
Region 4	7	6	85.7	32	23	71.9	4,059	2,698	66.5	457	346	75.7	3	2	66.7	544	410	75.4	73	53	72.6	5,178	3,539	68.4	
Region 5	7	6	85.7	16	14	87.5	1,431	933	65.2	200	156	78.0	3	2	66.7	322	249	77.3	50	39	78.0	2,061	1,422	69.0	
Region 6	9	4	44.4	26	22	84.6	1,383	827	59.8	735	510	69.4	0	—	—	256	191	74.6	36	19	52.8	2,447	1,574	64.3	
Region 7	3	2	66.7	7	6	85.7	263	181	68.8	35	28	80.0	0	—	—	77	59	76.6	19	14	73.7	404	290	71.8	
Region 8	3	2	66.7	5	5	100.0	48	33	68.8	71	53	74.7	1	1	100.0	73	43	58.9	9	5	55.6	211	143	67.8	
Region 9	9	6	66.7	68	53	77.9	339	201	59.3	577	391	67.8	8	4	50.0	231	151	65.4	26	18	69.2	1,261	827	65.6	
Region 10	7	5	71.4	8	6	75.0	21	17	81.0	24	19	79.2	0	—	—	49	42	85.7	5	2	40.0	116	93	80.2	
Poverty level																									
0–100%	37	23	62.2	149	116	77.9	7,982	5,075	63.6	2,609	1,846	70.8	11	6	54.6	1,401	1,014	72.4	244	167	68.4	12,487	8,284	66.3	
101–138%	6	4	66.7	29	25	86.2	938	667	71.1	344	276	80.2	2	1	50.0	226	178	78.8	36	26	72.2	1,589	1,184	74.5	
139–250%	4	4	100.0	33	27	81.8	1,163	829	71.3	387	303	78.3	2	2	100.0	287	232	80.8	43	35	81.4	1,925	1,436	74.6	
251–400%	0	—	—	11	9	81.8	263	209	79.5	86	65	75.6	3	2	66.7	97	84	86.6	11	9	81.8	472	379	80.3	
>400%	1	0	0.0	4	4	100.0	71	56	78.9	34	24	70.6	0	—	—	48	36	75.0	4	4	100.0	163	125	76.7	

Table 17b. Viral suppression among youth and young adults (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories (cont.)

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression		
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Health care coverage																								
Private employer	4	4	100.0	21	21	100.0	977	715	73.2	249	198	79.5	4	2	50.0	354	275	77.7	32	21	65.6	1,643	1,238	75.4
Private individual	4	3	75.0	26	24	92.3	706	531	75.2	202	152	75.3	1	1	100.0	213	168	78.9	27	20	74.1	1,182	900	76.1
Medicare	1	0	0.0	0	—	—	78	48	61.5	16	13	81.3	0	—	—	24	18	75.0	1	1	100.0	120	80	66.7
Medicaid	19	14	73.7	77	63	81.8	4,527	2,911	64.3	1,491	1,072	71.9	2	2	100.0	696	509	73.1	139	100	71.9	6,978	4,689	67.2
Medicare and Medicaid	1	1	100.0	0	—	—	121	86	71.1	45	34	75.6	0	—	—	33	25	75.8	8	7	87.5	208	153	73.6
Veterans Administration	1	0	0.0	0	—	—	27	20	74.1	8	7	87.5	0	—	—	8	8	100.0	1	1	100.0	45	36	80.0
Indian Health Service	4	3	75.0	0	—	—	1	1	100.0	2	2	100.0	0	—	—	0	—	—	0	—	—	7	6	85.7
Other plan	1	0	0.0	10	7	70.0	171	119	69.6	84	68	81.0	1	1	100.0	40	30	75.0	7	6	85.7	317	233	73.5
No coverage	12	5	41.7	67	49	73.1	3,102	1,867	60.2	1,025	690	67.3	4	1	25.0	475	332	69.9	72	41	56.9	4,787	3,006	62.8
Multiple coverages	3	3	100.0	30	22	73.3	868	648	74.7	354	289	81.6	6	4	66.7	249	207	83.1	56	45	80.4	1,573	1,225	77.9
Housing status																								
Stable	40	26	65.0	188	152	80.9	8,689	5,831	67.1	2,822	2,074	73.5	15	9	60.0	1,732	1,324	76.4	248	179	72.2	13,797	9,639	69.9
Temporary	6	3	50.0	30	25	83.3	1,328	793	59.7	505	359	71.1	2	2	100.0	238	175	73.5	66	44	66.7	2,182	1,406	64.4
Unstable	4	4	100.0	11	7	63.6	531	306	57.6	149	89	59.7	1	0	0.0	107	58	54.2	28	19	67.9	833	484	58.1
Total^b	50	33	66.0	234	189	80.8	10,683	7,015	65.7	3,496	2,539	72.6	18	11	61.1	2,114	1,586	75.0	344	243	70.6	17,012	11,667	68.6

Viral suppression was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit during the measurement year and whose most recent viral load test result was <200 copies/mL.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia and blood transfusion.

^e Includes any sexual transmission risk category reported by transgender clients.

^f See Technical Notes for the states/territories in each region.

Table 18a. Retention in care among young men who have sex with men (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained	
		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%
Transmission risk category																								
Male-to-male sexual contact	28	18	64.3	121	96	79.3	4,963	3,704	74.6	1,768	1,345	76.1	7	4	57.1	1,021	768	75.2	180	133	73.9	8,122	6,090	75.0
Male-to-male sexual contact and injection drug use	1	0	0.0	1	1	100.0	22	16	72.7	26	14	53.9	0	—	—	49	37	75.5	2	2	100.0	101	70	69.3
HHS region^c																								
Region 1	0	—	—	8	4	50.0	43	38	88.4	56	44	78.6	0	—	—	48	39	81.3	7	6	85.7	162	131	80.9
Region 2	1	1	100.0	21	20	95.2	355	272	76.6	347	284	81.8	0	—	—	64	52	81.3	15	13	86.7	809	647	80.0
Region 3	1	1	100.0	4	3	75.0	598	449	75.1	87	72	82.8	1	0	0.0	98	68	69.4	20	19	95.0	811	613	75.6
Region 4	7	5	71.4	19	14	73.7	2,038	1,625	79.7	230	172	74.8	1	1	100.0	264	214	81.1	28	25	89.3	2,589	2,057	79.5
Region 5	3	2	66.7	6	5	83.3	744	525	70.6	89	67	75.3	1	1	100.0	155	119	76.8	32	20	62.5	1,051	752	71.6
Region 6	3	1	33.3	15	14	93.3	663	430	64.9	459	365	79.5	0	—	—	134	106	79.1	22	15	68.2	1,296	931	71.8
Region 7	2	2	100.0	3	2	66.7	133	91	68.4	19	16	84.2	0	—	—	45	26	57.8	10	8	80.0	212	145	68.4
Region 8	1	0	0.0	3	3	100.0	18	16	88.9	44	33	75.0	1	1	100.0	44	32	72.7	3	1	33.3	115	87	75.7
Region 9	6	2	33.3	36	28	77.8	165	86	52.1	366	233	63.7	3	1	33.3	122	76	62.3	12	8	66.7	712	435	61.1
Region 10	3	3	100.0	2	1	50.0	5	3	60.0	17	11	64.7	0	—	—	32	24	75.0	3	1	33.3	62	43	69.4
Poverty level																								
0–100%	19	11	57.9	79	65	82.3	3,636	2,667	73.4	1,253	936	74.7	5	3	60.0	683	516	75.6	131	95	72.5	5,830	4,307	73.9
101–138%	4	2	50.0	17	15	88.2	459	359	78.2	212	164	77.4	1	1	100.0	119	101	84.9	21	17	81.0	836	662	79.2
139–250%	4	4	100.0	16	10	62.5	614	495	80.6	245	198	80.8	0	—	—	171	126	73.7	20	15	75.0	1,073	851	79.3
251–400%	0	—	—	6	4	66.7	130	96	73.9	54	40	74.1	1	0	0.0	53	33	62.3	7	6	85.7	252	180	71.4
>400%	0	—	—	2	2	100.0	23	16	69.6	13	10	76.9	0	—	—	27	19	70.4	2	2	100.0	67	49	73.1
Health care coverage																								
Private employer	4	3	75.0	15	12	80.0	604	471	78.0	161	128	79.5	1	1	100.0	220	151	68.6	20	13	65.0	1,025	779	76.0
Private individual	3	3	100.0	16	13	81.3	422	300	71.1	126	82	65.1	1	1	100.0	137	97	70.8	16	11	68.8	723	508	70.3
Medicare	0	—	—	0	—	—	24	15	62.5	4	3	75.0	0	—	—	6	4	66.7	1	0	0.0	35	22	62.9
Medicaid	9	4	44.4	31	24	77.4	1,470	1,081	73.5	603	445	73.8	1	1	100.0	243	193	79.4	63	47	74.6	2,424	1,797	74.1
Medicare and Medicaid	0	—	—	0	—	—	31	27	87.1	15	13	86.7	0	—	—	11	8	72.7	4	3	75.0	61	51	83.6
Veterans Administration	1	0	0.0	0	—	—	12	10	83.3	6	3	50.0	0	—	—	6	5	83.3	1	1	100.0	26	19	73.1
Indian Health Service	2	2	100.0	0	—	—	0	—	—	1	0	0.0	0	—	—	0	—	—	0	—	—	3	2	66.7
Other plan	0	—	—	4	3	75.0	88	63	71.6	41	36	87.8	1	0	0.0	23	17	73.9	5	4	80.0	163	124	76.1
No coverage	7	6	85.7	38	31	81.6	1,832	1,353	73.9	639	486	76.1	1	0	0.0	266	203	76.3	38	31	81.6	2,841	2,122	74.7
Multiple coverages	3	0	0.0	17	14	82.4	453	381	84.1	185	153	82.7	2	1	50.0	148	120	81.1	33	25	75.8	846	699	82.6
Housing status																								
Stable	24	15	62.5	100	79	79.0	3,997	3,042	76.1	1,404	1,082	77.1	4	2	50.0	870	651	74.8	119	97	81.5	6,546	4,987	76.2
Temporary	3	3	100.0	19	15	79.0	655	468	71.5	304	219	72.0	3	2	66.7	127	105	82.7	41	27	65.9	1,157	842	72.8
Unstable	2	0	0.0	3	3	100.0	270	179	66.3	79	53	67.1	0	—	—	57	39	68.4	21	11	52.4	432	285	66.0
Total^b	29	18	62.1	122	97	79.5	4,985	3,720	74.6	1,794	1,359	75.8	7	4	57.1	1,070	805	75.2	182	135	74.2	8,223	6,160	74.9

Note. Unless otherwise indicated, data presented here include clients who reported male-to-male sexual contact as well as those who reported male-to-male sexual contact *and* injection drug use.

Retention in care was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit by September 1 of the measurement year, with a second visit at least 90 days after.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c See Technical Notes for the states/territories in each region.

Table 18b. Viral suppression among young men who have sex with men (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression		
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Transmission risk category																								
Male-to-male sexual contact	31	22	71.0	149	122	81.9	5,644	3,778	66.9	2,014	1,488	73.9	10	7	70.0	1,197	910	76.0	204	147	72.1	9,281	6,497	70.0
Male-to-male sexual contact and injection drug use	1	0	0.0	1	0	0.0	25	14	56.0	25	16	64.0	0	—	—	58	36	62.1	2	2	100.0	112	68	60.7
HHS region^c																								
Region 1	0	—	—	8	7	87.5	47	35	74.5	58	51	87.9	0	—	—	55	44	80.0	9	7	77.8	177	144	81.4
Region 2	1	1	100.0	27	24	88.9	401	292	72.8	385	299	77.7	1	0	0.0	78	60	76.9	16	12	75.0	915	694	75.9
Region 3	1	1	100.0	5	5	100.0	670	483	72.1	103	84	81.6	1	1	100.0	112	87	77.7	21	16	76.2	915	679	74.2
Region 4	7	6	85.7	23	16	69.6	2,315	1,583	68.4	279	214	76.7	1	1	100.0	311	238	76.5	37	29	78.4	2,975	2,087	70.2
Region 5	3	3	100.0	7	7	100.0	854	550	64.4	98	82	83.7	1	1	100.0	181	145	80.1	32	26	81.3	1,194	826	69.2
Region 6	5	2	40.0	17	13	76.5	771	459	59.5	544	385	70.8	0	—	—	163	124	76.1	22	15	68.2	1,524	999	65.6
Region 7	3	2	66.7	4	4	100.0	150	103	68.7	22	17	77.3	0	—	—	56	43	76.8	12	9	75.0	247	178	72.1
Region 8	1	0	0.0	3	3	100.0	22	13	59.1	48	37	77.1	1	1	100.0	52	32	61.5	4	1	25.0	132	88	66.7
Region 9	7	5	71.4	48	38	79.2	182	99	54.4	404	263	65.1	5	3	60.0	146	92	63.0	13	9	69.2	806	510	63.3
Region 10	3	2	66.7	2	2	100.0	5	5	100.0	16	12	75.0	0	—	—	35	32	91.4	4	2	50.0	65	55	84.6
Poverty level																								
0–100%	21	13	61.9	98	78	79.6	4,133	2,661	64.4	1,425	1,023	71.8	6	4	66.7	800	579	72.4	148	105	71.0	6,655	4,480	67.3
101–138%	5	3	60.0	19	17	89.5	524	385	73.5	230	186	80.9	2	1	50.0	141	114	80.9	23	17	73.9	946	725	76.6
139–250%	4	4	100.0	21	16	76.2	700	509	72.7	287	226	78.8	1	1	100.0	205	166	81.0	23	19	82.6	1,244	943	75.8
251–400%	0	—	—	7	6	85.7	148	120	81.1	65	47	72.3	1	1	100.0	56	45	80.4	7	5	71.4	285	225	79.0
>400%	0	—	—	2	2	100.0	23	19	82.6	12	9	75.0	0	—	—	28	23	82.1	2	2	100.0	67	55	82.1
Health care coverage																								
Private employer	4	4	100.0	15	15	100.0	673	497	73.9	181	141	77.9	2	1	50.0	255	197	77.3	21	13	61.9	1,151	868	75.4
Private individual	4	3	75.0	19	19	100.0	471	356	75.6	152	115	75.7	1	1	100.0	160	130	81.3	18	14	77.8	827	639	77.3
Medicare	0	—	—	0	—	—	27	17	63.0	4	4	100.0	0	—	—	6	5	83.3	1	1	100.0	38	27	71.1
Medicaid	10	7	70.0	42	34	81.0	1,662	1,103	66.4	663	483	72.9	1	1	100.0	292	206	70.6	68	53	77.9	2,746	1,893	68.9
Medicare and Medicaid	0	—	—	0	—	—	35	27	77.1	15	14	93.3	0	—	—	14	11	78.6	5	4	80.0	69	56	81.2
Veterans Administration	1	0	0.0	0	—	—	15	9	60.0	5	5	100.0	0	—	—	6	6	100.0	1	1	100.0	28	21	75.0
Indian Health Service	2	2	100.0	0	—	—	0	—	—	0	—	—	0	—	—	0	—	—	0	—	—	2	2	100.0
Other plan	0	—	—	5	4	80.0	95	67	70.5	44	39	88.6	1	1	100.0	26	21	80.8	6	5	83.3	178	138	77.5
No coverage	9	4	44.4	47	32	68.1	2,150	1,316	61.2	763	521	68.3	2	1	50.0	325	231	71.1	51	29	56.9	3,363	2,144	63.8
Multiple coverages	2	2	100.0	21	17	81.0	489	369	75.5	198	172	86.9	3	2	66.7	158	132	83.5	34	28	82.4	910	727	79.9
Housing status																								
Stable	25	17	68.0	120	96	80.0	4,537	3,119	68.8	1,614	1,205	74.7	7	5	71.4	1,018	786	77.2	139	105	75.5	7,488	5,354	71.5
Temporary	5	3	60.0	25	22	88.0	751	448	59.7	333	240	72.1	2	2	100.0	150	110	73.3	45	31	68.9	1,315	858	65.3
Unstable	2	2	100.0	4	3	75.0	316	185	58.5	84	53	63.1	1	0	0.0	69	37	53.6	20	12	60.0	496	292	58.9
Total^b	32	22	68.8	150	122	81.3	5,669	3,792	66.9	2,039	1,504	73.8	10	7	70.0	1,255	946	75.4	206	149	72.3	9,393	6,565	69.9

Note. Unless otherwise indicated, data presented here include clients who reported male-to-male sexual contact as well as those who reported male-to-male sexual contact *and* injection drug use. *Viral suppression* was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit during the measurement year and whose most recent viral load test result was <200 copies/mL.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c See Technical Notes for the states/territories in each region.

Table 19a. Retention in care among young women (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained		Total No.	Retained	
		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%		No.	%
Transmission risk category																								
Injection drug use	0	—	—	0	—	—	7	4	57.1	11	7	63.6	0	—	—	20	14	70.0	1	0	0.0	40	25	62.5
Heterosexual contact ^c	4	3	75.0	12	10	83.3	1,188	904	76.1	271	216	79.7	2	2	100.0	198	139	70.2	28	22	78.6	1,710	1,298	75.9
Perinatal infection	2	2	100.0	18	16	88.9	1,338	1,151	86.0	397	326	82.1	2	2	100.0	191	152	79.6	46	43	93.5	1,999	1,696	84.8
Other ^d	0	—	—	0	—	—	9	8	88.9	7	4	57.1	0	—	—	3	2	66.7	0	—	—	19	14	73.7
HHS region^e																								
Region 1	0	—	—	3	2	66.7	64	56	87.5	47	37	78.7	0	—	—	28	22	78.6	4	4	100.0	147	122	83.0
Region 2	0	—	—	7	7	100.0	370	290	78.4	266	216	81.2	0	—	—	43	34	79.1	7	7	100.0	698	557	79.8
Region 3	0	—	—	2	2	100.0	415	353	85.1	58	47	81.0	0	—	—	50	36	72.0	11	10	90.9	536	448	83.6
Region 4	0	—	—	2	2	100.0	923	775	84.0	86	73	84.9	0	—	—	132	102	77.3	19	14	73.7	1,162	966	83.1
Region 5	3	2	66.7	1	1	100.0	301	231	76.7	30	25	83.3	2	2	100.0	52	34	65.4	6	5	83.3	403	302	74.9
Region 6	2	1	50.0	5	4	80.0	327	240	73.4	92	74	80.4	0	—	—	45	30	66.7	9	8	88.9	480	357	74.4
Region 7	0	—	—	3	3	100.0	55	45	81.8	6	4	66.7	0	—	—	12	11	91.7	5	4	80.0	81	67	82.7
Region 8	1	1	100.0	1	1	100.0	15	13	86.7	12	11	91.7	0	—	—	10	9	90.0	3	3	100.0	42	38	90.5
Region 9	0	—	—	9	7	77.8	70	49	70.0	91	71	78.0	2	2	100.0	40	32	80.0	8	8	100.0	220	169	76.8
Region 10	1	1	100.0	0	—	—	9	8	88.9	1	1	100.0	0	—	—	2	1	50.0	0	—	—	13	11	84.6
Poverty level																								
0–100%	8	6	75.0	20	18	90.0	2,063	1,647	79.8	603	488	80.9	3	3	100.0	315	227	72.1	54	45	83.3	3,075	2,439	79.3
101–138%	0	—	—	4	4	100.0	202	170	84.2	47	37	78.7	0	—	—	30	24	80.0	8	8	100.0	295	244	82.7
139–250%	0	—	—	7	6	85.7	211	186	88.2	42	36	85.7	0	—	—	38	31	81.6	11	11	100.0	310	270	87.1
251–400%	0	—	—	1	1	100.0	52	46	88.5	8	4	50.0	1	1	100.0	22	21	95.5	1	1	100.0	85	74	87.1
>400%	0	—	—	1	0	0.0	23	21	91.3	3	3	100.0	0	—	—	4	2	50.0	2	2	100.0	33	28	84.9
Health care coverage																								
Private employer	0	—	—	4	3	75.0	153	124	81.1	29	24	82.8	1	1	100.0	40	35	87.5	4	4	100.0	231	191	82.7
Private individual	0	—	—	2	2	100.0	86	62	72.1	17	9	52.9	0	—	—	26	20	76.9	6	3	50.0	137	96	70.1
Medicare	0	—	—	0	—	—	25	20	80.0	6	5	83.3	0	—	—	6	4	66.7	0	—	—	37	29	78.4
Medicaid	5	3	60.0	19	17	89.5	1,639	1,343	81.9	462	381	82.5	0	—	—	236	173	73.3	38	33	86.8	2,404	1,953	81.2
Medicare and Medicaid	1	1	100.0	0	—	—	44	41	93.2	13	12	92.3	0	—	—	7	4	57.1	2	2	100.0	67	60	89.6
Veterans Administration	0	—	—	0	—	—	8	5	62.5	2	2	100.0	0	—	—	1	1	100.0	0	—	—	11	8	72.7
Indian Health Service	0	—	—	0	—	—	0	—	—	1	1	100.0	0	—	—	0	—	—	0	—	—	1	1	100.0
Other plan	0	—	—	0	—	—	35	28	80.0	15	10	66.7	0	—	—	4	3	75.0	1	1	100.0	56	43	76.8
No coverage	1	1	100.0	6	5	83.3	357	266	74.5	83	62	74.7	1	1	100.0	49	30	61.2	11	10	90.9	516	377	73.1
Multiple coverages	1	1	100.0	3	3	100.0	247	214	86.6	79	66	83.5	2	2	100.0	48	41	85.4	15	14	93.3	395	341	86.3
Housing status																								
Stable	7	6	85.7	29	25	86.2	2,164	1,786	82.5	597	491	82.2	4	4	100.0	352	264	75.0	65	56	86.2	3,230	2,638	81.7
Temporary	0	—	—	2	2	100.0	316	234	74.1	76	55	72.4	0	—	—	47	34	72.3	10	10	100.0	452	335	74.1
Unstable	1	0	0.0	3	3	100.0	104	78	75.0	31	23	74.2	0	—	—	17	13	76.5	2	1	50.0	159	118	74.2
Total^b	8	6	75.0	34	30	88.2	2,620	2,116	80.8	708	573	80.9	4	4	100.0	425	317	74.6	77	67	87.0	3,890	3,119	80.2

Retention in care was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit by September 1 of the measurement year, with a second visit at least 90 days after.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia and blood transfusion.

^e See Technical Notes for the states/territories in each region.

Table 19b. Viral suppression among young women (aged 13–24 years) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression		
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Transmission risk category																								
Injection drug use	1	1	100.0	1	1	100.0	7	2	28.6	9	8	88.9	0	—	—	28	18	64.3	0	—	—	48	31	64.6
Heterosexual contact ^c	4	3	75.0	15	12	80.0	1,316	826	62.8	298	221	74.2	2	1	50.0	227	163	71.8	30	20	66.7	1,898	1,250	65.9
Perinatal infection	2	1	50.0	18	16	88.9	1,367	879	64.3	396	273	68.9	2	0	0.0	198	165	83.3	47	32	68.1	2,035	1,369	67.3
Other ^d	0	—	—	0	—	—	9	6	66.7	7	6	85.7	0	—	—	3	3	100.0	2	1	50.0	21	16	76.2
HHS region^e																								
Region 1	0	—	—	3	3	100.0	70	46	65.7	51	36	70.6	0	—	—	32	30	93.8	4	4	100.0	161	120	74.5
Region 2	0	—	—	7	6	85.7	387	254	65.6	274	194	70.8	0	—	—	46	37	80.4	7	6	85.7	726	499	68.7
Region 3	0	—	—	2	2	100.0	432	278	64.4	60	44	73.3	0	—	—	60	50	83.3	11	7	63.6	565	381	67.4
Region 4	0	—	—	3	2	66.7	990	627	63.3	89	67	75.3	0	—	—	144	107	74.3	19	13	68.4	1,245	816	65.5
Region 5	3	3	100.0	3	2	66.7	297	194	65.3	32	21	65.6	2	1	50.0	58	44	75.9	8	6	75.0	411	276	67.2
Region 6	2	1	50.0	5	5	100.0	364	208	57.1	100	72	72.0	0	—	—	55	43	78.2	9	2	22.2	535	331	61.9
Region 7	0	—	—	3	2	66.7	67	46	68.7	7	5	71.4	0	—	—	13	11	84.6	7	5	71.4	97	69	71.1
Region 8	1	1	100.0	1	1	100.0	18	13	72.2	15	10	66.7	0	—	—	13	6	46.2	3	2	66.7	51	33	64.7
Region 9	0	—	—	9	8	88.9	75	50	66.7	85	61	71.8	2	0	0.0	42	28	66.7	8	5	62.5	221	152	68.8
Region 10	2	2	100.0	1	0	0.0	9	7	77.8	1	1	100.0	0	—	—	2	1	50.0	0	—	—	15	11	73.3
Poverty level																								
0–100%	9	7	77.8	23	18	78.3	2,197	1,368	62.3	624	437	70.0	3	1	33.3	351	263	74.9	55	34	61.8	3,271	2,133	65.2
101–138%	0	—	—	4	4	100.0	217	139	64.1	49	39	79.6	0	—	—	40	28	70.0	8	7	87.5	322	220	68.3
139–250%	0	—	—	8	7	87.5	216	149	69.0	44	36	81.8	0	—	—	43	38	88.4	14	11	78.6	326	241	73.9
251–400%	0	—	—	1	1	100.0	56	44	78.6	8	8	100.0	1	0	0.0	22	22	100.0	1	1	100.0	89	76	85.4
>400%	0	—	—	1	1	100.0	25	22	88.0	3	2	66.7	0	—	—	4	3	75.0	2	2	100.0	35	30	85.7
Health care coverage																								
Private employer	0	—	—	4	4	100.0	163	114	69.9	31	26	83.9	1	0	0.0	44	36	81.8	5	3	60.0	248	183	73.8
Private individual	0	—	—	3	2	66.7	96	70	72.9	19	15	79.0	0	—	—	27	20	74.1	6	5	83.3	151	112	74.2
Medicare	0	—	—	0	—	—	28	16	57.1	6	5	83.3	0	—	—	7	5	71.4	0	—	—	41	26	63.4
Medicaid	5	4	80.0	20	18	90.0	1,729	1,075	62.2	470	329	70.0	0	—	—	262	200	76.3	38	25	65.8	2,529	1,654	65.4
Medicare and Medicaid	1	1	100.0	0	—	—	46	31	67.4	14	9	64.3	0	—	—	9	7	77.8	2	2	100.0	72	50	69.4
Veterans Administration	0	—	—	0	—	—	9	8	88.9	1	1	100.0	0	—	—	1	1	100.0	0	—	—	11	10	90.9
Indian Health Service	1	1	100.0	0	—	—	0	—	—	1	1	100.0	0	—	—	0	—	—	0	—	—	2	2	100.0
Other plan	0	—	—	0	—	—	35	26	74.3	16	13	81.3	0	—	—	5	3	60.0	1	1	100.0	58	43	74.1
No coverage	1	0	0.0	7	6	85.7	403	235	58.3	93	63	67.7	1	0	0.0	64	46	71.9	13	7	53.9	590	362	61.4
Multiple coverages	1	1	100.0	4	2	50.0	245	176	71.8	81	63	77.8	2	1	50.0	51	43	84.3	16	12	75.0	400	298	74.5
Housing status																								
Stable	7	5	71.4	32	27	84.4	2,311	1,490	64.5	624	453	72.6	4	1	25.0	399	310	77.7	69	46	66.7	3,459	2,339	67.6
Temporary	0	—	—	2	2	100.0	329	192	58.4	77	51	66.2	0	—	—	53	41	77.4	10	7	70.0	472	294	62.3
Unstable	2	2	100.0	4	3	75.0	109	64	58.7	30	19	63.3	0	—	—	19	11	57.9	2	2	100.0	166	101	60.8
Total^b	9	7	77.8	38	32	84.2	2,785	1,770	63.6	734	526	71.7	4	1	25.0	478	367	76.8	81	55	67.9	4,143	2,766	66.8

Viral suppression was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit during the measurement year and whose most recent viral load test result was <200 copies/mL.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes hemophilia and blood transfusion.

^e See Technical Notes for the states/territories in each region.

Table 20a. Retention in care among people who inject drugs (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories (cont.)

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Retained			Retained			Retained			Retained			Retained			Retained			Retained			Retained		
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Housing status																								
Stable	88	70	79.6	82	67	81.7	7,846	6,609	84.2	4,657	4,065	87.3	14	12	85.7	4,645	3,759	80.9	247	202	81.8	17,629	14,816	84.0
Temporary	16	14	87.5	15	13	86.7	1,098	840	76.5	668	539	80.7	1	1	100.0	724	523	72.2	45	38	84.4	2,584	1,976	76.5
Unstable	24	17	70.8	2	1	50.0	664	515	77.6	371	282	76.0	2	2	100.0	432	287	66.4	49	39	79.6	1,555	1,148	73.8
Total^b	129	101	78.3	101	82	81.2	9,744	8,058	82.7	5,750	4,927	85.7	18	16	88.9	5,893	4,634	78.6	343	280	81.6	22,057	18,143	82.3

Note. Data presented in this table represent persons who reported injection drug use as their transmission risk category; data may not be reflective of current injection drug use behavior. Data are included only for persons with the transmission risk category injection drug use; data do not include male clients who reported male-to-male sexual contact *and* injection drug use or transgender clients who reported sexual contact and injection drug use.

Retention in care was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit by September 1 of the measurement year, with a second visit at least 90 days after.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c See Technical Notes for the states/territories in each region.

Table 20b. Viral suppression among people who inject drugs (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression		
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Gender																								
Male	70	59	84.3	18	14	77.8	3,692	2,986	80.9	1,475	1,200	81.4	9	7	77.8	2,416	1,959	81.1	179	148	82.7	7,890	6,398	81.1
Female	64	56	87.5	89	77	86.5	6,275	5,217	83.1	4,360	3,627	83.2	8	8	100.0	3,714	3,180	85.6	174	140	80.5	14,738	12,350	83.8
Transgender	2	2	100.0	0	—	—	13	5	38.5	15	11	73.3	1	1	100.0	15	12	80.0	2	1	50.0	49	32	65.3
Age group (yr)																								
13–14	0	—	—	0	—	—	0	—	—	0	—	—	0	—	—	0	—	—	0	—	—	0	—	—
15–19	0	—	—	0	—	—	2	2	100.0	1	0	0.0	0	—	—	0	—	—	0	—	—	3	2	66.7
20–24	1	1	100.0	2	2	100.0	18	7	38.9	20	15	75.0	0	—	—	45	27	60.0	1	1	100.0	91	56	61.5
25–29	2	2	100.0	3	3	100.0	64	44	68.8	58	42	72.4	1	1	100.0	170	116	68.2	6	5	83.3	311	218	70.1
30–34	10	6	60.0	19	15	79.0	120	75	62.5	144	105	72.9	0	—	—	355	252	71.0	15	10	66.7	673	469	69.7
35–39	10	8	80.0	16	13	81.3	204	132	64.7	380	283	74.5	5	4	80.0	473	356	75.3	25	20	80.0	1,121	822	73.3
40–44	11	8	72.7	22	19	86.4	382	274	71.7	523	408	78.0	1	1	100.0	566	442	78.1	27	18	66.7	1,542	1,176	76.3
45–49	31	27	87.1	20	18	90.0	998	763	76.5	943	751	79.6	6	5	83.3	1,061	851	80.2	55	41	74.6	3,129	2,469	78.9
50–54	30	25	83.3	12	10	83.3	2,076	1,649	79.4	1,389	1,144	82.4	3	3	100.0	1,461	1,266	86.7	86	75	87.2	5,071	4,185	82.5
55–59	27	26	96.3	6	5	83.3	2,745	2,298	83.7	1,268	1,094	86.3	1	1	100.0	1,201	1,084	90.3	75	62	82.7	5,332	4,579	85.9
60–64	10	10	100.0	2	1	50.0	2,307	2,013	87.3	755	668	88.5	1	1	100.0	580	537	92.6	45	38	84.4	3,703	3,271	88.3
≥65	4	4	100.0	5	5	100.0	1,064	951	89.4	369	328	88.9	0	—	—	233	220	94.4	20	19	95.0	1,701	1,533	90.1
HHS region^c																								
Region 1	2	2	100.0	3	2	66.7	660	577	87.4	984	847	86.1	2	2	100.0	723	633	87.6	22	20	90.9	2,398	2,085	87.0
Region 2	5	3	60.0	14	12	85.7	1,735	1,399	80.6	2,696	2,179	80.8	2	2	100.0	625	538	86.1	37	29	78.4	5,132	4,179	81.4
Region 3	2	2	100.0	12	10	83.3	2,865	2,435	85.0	619	535	86.4	0	—	—	861	742	86.2	126	107	84.9	4,492	3,837	85.4
Region 4	15	14	93.3	11	11	100.0	2,048	1,671	81.6	355	293	82.5	2	2	100.0	1,172	963	82.2	30	26	86.7	3,634	2,981	82.0
Region 5	10	8	80.0	7	6	85.7	928	778	83.8	239	208	87.0	0	—	—	370	310	83.8	33	27	81.8	1,636	1,374	84.0
Region 6	12	9	75.0	10	9	90.0	778	601	77.3	211	170	80.6	0	—	—	496	381	76.8	29	23	79.3	1,538	1,195	77.7
Region 7	1	1	100.0	8	7	87.5	94	81	86.2	14	13	92.9	0	—	—	189	162	85.7	5	5	100.0	311	269	86.5
Region 8	12	12	100.0	2	2	100.0	61	47	77.1	93	68	73.1	0	—	—	257	208	80.9	2	2	100.0	427	339	79.4
Region 9	45	38	84.4	32	26	81.3	602	445	73.9	489	403	82.4	9	8	88.9	1,042	868	83.3	38	31	81.6	2,260	1,820	80.5
Region 10	32	28	87.5	6	5	83.3	62	54	87.1	39	33	84.6	3	2	66.7	280	241	86.1	14	10	71.4	440	377	85.7
Poverty level																								
0–100%	120	102	85.0	72	60	83.3	8,010	6,482	80.9	5,066	4,138	81.7	11	9	81.8	4,573	3,726	81.5	313	251	80.2	18,225	14,815	81.3
101–138%	5	5	100.0	15	12	80.0	852	746	87.6	366	335	91.5	4	4	100.0	598	540	90.3	15	14	93.3	1,863	1,662	89.2
139–250%	7	7	100.0	14	13	92.9	668	602	90.1	259	228	88.0	3	3	100.0	562	526	93.6	21	19	90.5	1,548	1,412	91.2
251–400%	3	3	100.0	4	4	100.0	194	179	92.3	73	66	90.4	0	—	—	229	209	91.3	3	3	100.0	509	467	91.8
>400%	0	—	—	0	—	—	55	47	85.5	23	23	100.0	0	—	—	68	65	95.6	0	—	—	146	135	92.5
Health care coverage																								
Private employer	1	1	100.0	7	6	85.7	342	306	89.5	119	109	91.6	2	2	100.0	322	293	91.0	6	6	100.0	801	725	90.5
Private individual	4	4	100.0	9	8	88.9	267	235	88.0	94	87	92.6	0	—	—	267	227	85.0	13	8	61.5	654	569	87.0
Medicare	7	7	100.0	3	2	66.7	1,307	1,128	86.3	484	431	89.1	0	—	—	735	663	90.2	34	32	94.1	2,578	2,271	88.1
Medicaid	66	55	83.3	39	33	84.6	4,648	3,719	80.0	3,492	2,824	80.9	9	8	88.9	2,498	2,062	82.6	168	139	82.7	10,942	8,861	81.0
Medicare and Medicaid	15	12	80.0	8	8	100.0	1,339	1,171	87.5	614	536	87.3	0	—	—	758	678	89.5	50	39	78.0	2,784	2,444	87.8
Veterans Administration	0	—	—	0	—	—	7	6	85.7	1	1	100.0	0	—	—	11	11	100.0	0	—	—	19	18	94.7
Indian Health Service	12	10	83.3	0	—	—	2	2	100.0	0	—	—	0	—	—	3	1	33.3	0	—	—	17	13	76.5
Other plan	2	1	50.0	0	—	—	95	79	83.2	98	83	84.7	1	1	100.0	82	70	85.4	3	2	66.7	283	238	84.1
No coverage	9	8	88.9	26	23	88.5	913	670	73.4	410	309	75.4	1	1	100.0	738	527	71.4	21	14	66.7	2,167	1,588	73.3
Multiple coverages	19	18	94.7	14	10	71.4	1,012	859	84.9	508	434	85.4	5	4	80.0	702	594	84.6	59	48	81.4	2,321	1,968	84.8

Table 20b. Viral suppression among people who inject drugs (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2015—United States and 3 territories (cont.)

	American Indian/ Alaska Native			Asian			Black/African American			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total ^b		
	Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression			Viral suppression		
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Housing status																								
Stable	90	83	92.2	85	72	84.7	7,990	6,733	84.3	4,716	4,001	84.8	14	13	92.9	4,815	4,166	86.5	250	213	85.2	18,012	15,326	85.1
Temporary	18	15	83.3	18	17	94.4	1,155	882	76.4	691	543	78.6	1	1	100.0	763	608	79.7	51	37	72.6	2,719	2,120	78.0
Unstable	27	18	66.7	3	1	33.3	699	492	70.4	388	253	65.2	2	1	50.0	474	305	64.4	51	36	70.6	1,654	1,113	67.3
Total^b	136	117	86.0	107	91	85.1	9,980	8,208	82.2	5,850	4,838	82.7	18	16	88.9	6,145	5,151	83.8	355	289	81.4	22,591	18,710	82.8

Note. Data presented in this table represent persons who reported injection drug use as their transmission risk category; data may not be reflective of current injection drug use behavior. Data are included only for persons with the transmission risk category injection drug use; data do not include male clients who reported male-to-male sexual contact *and* injection drug use or transgender clients who reported sexual contact and injection drug use.

Viral suppression was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit during the measurement year and whose most recent viral load test result was <200 copies/mL.

^a Hispanics/Latinos can be of any race.

^b Because totals were calculated independently of the values for the subpopulations, the values in each column and row may not sum to the column and row totals.

^c See Technical Notes for the states/territories in each region.